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Abstract 
Zika virus (ZIKV) an arbovirus that became widely known in 2015 due to the 
epidemic in Brazil, spreading across South and North America. Whilst previous 
Old World ZIKV outbreaks comprised largely mild, or even asymptomatic 
infections, the New World epidemic became notorious for its association with 
foetal microcephaly following maternal infection, and an increased incidence of 
various neurological symptoms, including Guillain-Barré syndrome.  
Mature, infectious ZIKV particles comprise three structural proteins, Capsid (C), 
small Membrane (M) and the envelope (E) glycoprotein; the latter is responsible 
for receptor binding and mediates membrane fusion upon encountering low pH 
within the acidifying endosome. However, the function of M within this context is 
unknown. 
Based upon its structural similarity to “viroporins”, a class of virus-coded ion 
channels mediating virus entry and uncoating, we investigated whether M could 
form alternative oligomeric forms to the dimeric structure seen within mature 
virions, and in so doing exhibit channel activity. Gratifyingly, M peptides adopted 
higher order structures within membrane-mimetic environments and displayed 
channel activity in vitro, sensitive to the prototypic viroporin inhibitor, 
Rimantadine. Accordingly, ZIKV entry was blocked in a dose-dependent fashion 
by the drug, which also prevented virus spread in mouse models of ZIKV 
infection. Molecular dynamics simulations supported that M protein is able to 
oligomerise into a hexameric viroporin channel, opening of which was within 
acidified environments via protonation of a conserved histidine residue. 
Rimantadine was predicted in silico to interact at a lumenal binding site, against 
which we derived improved inhibitors from a library of generic, FDA-approved 
and other bio-active small molecules, providing a basis for novel M protein 
targeted drug discovery. Significantly, due to its role during virus entry, M-
targeted drugs might either prevent or reduce the severity of ZIKV infections, 
including those crossing the placenta, and may also show activity against 
closely related M proteins from other Flaviviruses. 
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Chapter 1 Introduction 
1.1 Flaviviruses 
The Flavivirus genus within the Flaviviridae family comprises many viruses, all 
of which possess a genome with a unique 5' cap feature (m7GpppAmp). The 
positive sense viral single-stranded genomic RNA encodes an approx. 3000 
kDa polyprotein, which is processed by both viral and host proteases. All have 
three structural proteins C, E and prM/M which organise to form the enveloped 
virion, along with the genomic RNA. There are also seven non-structural 
proteins encoded by the genome: NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS5, which enable viral replication.  
Flaviviruses are transmitted predominantly by arthropods and are known as 
arboviruses (arthropod-borne), utilising their capabilities to jump between hosts. 
Over half of Flaviviruses have been linked to human pathogenesis; many are 
well-known including yellow fever virus (YFV), dengue virus (DENV) and Zika 
virus (ZIKV). These infections often cause symptoms related to the central 
nervous system, fever, rashes and haemorrhagic fever. Fewer Flaviviruses are 
also known to cause pathogenesis in other animals including rodents.  
There are over 50 Flavivirus species, yet there are currently only three viruses 
with commercial vaccines: first introduced in 1937 the YFV 17D vaccine (Theiler 
and Smith, 1937), the Tick-borne Encephalitis virus (TBEV) vaccine (Kunz et 
al., 1976) then Japanese encephalitis virus vaccine (Yun and Lee, 2014). 
However, highly pathogenic and prevalent Flaviviruses including well-known 
DENV, ZIKV, and lesser-known Kyassanur Forest virus and Louping Ill virus 
have no current vaccines or antivirals (Kasabi et al., 2013; Jeffries et al., 2014). 
1.2 Zika virus (ZIKV) 
1.2.1 Origin and Discovery 
Discovered in 1947 in Uganda whilst surveying for yellow fever in the Zika 
forest, ZIKV was isolated from a sentinel rhesus monkey sample. The virus was 
isolated again in the following year, 1948, however, from an Aedes africanus 
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mosquito, again from within the Zika forest (Dick et al., 1952). It is not known 
when Zika crossed the species barrier and entered the human population, 
however in 1952 it was detected in human samples in both Uganda and 
Tanzania, and again in 1954 in Nigeria (Smithburn, 1952; Macnamara, 1954). In 
1964 the first symptomatic patient had Zika isolated from them. Symptoms were 
described as mild with a rash covering the majority of their body, and differing to 
DENV and the alphavirus chikungunya (CHIKV) by the absence of joint/bone 
pain (Simpson, 1964). The similarity of these symptoms highlights why ZIKV 
may not have been investigated previously. Throughout the 1970s and 80s, 
ZIKV was detected across equatorial Africa within mosquitoes and sentinel 
rhesus monkeys, as well as rare cases within the human population (Moore et 
al., 1975; Jan et al., 1978; Robin and Mouchet, 1975; Fagbami, 1977; Saluzzo 
et al., 1981). However, during this time ZIKV spread across India, Indonesia, 
Malaysia and Pakistan, again predominantly within mosquitos and rarely within 
humans (Marchette et al., 1969; Olson et al., 1981; Darwish et al., 1983). 
However, the presence of clinically similar virus infections, including CHIKV and 
DENV, could have masked the volume of ZIKV cases. 
1.2.2 Transmission 
Two different transmission cycles exist for ZIKV, the sylvatic and urban cycles 
involving Aedes mosquitos and either non-human primates or humans (Figure 
1.1).  
ZIKV is thought to only display tropism within humans, non-human primates and 
mosquitos. However, ZIKV is commonly used in cell culture in cell lines of other 
vertebrates (e.g. Baby Hamster Kidney (BHK) cells), and antibodies specific to 
ZIKV have been identified in other vertebrates including rodents and cattle, 
highlighting that they may play a role in virus circulation (Johnson et al., 1977).  
ZIKV is primarily transmitted to humans through a female Aedes mosquito bite, 
commonly A. aegypti, which are found only in tropical areas, or A. albopictus, 
which are more widespread and can survive in more temperate regions; the 
former species is thought to transmit the majority of ZIKV infections (Thomas et 
al., 2012; Ferreira-de-Brito et al., 2016; Peterson et al., 2016). However, the 
recent outbreaks in Yap and French Polynesia likely resulted from A. aegypti in 
addition to A. hensilli and A. polynesiensis, respectively (Duffy et al., 2009; 
Lazear and Diamond, 2016). 
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Figure 1.1  ZIKV transmission cycles schematic 
In Africa ZIKV circulates in the sylvatic transmission cycle between non-human primates and 
forest-dwelling Aedes mosquitoes.  However, in the suburban and urban environment ZIKV is 
primarily transmitted in a human – Aedes mosquito transmission cycle. Additionally, ZIKV can 
be transmitted between humans in utero, through sexual contact and blood transfusion. Figure 
taken from (Kurscheidt et al., 2019). 
 
The African lineage of ZIKV is sustained predominantly via the sylvatic cycle 
(Figure 1.1) through non-human primates and mosquitos, whilst humans 
occasionally become incidental hosts (Althouse et al., 2016). However, critical 
amino acid substitutions led to the evolution of an Asian lineage of ZIKV (Gong 
et al., 2017), which predominantly infects humans as opposed to non-human 
primates, sustaining transmission via the urban transmission cycle (Saiz et al., 
2016). This involves humans as the carrier, replicator and source of ZIKV for 
uninfected mosquitos, and the extrinsic incubation period of a mosquito is 
thought to be 10 days (Hayes, 2009; Boorman and Porterfield, 1956).   
Non-mosquito modes of ZIKV transmission also exist, albeit with much lower 
incidence. The most reported non-mosquito transmission event occurs vertically 
from pregnant mothers transmitting ZIKV to their foetus through the placenta 
(Mysorekar, 2017). It is reported this is most likely to occur and cause 
congenital defects when the mother becomes infected in the 1st trimester 
(Rasmussen et al., 2016). In murine models, ZIKV RNA and antigens have 
been found in amniotic fluid, placenta and foetal brain, whilst both blood and 
cerebrospinal fluid (CSF) are positive in human studies. Furthermore, infectious 
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ZIKV particles have been isolated from the brain (Tai et al., 2019; Brito et al., 
2018; Krauer et al., 2017). 
Other routes of perinatal transmission are possible. ZIKV RNA and infectious 
particles have been detected in breast milk of infected mothers. A study in 2014 
with two mother-infant pairs who were not infected throughout pregnancy 
detected ZIKV RNA in the milk and serum of the mothers, which then presented 
in the infants serum (Besnard et al., 2014). However, inoculation of Vero cells 
with breast milk did not result in virus replication. It is not certain ZIKV was 
transmitted via breast milk; other routes include transplacental, during delivery 
and by close contact between the mother and her newborn. However, breast 
milk transmission has previously been reported in DENV and WNV, but is 
thought to be very rare in both cases (Barthel et al., 2013; Hinckley et al., 2007). 
Furthermore, breastmilk has shown antiviral activity upon endogenous lipase-
dependent production of fatty acids known to disrupt enveloped viruses 
(Cortese et al., 2017; Pfaender et al., 2013)  
Additionally, sexual transmission has been reported. This was first indicated in 
2008 after an American scientist returned home from Senegal, upon his return 
he became symptomatic with ZIKV. The scientists’ wife had remained within the 
US and subsequently contracted ZIKV, likely to be transmitted sexually (Foy et 
al., 2011).  
Sexual transmission was again indicated when ZIKV particles were isolated 
from the semen of a patient from French Polynesia in 2013 as he underwent 
treatment for haematospermia (Musso et al., 2015). There have since been 
further reports of sexually transmitted ZIKV. As of January 2018 in non-endemic 
areas there have been 27 reports of sexually transmitted ZIKV from 18 studies 
(Kim et al., 2018). ZIKV RNA and replicative ZIKV have both been isolated from 
semen, and viral RNA has been detected up to 62 days post symptoms 
(Atkinson et al., 2016).  
Furthermore, Brazilian officials confirmed there had been two cases of ZIKV 
infections originating from blood transfusions, one of which was asymptomatic; 
these both happened in 2015 prior to the outbreak. Blood banks now only allow 
donations 30 days after a symptomatic infection of ZIKV (Magnus et al., 2018; 
Schnirring, 2016).  
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1.2.3 Symptoms 
Only 20-25 % of infected individuals present with classical ZIKV symptoms, the 
majority remaining asymptomatic. Classical symptoms present as a non-specific 
malaise and can mimic flu-like symptoms or other arbovirus infections e.g. 
DENV, CHIKV, making identification difficult in the absence of molecular 
diagnostics (Patterson et al., 2016). Symptoms include: skin rash, headache, 
fever, conjunctivitis, muscle pain, joint pain & joint swelling (Cerbino-Neto et al., 
2016).  
During the South American outbreak in Columbia, 270 of 2603 ZIKV infected 
individuals displaying classical symptoms developed Guillain-Barré syndrome 
(GBS), increasing the baseline average from 20 to 90 cases/month (Parra et al., 
2016). GBS comprises neurological symptoms including progressive weakness 
and loss of sensation in limbs, leading to paralysis of legs, arms, chest & facial 
muscles. GBS is an autoimmune disease attacking the peripheral nervous 
system and can be fatal due to ensuing respiratory failure occurring in 30 % of 
patients (Orlikowski et al., 2004). This was illustrated in 1976 when 5 % of GBS 
cases associated with a particular Influenza A virus (IAV) vaccine were fatal 
(Schonberger et al., 1979). The mechanism by which ZIKV causes GBS is 
unknown.  
During an outbreak of ZIKV in French Polynesia, GBS incidence was estimated 
to be approximately 20-fold higher than the normal incidence rate of 1-2 cases 
per 100,000 per year (Oehler et al., 2014). GBS is triggered by a preceding 
event including infection or immunisation and comprises two main types: Acute 
motor axonal neuropathy (AMAN) and Acute Inflammatory Demyelinating 
Polyradiculoneuropathy (AIDP). AMAN is caused by pathogen cross-reactivity 
with epitopes on peripheral nerves, resulting in degeneration of the axons, 
whereas in AIDP epitopes are cross-reactive with Schwann cells and/or myelin, 
resulting in axonal demyelination (Kuwabara, 2004). Studies have shown T cells 
infiltrate GBS neuronal lesions, implying a role in mediating the production of 
auto-antibodies (Yang, M. et al., 2015). 
Another serious ZIKV neurological consequence is microcephaly, where 
impaired foetal brain development results in heads of smaller than normal size 
and is associated with intellectual disability (Alcantara and O'Driscoll, 2014). 
During the 2015 Brazil outbreak, causal association between prenatal ZIKV 
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infection and microcephaly was documented, with a 405 % increase over 
baseline incidence (Microcephaly Epidemic Research, 2016; Magalhaes-
Barbosa et al., 2016). Retrospectively, analysis of the 2013 ZIKV outbreak in 
French Polynesia revealed out of 8750 ZIKV cases, 7 cases of microcephaly 
occurred when the mother was infected during the first trimester of pregnancy 
(de Oliveira et al., 2017a). 
The greatest loss of neurons in microcephaly occurs in the cerebral cortex 
found in the forebrain, encompassing 80 % of the total brain mass. The 
absence of a fully formed cortex results in impaired higher-order processes, 
including cognition and sensation (Geschwind and Rakic, 2013). Formation of 
the cortex during foetal development originates from three different types of cell 
divisions of the neural tube. Along with programmed cell death, the proportion of 
these different divisions is tightly regulated. Imbalances in the proportions of 
these divisions can impact the development of the central nervous system, 
therefore leading to microcephaly (Rakic, 2009). 
ZIKV impacts the development of the developing cerebral cortex by infecting 
neural progenitor cells often resulting in cytotoxic effects (Brault, J.B. et al., 
2016) and also infects cranial neural crest cells which develop into cranial 
bones and secrete hormones promoting neural differentiation (Bayless et al., 
2016). Upon infection, ZIKV promotes cell cycle arrest and apoptotic cell death 
(Li, C. et al., 2016b; Tang et al., 2016; Hanners et al., 2016; Garcez et al., 
2016) autophagy or possibly by early differentiation through hormone release 
(Merfeld et al., 2017). 
1.3 Epidemiology  
In 2007, the first large human ZIKV outbreak occurred on Yap, a small Pacific 
island of 11250 people. Surveys suspected 185 Zika cases and it was 
estimated 73 % of Yap residents were infected. However, there were no deaths, 
hospitalisations or neurological complications as a result of the outbreak (Duffy 
et al., 2009; Lanciotti et al., 2008). It is not known how ZIKV was introduced to 
Yap; it is possible mosquitoes can travel considerable distances by wind, yet it 
was most likely introduced by an infected person or mosquito by travel or trade. 
Unlike the African and Asian population, the Yap population are thought to lack 
herd immunity, an indirect protection occurring when the majority of the 
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population is immune to the pathogen, providing protection to those who are 
not.  
In 2012 Zika virus strain research for African strains: MR 766 (Prototype, 
Uganda, 1947); IbH 30656 (Nigeria, 1968) and ArD 41519 (Senegal 1984) and 
Asian strains: P6-740 (Malaysia, 1966); EC Yap (Yap Island, Micronesia, 2007) 
and FSS13025 (Cambodia, 2010) were published, indicating differing Asian and 
African lineages, strengthening the thought the ZIKV outbreak in Yap originated 
from Asia (Haddow et al., 2012) (Figure 1.2 & Figure 1.3). 
ZIKV subsequently caused outbreaks throughout 2013 and 2014 isolated to 
Pacific island groups including French Polynesia (Cao-Lormeau and Musso, 
2014; Roth et al., 2014), which generated thousands of suspected infections. 
For the first time ZIKV was suggested to be associated with GBS and 
congenital malformations (Oehler et al., 2014). However, during this time 
French Polynesia was also experiencing a DENV outbreak, which prevented 
conclusive studies (Cao-Lormeau et al., 2014). 
ZIKV was first detected in South America in 2015. In the February, an illness 
characterised by a rash was present in Brazil and by May it was identified as 
ZIKV and declared an outbreak by the National Ministry of Health. The illness 
was described as mild but caused 7000 cases in north-eastern states of Brazil. 
In July, reports of GBS associated with a prior virus infection were associated. 
However, by October, the cases of GBS had increased and Brazil first reported 
a rise in new-born microcephaly cases (de Oliveira et al., 2017b). Over the next 
year ZIKV spread throughout South America & Central America (Figure 1.4). As 
of 4th January 2018 throughout the Americas there have been over 1,000,000 
cases of ZIKV, and 3720 cases of confirmed congenital syndrome associated 




Figure 1.2 Evolutionary timescales of ZIKV 
Maximum Clade Credibility (MCC) tree of ZIKV. The Asian and African lineages 




Figure 1.3 ZIKV nucleotide and amino acid alignments 
Neighbour-joining phylogeny tree generated from ZIKV strain open reading frames. 
Tree routes with Spondweni virus. Genetic distance in nucleotide substitutions per site 
is shown by scale at the bottom. Numbers at the nodes represent percent bootstrap 
support values based on 1,000 replicates. Source (Haddow et al., 2012). 
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Figure 1.4 Countries and territories showing the spread of ZIKV (2013-2016) 
Source  (ZIKA VIRUS MICROCEPHALY GUILLAIN-BARRÉ SYNDROME 2016)
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1.4 Molecular biology of Zika virus (ZIKV) 
1.4.1 Zika virus genome structure 
Similar to all Flaviviruses, Zika virus has a single-stranded positive-sense RNA 
genome of around 11kb. The 5ʹ-end of the viral RNA possesses a type I cap (m-
7GpppAmp) and a 5ʹ untranslated region (UTR) of 106 nucleotides (nt). This is 
followed by a single open reading frame (ORF), then by a 3ʹ UTR of 428 nt. 
UTRs contain sequence motifs which play multiple roles during translation and 
replication of the RNA, functioning as positive and negative regulators (Song et 
al., 2019). 
Additionally, the 3ʹ UTR loop structure leads to formation of two subgenomic 
Flavivirus RNA (sfRNA) species, which are likely involved in virus transmission 
and replication. sfRNA is an extension of the 3ʹ UTR and is produced by 
incomplete degradation of the viral RNA by host RNA exonuclease protein 5'-3' 
exoribonuclease 1 (XRN1). Stalling of XRN1 at RNA stem-loops results in 
sfRNA formation (Pijlman et al., 2008). ZIKV sfRNA is reported to inhibit type 1 
IFN responses through antagonism of RIG-I and, to a lesser extent, MDA5 
(Donald et al., 2016). 
The ZIKV polyprotein is processed co- and post- translationally by both host 
and viral proteases, including furin and Non-structural protein (NS) 3 
respectively (Stadler et al., 1997; Amberg et al., 1994). NS2B – NS3 is known to 
cleave Capsid (C) – Intracellular capsid protein (Ci), NS2A – NS2B, NS2B – 
NS3, NS3 – NS4A, NS4A-2K, NS4B – NS5 on the cytoplasmic side of the ER 
and Ci – precursor membrane (prM), small membrane (M) – Envelope (E), E – 
NS1, NS1 – NS2, peptide 2K (2K) – NS4B within the ER lumen.  
1.4.2 Zika virus structural proteins 
Like all members of the Flaviviridae, ZIKV proteins are organised spatially with 
structural elements at the N-terminus and NS proteins at the C-terminus. There 
are three structural proteins: C, M synthesised as a longer precursor (prM) and 
E. The functions of these proteins have been studied in ZIKV to a degree, 
although some are inferred based upon related Flaviviruses. 
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1.4.2.1 Capsid protein 
The Capsid (C) protein has many different roles. Its primary role is to associate 
with viral RNA to form the nucleocapsid during assembly, protecting the RNA 
genome (Kuhn et al., 2002). However, C also interacts with multiple host 
proteins including Regulator of nonsense transcripts 1 (UPF1), Zinc Finger 
CCCH-Type Containing Antiviral 1 (ZC3HAV1) and La-related protein 1 (LARP) 
involved in evading the immune response through dysregulation or expression 
of specific transcripts (Fontaine et al., 2018; Scaturro et al., 2018; Scaturro et 
al., 2019) and interactions with Ly1 Antibody Reactive (LYAR) maintaining 
embryonic stem cell properties and neuroguidin (NGDN) preventing neuronal 
development (Scaturro et al., 2018; Scaturro et al., 2019). 
DENV C protein has been shown to act as an RNA chaperone, aiding viral RNA 
structure formation, by forming dimers which are capable of binding RNA (Pong 
et al., 2011). Moreover, YFV C protein inhibits the mosquito immune system by 
preventing RNA silencing mediated through binding to long dsRNAs, interfering 
with the production of virus-derived small interfering RNAs (vsiRNAs) by dicer 
(Samuel et al., 2016).  
Flavivirus C proteins localise in several cellular compartments after translation. 
C is found accumulated around endoplasmic reticulum (ER) derived organelles 
called lipid droplets, in parallel with other viruses including hepatitis C virus 
(HCV) (Samsa et al., 2009; Ogawa et al., 2009), which could help to sequester 
capsid proteins and allow genome encapsulation.  Nuclear localisation of capsid 
allows interactions with many different host proteins, primarily preventing 
apoptosis and interactions leading to increased replication. These include 
interactions of DENV C with Death Domain Associated Protein (DAXX) leading 
to Fas-mediated apoptotic activity, WNV C interactions with DDX56 after re-
locating from nucleolus to cytoplasmic site and phosphorylated WNV C 
interactions with HDM2 induce p53-dependent apoptosis. (Netsawang et al., 
2010; Limjindaporn et al., 2007; Xu, Z. et al., 2011; Yang, M.R. et al., 2008). 
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Figure 1.5 ZIKV genome organisation schematics  
A. Polyprotein structure showing 5 and 3 RNA structures. B. Polyprotein schematic 
of the proteases involved and cleavage products. C. Topology of the polyprotein 








PrM protein acts as a chaperone protein assisting the folding of E during 
intracellular virion assembly. Preventing premature fusion of the immature virion 
prior to release from the host cell by maintaining E in a non-fusogenic state, 
masking and inactivating the E fusion peptide (Lorenz et al., 2002; Yu et al., 
2009; Li, L. et al., 2008). 
During the transport of the virion through the trans-Golgi network (TGN) the 
virion encounters a decrease in pH from neutral to around 6. Virion acidification 
causes the prM-E trimers to reorganise into a herringbone-like arrangement, in 
which prM molecules cover the fusion loop of E protein. Making the fusion loop 
of E inaccessible, prevents premature fusion of the virion in the acidic Golgi 
compartment prior to virion release. Subsequently, host protease furin and furin-
like proteases are responsible for cleaving prM to M protein (Yu et al., 2008; Yu 
et al., 2009; Stadler et al., 1997). 
The aforementioned prM cleavage is inefficient, and many virions remain only 
partially matured. These uncleaved prM proteins may play a role in immune 
evasion as immature DENV prM-containing particles are more likely to lead to 
Antibody Dependent Enhancement (ADE) in patients than an infection with fully 
mature DENV particles (Rodenhuis-Zybert et al., 2011). 
Additionally, a prM protein S139N substitution mutation, which first emerged in 
May 2013, has been shown to significantly increase infectivity of ZIKV when 
cultured with neural progenitor cells, leading to more pronounced microcephaly 
in foetal mice of infected mothers (Yuan et al., 2017). The mutation is found 
within the region of prM which is involved in interactions within trimeric spikes in 
the immature virus particle (Prasad et al., 2017). Therefore, the mutation may 
be involved in the transition of ZIKV from immature to mature virions; in turn the 
maturity heterogeneity of virus may affect “viral fitness” and so neurovirulence. 
The substitution mutation occurred prior to the French Polynesia outbreak in 
2013 and has been maintained in the epidemic strain that spread across the 





Figure 1.6  Flavivirus maturation 
The maturation pathway for Flaviviruses. The conformational changes of surface glycoproteins prM/M and E and the cleavage of prM by host 




Once pr is cleaved, M remains within the virion membrane as a short 
hydrophobic protein of 75 amino acids. The role of M within the mature virion 
membrane is unclear. However, several Flavivirus studies have investigated the 
possibility of M protein exhibiting viroporin activity, playing a role during virus 
entry and uncoating. It is thought the activity could compare to that of Influenza 
A virus (IAV) M2. However, there have been conflicting results of channel 
activity using lipid membranes in vitro and Xenopus oocytes (Premkumar et al., 
2005; Wong et al., 2011).  
DENV M protein has been shown to have cytotoxic effects and the ability to 
induce apoptosis. Through deletion mutagenesis, nine C-terminal amino acids 
were identified within the ectodomain of M protein that appeared responsible for 
this phenotype. This region is referred to as “ApoptoM”. Further investigation 
showed ApoptoM transport through the secretory pathway is an essential part of 
this process, and interactions of ApoptoM with pro-apoptotic protein Bax, of 
which levels increase during Flaviviral infection, may be required (Catteau et al., 
2003).  
Cryo-EM structures of mature virus particles reveal that mature M protein 
comprises two helical transmembrane domains within the mature virus particle 
membrane, which are present in a dimeric form (Section 1.9) (Sirohi et al., 
2016; Sevvana et al., 2018).  
1.4.2.4 E 
ZIKV E protein is a class II fusion protein with a unique structure of three 
ectodomains (EDI, II & III) and two transmembrane domains (TMD1 & 2) in a 
hairpin like structure (Figure 1.7). Upon virus entry via clathrin-mediated 
endocytosis (section 1.5.1), 90 envelope protein dimers transition from a 
herringbone-like formation on the virus surface, into 60 E trimers upon low pH 
conditions within endosomes. All domains of E protein are involved in this 
irreversible structural rearrangement leading to membrane fusion (Figure 1.8) 
(Dai et al., 2016; Sirohi et al., 2016). 
ZIKV has a broad tropism, mediated through a variety of receptors. The many 
different cell types include cells of the brain, placenta, skin, testis, kidneys, 
retina and immune cells. Known ZIKV receptors include: Axl receptor tyrosine 
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kinase (AXL), Tyrosine-protein kinase receptor TYRO3 (Tyro3), T-cell 
immunoglobulin and mucin domain 1 (TIM-1), Toll-like receptor 3 (TLR3), Toll-
like receptor 8 (TLR8), Melanoma-differentiation-associated gene 5 (MDA5) and 
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
(DC-SIGN) (section 1.5.1 and Table 1.1) (Meertens et al., 2017; Wang, Z.Y. et 
al., 2017; Nowakowski et al., 2016; Tabata, T. et al., 2016; Hamel et al., 2015).  
The receptor binding promotes virus attachment, followed by clathrin-mediated 
endocytosis, virion acidification and fusion of the virion membrane with the 
endosomal membrane during viral entry involving the structural rearrangement 
of E protein (section 1.5.1 and   
Figure 1.12) (Mukhopadhyay et al., 2005; Elshuber et al., 2003; Roby et al., 
2015; Saiz et al., 2016).  
E protein is translated in the endoplasmic reticulum and forms heterodimers 
with protein prM. The glycoprotein heterodimers reside within the ER membrane 
and RNA produced in the replication complexes associates with C protein and 
buds into the glycoprotein containing ER membrane. The newly formed 
immature particle is covered with 60 spikes composed of prM-E heterodimers 
(Figure 1.9). The virion is transported to the TGN where the low pH causes 
dissociation of the heterodimers and formation of E homodimers (Yu et al., 
2008). However, as previously mentioned in section 1.4.2.2, prM-E cleavage is 






Figure 1.7 E protein 
A. The E protein dimer in represented by ribbons, viewed down the two-fold 
axis. The colour code aligns with the standard labelling of E protein domains I 
(red), domain II (yellow) and domain III (blue). The stem and transmembrane 
residues are shown (pink). The fusion loop (green). B. Side view of the E-M 
dimer showing the three E ectodomains, the E stem/transmembrane domains 
(pink) and the M protein (light blue), annotated with virus membrane (grey). 






Figure 1.8 Flavivirus membrane fusion schematic 
Schematic of the Flavivirus membrane fusion process. A. Pre-fusion E dimer in a 
herringbone pattern on the virus surface. B. Low-pH-induced dissociation of E dimers 
(~pH6.6), E monomers project away from the membrane, and interact with proteins on 
target membrane. C. Trimer formation and “zippering” of the stem. D. Hemifusion 
intermediate, the outer leaflets mix. E. Formation of the post-fusion E trimer and pore 





Figure 1.9 Mature and Immature ZIKV structure  
A & B. The surface and cross-section view of mature ZIKV. C & D. Immature 
ZIKV. Both sections coloured corresponding to the adjacent key. The Black 
triangle in A & C shows the asymmetric unit. Numbered arrows in B & D 
indicate the icosahedral symmetry axes. Thick arrows in D show the difference 
in density of the RNA core and viral membrane. Double-ended arrows in D 
show the distance between the inner and outer layers of the virus membrane. 




E proteins form the outer surface of the virion, interacting with M protein forming 
heterotetramers that arrange into an icosahedral virus surface. E has two 
transmembrane domains which reside adjacent to M protein, and three 
ectodomains which are found on the virion surface (Figure 1.7) (Sirohi et al., 
2016). The tetrameric E/M protein structure is formed of Envelope and M 
protein homodimers, however these structures do not remain throughout entry 
of the virus particle. Upon virion endocytosis, the virus particles are exposed to 
a drop in pH as the endosomes mature, and the structure of the TBEV and 
DENV envelope protein has been resolved at this point. The E dimer changes 
conformation from lying on the surface to protruding away from the virion, 
additionally the E proteins change from dimeric to trimeric (Figure 1.8) 
(Bressanelli et al., 2004; Modis et al., 2004). 
1.4.3 Zika virus Non-structural proteins 
1.4.3.1 NS1 
NS1 is a highly multi-functional protein, which adopts different tertiary and 
quaternary forms, each with diverse roles. Dimeric NS1 localises intracellularly, 
particularly to the ER membrane and lumen ( 
Figure 1.10) (Akey et al., 2014). By contrast, NS1 also forms a hexamer that is 
secreted from the infected cell, primarily known for its involvement in immune 
evasion. A single mutation in NS1 during the ZIKV African to Asian evolution 
exacerbate its immune evasion capabilities through the A188V substitution 
which interacts with TBK1 reducing its phosphorylation leading to a reduction in 
IFN-β production (Xia et al., 2018). 
Dimeric NS1 found associated with membranes (mNS1) is reported to be 
involved in viral genome replication. DENV and WNV mNS1 associate and 
rearrange liposome membranes in vitro, and mNS1 along with NS4A/B play an 
essential but poorly defined role in virus replication within the ER at replication 
complexes (Akey et al., 2014; Akey et al., 2015; Welsch et al., 2009). 
Furthermore, mNS1 interacts with 60S ribosome subunits, retargeting them to 





Figure 1.10 NS1 Structures 
A. Dimeric DENV NS1 3D crystal structure shown in ribbon representation (Protein 
Data Bank accession no. 4O6B) (Akey et al., 2014). The β-roll, Wing and β-ladder 
domains are highlighted in blue, yellow and red, respectively. B. Hexameric DENV 
structure shown by surface representation, colour coded in the same manner as A. 




Dimeric NS1 also localises to the TGN and interacts with host glycosidases and 
glycosyltransferases. This results in the removal of NS1 carbohydrate moieties, 
leading to the formation of a soluble hexameric NS1 complex with an open 
barrel shaped conformation that is secreted from the infected cell (sNS1) 
(Flamand et al., 1999; Gutsche et al., 2011; Muller et al., 2012). sNS1 interacts 
with Toll-like receptor (TLR) 4, leading to activation of macrophages and 
PBMCs and increased pro-inflammatory cytokine expression. This disrupts 
endothelial cell integrity, which is linked to increased disease severity during 
DENV infection (Modhiran et al., 2015). Both dimeric and hexameric NS1 
conformations are also thought to form membrane attack complexes (MAC), 
further increasing the secretion of vasoactive cytokines resulting in deteriorating 
disease (Avirutnan et al., 2006).  
An additional form of NS1 is reported in JEV, WNV & DENV. NS1’ results from 
the presence of a slippery heptanucleotide and pseudoknot structure causing a 
–1 ribosomal frameshift near the start of the NS1 sequence during translation, 
at a frameshifting efficiency of 20-50% (Firth et al., 2010). WNV NS1’ has a 52 
amino acid extension at the C terminus (Melian et al., 2010; Firth and Atkins, 
2009). Disrupting the formation of NS1’ reduces neuroinvasiveness and NS1’ 
can substitute for NS1 function (Melian et al., 2010; Ye, Q. et al., 2012; Young 
et al., 2013). Additionally NS1’ has been found to co-localise with NS3 and NS5 
within the replication complex (Satchidanandam et al., 2006; Takamatsu et al., 
2014). 
1.4.3.2 NS2A  
NS2A is small multifunctional hydrophobic protein and predominantly resides in 
the viral replication complex playing a role in virus RNA replication and virion 
assembly. However, ZIKV NS2A has also been shown to antagonise the host 
immune response (Mackenzie et al., 1998; Chambers et al., 1989; Munoz-
Jordan et al., 2003).  
The N-terminus of NS2A is cleaved in the ER lumen by an unknown host 
protease, and the C terminus is produced by NS2B/NS3 viral protease in the 
cytoplasm (Falgout and Markoff, 1995; Chambers et al., 1990).  
Once cleaved, Flavivirus NS2A along with NS4A and NS4B provide the 
scaffolding for the replication complex in the ER (Welsch et al., 2009). Within 
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this compartment, NS2A is involved with viral RNA synthesis, binding to the 
viral RNA 3'UTR, NS3 and NS5 (Mackenzie et al., 1998; Xie et al., 2015; Wu, 
R.H. et al., 2015). The mechanism ZIKV NS2A plays in viral RNA synthesis is 
not known. However, a single A175V mutation within NS2A was shown to 
impair ZIKV RNA synthesis in vivo (Zhu, X. et al., 2019).  
A further replicative role of NS2A is assembly of ZIKV virions. NS2A has been 
shown to recruit viral RNA, C-prM-E and NS2B/NS3 to assembly sites. The 
presence of NS2B/N3 cleaves the C-prM-E polyprotein, leading to RNA 
encapsidation by C and prM/E envelopment (Zhang, X. et al., 2019). 
Additionally, NS2A is involved in modulating the interferon response initiated by 
the infected host cell as an antiviral response (Munoz-Jordan et al., 2003; Liu, 
W.J. et al., 2006). NS2A along with NS4A and NS4B inhibits the JAK/STAT 
signalling pathway in DENV by decreasing STAT1 phosphorylation through 
“prohibiting its nuclear localisation and preventing IFN-β promoter driven 
transcription from two ISREs’ (Munoz-Jordan et al., 2003). NS2A downregulates 
IFN-β promoter, through inhibiting signal activation molecules of IFN-β such as 
interferon regulatory factors (IRFs). NS2A was also shown to suppress RIG-I 
(Ngueyen et al., 2019). 
NS2A alone has inferred a role in the cause of microcephaly. ZIKV NS2A 
depletes adherens junction proteins, reducing radial glial cell proliferation and 
premature differentiation of newborn neurons (Yoon et al., 2017). 
NS2A also contributes to the generation of the aforementioned NS1’, through a 
Flavivirus-conserved slippery heptanucleotide motif found at the N terminus of 
NS2A (Melian et al., 2010).  
1.4.3.3 NS2B & NS3  
NS2B is a small protein of 242 amino acids, with a conserved central 
hydrophilic region surrounded by three hydrophobic regions, likely to be 
transmembrane domains. It has been shown the hydrophilic region of NS2B is 
an essential cofactor for the activation of the viral protease NS3 (Falgout et al., 
1991). The NS2B-NS3 protease, alongside host proteases cleaves the viral 
polypeptide into individual viral proteins at the ER. The N terminal domain of 
NS3 is a chymotrypsin-like serine protease and can cleave the polyprotein in cis 
and trans (Bera et al., 2007; Chambers et al., 1990; Li, J. et al., 2005). The 
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necessary cofactor for the protease resides in the centre of NS2B between N 
and C terminal transmembrane domains (Clum et al., 1997).  
The vital roles of NS2B-NS3 during the virus life cycle have been explored as 
targets for inhibitors. However, despite the structural and biochemical 
information known about the protein no compounds have reached clinical trials. 
There have been difficulties in finding a peptide capable of competing with RNA 
binding due to the shallow binding pocket of the protease, and its exposure to 
the surrounding (Lim et al., 2013b).  
Additionally, NS3 also has further enzymatic activity on its own, as a helicase 
(Fairman-Williams et al., 2010). NS3 has three subdomains, subdomain 1 and 2 
contain conserved motifs which have RNA binding and ATP hydrolysis activity 
(Xu, S. et al., 2019). The third subdomain forms a ssRNA binding tunnel (Tian 
et al., 2016). NS3 also has RNA 5' triphosphatase activity (RTPase) and 
triphosphatase hydrolysis is the first step for viral RNA capping (Decroly et al., 
2011). 
1.4.3.4 NS4A 
NS4A is an integral membrane protein found within the ER playing a role in 
membrane rearrangement for virus replication. NS4A is linked to NS4B by a 23 
amino acid signal peptide conserved across Flaviviruses with a molecular 
weight of 2000 Da, named 2K. NS4A and 2K are cleaved by the 
aforementioned NS2B-NS3 protease, which is required prior to cleavage of 
NS4B from 2K by a host signalase (Lin, C. et al., 1993). 
In DENV and WNV, NS4A expressed alone and NS4A-2K are able to induce 
rearrangements to the ER membrane similar to that seen in virus infected cells, 
this is thought to anchor the replication complex to the ER membrane utilising 
the NS4A TMDs (Kaufusi et al., 2014; Miller et al., 2007; Roosendaal et al., 
2006). NS4A is also reported to oligomerise at its N-terminus and bind to host 
cell protein vimentin. Vimentin binds to NS4A within the replication complexes, 
providing supportive anchorage for the replication complexes during DENV 
replication forming a scaffold as well as rearranging the ER membrane (Stern et 
al., 2013; Teo and Chu, 2014).   
However, within the Flavivirus genus there are differences in the localisation of 
these integral membrane proteins. WNV NS4A-2K induces ER membrane 
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rearrangement, whereas without the 2K peptide, NS4A localises to the Golgi 
apparatus (Roosendaal et al., 2006). By contrast, DENV-2 NS4A does not 
require peptide 2K to rearrange the ER membrane and 2K inhibits this 
rearrangement (Miller et al., 2007), suggesting the mechanisms behind this 
rearrangement are distinct between Flaviviruses.   
DENV-2 NS4A keeps infected cells alive by inducing and upregulating 
autophagy and lipophagy to aid viral replication (McLean et al., 2011; Zhang, J. 
et al., 2018). To further maintain cells as virus factories, NS4A also plays a role 
in evading the host immune response. NS4A contributes to the inhibition of 
interferon signalling and completely blocks IFN signalling when expressed 
alongside NS2A and NS4B (Munoz-Jordan et al., 2003). It has been shown 
KUNV NS4A and NS4B induce the unfolded protease response (UPR), a 
cellular stress response linked to ER stress when unfolded or misfolded 
proteins accumulate in the ER lumen. UPR is thought to inhibit JAK-STAT 
signalling when IFN-α is produced (Ambrose and Mackenzie, 2011). 
Furthermore, NS4A interacts with NS3 helicase as a cofactor allowing it to 
conserve energy to keep unwinding the viral RNA when ATP levels are low 
(Shiryaev et al., 2009). 
1.4.3.5 NS4B 
NS4B is another membrane integral protein and is the largest hydrophobic non-
structural protein, consisting of three TMDs. NS4B is translocated into the ER 
lumen by the 2K signal sequence at the N terminus, after translocation 2K is 
cleaved off by a host signalase (Miller et al., 2007). Within the ER lumen NS4B 
is likely to form dimers, as it has been shown to be capable of dimerising when 
expressed alone and also during virus infection in vitro (Zou et al., 2014).  
Similarly to NS4A, NS4B interacts with and contributes to forming the replication 
complex (Miller et al., 2006; Yi, Z. et al., 2012) and evading immune response 
through ISRE-54 and ISRE-9-27 promoter activation inhibition, therefore leading 
to decreased STAT1 phosphorylation and IFN suppression, along with NS4A 
and NS2B (Munoz-Jordan et al., 2005; Munoz-Jordan et al., 2003). The 
similarity in these functions suggests that NS4A and NS4B may function 
cooperatively (Zou et al., 2015) and were shown to directly interact in JEV (Li, 
X.D. et al., 2015). More recently, ZIKV NS4A and NS4B interactions have been 
reported to induce autophagy to benefit the virus life cycle (Liang et al., 2016). 
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Additionally, NS4B interacts with NS3 within the replication complex, 
dissociating the NS3 helicase from ssRNA enhancing helicase activity 
(Umareddy et al., 2006). 
1.4.3.6 NS5 
NS5 is responsible for viral genome replication across the Flavivirus genus. The 
N terminus of NS5 contains a methyltransferase (MT) domain, which caps the 5' 
end of the positive strand viral RNA. The virus cap aids polyprotein translation 
and helps the virus to evade the host immune response, preventing 
identification by pattern recognition receptors (Egloff et al., 2002; Ray et al., 
2006; Issur et al., 2009; Daffis et al., 2010). The MT domain is followed by a 
short linker region to the RNA-dependent RNA polymerase (RdRp) domain. The 
RdRp has two mechanisms of RNA synthesis; de novo or primer-dependent 
initiation (Ackermann and Padmanabhan, 2001; Surana et al., 2014; Lim et al., 
2013a; Xu, H.T. et al., 2017; Potisopon et al., 2017; Hercik et al., 2017). The 
activity of NS5 RdRp is affected by the highly conserved MT domain, which can 
increase RNA synthesis by altering RdRp conformation (Zhao, B. et al., 2017). 
The presence of the MT domain is essential for RNA synthesis by either de 
novo or elongation of a primed template, as shown by loss-of-function mutations 
(Potisopon et al., 2014). The functional ZIKV RdRp forms three different 
channels, to interact with the template RNA, the nascent RNA and NTPs (Fig 
1.10) (Butcher et al., 2001). 
Comparative analysis between Ugandan ZIKV strain MR766 NS5 and Brazilian 
strain PE243 NS5 has identified over 35 amino acid substitutions, yet the NS5 
RdRp activities are very similar. Upon identification of these substitutions within 
the structure, they are found on the protein surface and do not affect the RNA 
synthesis activity in the RdRp centre. The substitutions could affect other host 




Figure 1.11 ZIKV NS5 Structure  
A. Ribbon representation of ZIKV NS5 showing the arrangement of the MT and 
RdRp domains from top down and side on. B. Schematic of ZIKV NS5 protein 
showing structural motifs and key residues. Source (Zhao, B. et al., 2017).  
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1.5 Zika virus life cycle 
1.5.1 Entry 
ZIKV and other Flaviviruses are transmitted by a mosquito bite on the surface of 
the skin e.g. A. aegypti. The arboviral transmission route of a mosquito bite 
leads to skin cell and immune cell susceptibility. ZIKV particles enter the host 
cell by the envelope glycoprotein first binding multiple cellular receptors and 
adhesion factors (Table 1.1). Once engulfed into the cell by clathrin-mediated 
endocytosis the virus remains within the endosome as it matures until the virus 
fuses with the endosomal membrane. 
1.5.1.1 Receptor binding & susceptible tissues 
ZIKV infection utilises cellular receptors AXL, TIM-1 and others to infect dermal 
fibroblasts and epidermal keratinocytes, and DC-SIGN to enter dendritic cells 
and CD16+ monocytes (Hamel et al., 2015; Sun, X. et al., 2017; Persaud et al., 
2018; Foo et al., 2017; Michlmayr et al., 2017; Lum et al., 2018). ZIKV is also 
highly infectious within embryonic brains and, to a lesser extent, adult brains, 
requiring AXL & TLR3 for infection of neural progenitor cells, astroglial and 
microglial cells (Nowakowski et al., 2016; Wells et al., 2016; Wang, Z.Y. et al., 
2017; Meertens et al., 2017; Hamel et al., 2017; Stefanik et al., 2018). 
ZIKV can also be transmitted via sexual contact. The human testis is well 
established to be infectable by ZIKV, with viral RNA detectable up to 100+ days 
post infection (Eurosurveillance editorial, 2016; Paz-Bailey et al., 2018). Sertoli 
cells and spermatozoa are also known to require AXL and Tyro3 respectively to 
become infected (Ma et al., 2017; Sheng et al., 2017; Siemann et al., 2017; 
Salam and Horby, 2018; Bagasra et al., 2017).  
The most severe consequence of ZIKV infection is microcephaly of unborn 
children due to infection of neural progenitor cells (NPC), leading to restricted 
brain development (Qian et al., 2017; Li, C. et al., 2016a). Infection of NPC’s 
requires virus to pass through the placenta where ZIKV-susceptible 
trophoblasts, hofbauer and endothelial cells reside, rendering the tissue 
susceptible to virus infection via ZIKV interaction with receptors AXL, tyro3, 
TIM-1, TLR3 and TLR8 (Bayer et al., 2016; Quicke et al., 2016; Tabata, T. et 
al., 2016).  
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Additionally, other tissues have shown to be infected including the retina 
requiring AXL & tyro3 receptors (Zhao, Z. et al., 2017; Roach and Alcendor, 
2017) and kidneys, however the receptors for kidney cell infections are currently 
unknown (Alcendor, 2017). 
Primary Cell Receptor References 
Brain   
Neural progenitor cells 
(NPCs) 
AXL, TLR3 (Nowakowski et al., 
2016; Wells et al., 2016; 
Wang, Z.Y. et al., 2017) 
Astroglial cells AXL (Hamel et al., 2017; 
Stefanik et al., 2018; 
Chen, J. et al., 2018) 
Microglial cells AXL (Meertens et al., 2017) 
Placenta   
Hofbauer cells AXL, Tyro3, TIM1 (Bayer et al., 2016; 
Quicke et al., 2016; 
Tabata, T. et al., 2016) 
Trophoblasts AXL, Tyro3, TIM1, TLR3, TLR8 (Bayer et al., 2016; 
Quicke et al., 2016; 
Tabata, T. et al., 2016) 
Endothelial cells AXL, Tyro3, TIM1 (Tabata, T. et al., 2016; 
Miner et al., 2016) 
Skin   
Dermal fibroblasts AXL, TIM-1, TYRO3, TLR3, RIG-I, MDA5 (Hamel et al., 2015; 
Persaud et al., 2018) 
Epidermal keratinocytes AXL, TIM-1, TYRO3, TLR3, RIG-I, MDA5 (Hamel et al., 2015) 
Immune cells   
Immature dendritic cells DC-SIGN (Hamel et al., 2015; 
Bowen et al., 2018) 
Dendritic cells DC-SIGN (Sun, X. et al., 2017) 
CD14+ monocytes Unknown (Foo et al., 2017; Lum et 
al., 2018) 
CD14+CD16+ monocytes Unknown (Foo et al., 2017) 
Testis   
Sertoli cell AXL (Ma et al., 2017; Sheng 
et al., 2017; Siemann et 
al., 2017) 
Spermatozoa Tyro3 (Bagasra et al., 2017; 
Salam and Horby, 2018) 
Kidney   
Renal mesangial cell Unknown (Alcendor, 2017) 




Retina   
Retinal pericytes Tyro3, AXL (Zhao, Z. et al., 2017) 
Retinal microvascular 
endothelial cells 
Tyro3, AXL  




1.5.1.2 Clathrin-mediated endocytosis 
Clathrin has been reported to associate with the virus-containing vesicles for 80 
seconds during DENV entry (van der Schaar et al., 2008), and is thought to be 
a necessary part of Flaviviruses entering cells, as WNV entry into Vero cells 
was inhibited with chloropromazine, preventing clathrin-coated pit formation 
(Nawa et al., 2003). However DENV-2 can enter cells in the absence of clathrin, 
insinuating it is cell and virus-type dependent (Acosta et al., 2009). 
Following receptor engagement adaptor proteins bind to the receptors 
cytoplasmic tails, subsequently a clathrin pit then surrounds the invaginating 
membrane containing the virion, eventually encapsulating it in a clathrin-coated 
vesicle (Chu and Ng, 2004). This separates from the plasma membrane via 
dynamin-mediated scission, forming an internalised clathrin-coated vesicle 
(Cocucci et al., 2014).  
Once the virus is encapsulated, clathrin disassociates from the vesicle 
membrane (van der Schaar et al., 2008) and is transported by lymphocyte 
antigen 6 locus E (LY6E) tubules through the endocytic pathway (Hackett and 
Cherry, 2018). Five minutes post-entry of WNV and DENV the vesicles have 
matured to early endosomes (van der Schaar et al., 2008; Chu and Ng, 2004) 
which further mature to late endosomes. The endocytic compartment where 
Flavivirus membrane fusion occurs varies dependent upon the virus in question. 
1.5.1.3 Membrane Fusion  
The low-pH environment inside endosomes triggers conformational changes of 
the envelope homodimers on the virion surface (Figure 1.8 &   
Figure 1.12).     
Flavivirus envelope proteins are well known for their pre and post fusion 
conformations. Prior to fusion the low pH environment in the endosomes results 
in one or more histidine residues on E become protonated (Harrison, 2008). 
Protonation results in the homodimers disassociating into monomers on the 
virion surface, releasing the fusion peptide loop previously hidden by 
interactions with domain I and II within a hydrophobic pocket. E proteins are 
very similar across the genus and contain three domains on the surface, the 
monomeric envelope proteins protrude domain II into the outer leaflet of the 
target membrane, exposing the fusion peptide at the tip of EDII (  
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Figure 1.12) (Bressanelli et al., 2004; Modis et al., 2005; Nayak et al., 2009; 
Zhang, Y. et al., 2004). Domain II of envelope mediates interactions between 
monomers leading to unstable trimerisation, which is then stabilised by domain I 
interactions (Liao et al., 2010).  
Once E protein oligomerises into trimers and is bound to the target membrane, 
domain III folds back into a hairpin-like conformation forming a hemifusion 
intermediate where the inner leaflets remain intact and the outer leaflets interact 
with the target membrane. As the envelope protein continues to fold, the fusion 
pore forms and enlarges releasing the nucleocapsid (Bressanelli et al., 2004; 
Modis et al., 2004; Modis et al., 2005; Nayak et al., 2009). 
Uncoating of the viral nucleocapsid is one of the least-studied steps in virus life-
cycles. After virus envelope fusion with the endosome, the viral nucleocapsid 
remains intact, enters the host cell cytoplasm and must uncoat to release the 
viral genome to establish initial translation. However, the capsid protein is 
bound to the viral RNA with high affinity due to its negative charge, and forms 
oligomers. It is not known in-depth how the nucleocapsid dissociates.  
The DENV capsid protein is degraded by a ubiquitin-proteasome-dependent 
process. During virus endocytosis, inhibition of host cellular E1 ubiquitin-
activating enzyme prevents viral RNA uncoating (Byk et al., 2016). Additionally, 
inhibition of Hsp70 strongly reduces capsid stability and function, and reduced 
capsid oligomerisation, therefore suggestive of a role during virus coating and 
uncoating (Byk et al., 2016). Furthermore, Valosin-Containing Protein (VCP) 
and p97 are proposed to disassemble ubiquitylated nucleocapsids of YFV 
(Ramanathan et al., 2019). ST-148 is a novel inhibitor of DENV uncoating and 







Figure 1.12 Conformational states of the dengue virus E protein 
A. Dimeric DENV E protein structure present on the mature virion surface, viewed side 
on with the viral membrane represented in grey and the protein ectodomain in ribbons, 
with one monomer coloured coded as in previous figures, domains I, II and III in red, 
yellow and blue respectively. E stem and TM domains shown as helix-loop-helix. 
Structure based on (Zhang, W. et al., 2003). B. Trimeric DENV E protein conformation 
upon virion acidification (Schmidt et al., 2010). 
 
1.5.2 Translation  
The Flavivirus RNA genome comprises a single open reading frame (ORF), 
which is translated into a polyprotein. The N-terminus of the nascent polyprotein 
contains an ER-localisation signal that promotes rapid association of ribosomes 
translating the viral RNA within the ER membrane. The resulting translated 
polyprotein remains associated within the membrane and is then co- and post-
translationally processed by both host and viral proteases.  
Flavivirus RNA similarly to cellular mRNA contains a 5' cap enabling canonical 
translation initiation (Garcia-Blanco et al., 2016). Conversely, it does not 
possess a poly-A tail, which is required by cellular mRNA for stability and 
association with poly-(A) binding protein (PABP) to initiate translation. Although, 
viral RNA overcomes this, and DENV 3' associates with PABP through binding 
to the conserved 3’ stem-loop adjacent to the two dumb-bell structures. 
(Polacek et al., 2009). 
Additionally, DENV can also translate by cap-independent mechanisms when 
cap-dependent translation is inhibited, this is likely regulated by both 5' and 3' 
UTRs (Edgil et al., 2006). More recently, uncapped ZIKV RNA has been shown 
to initiate infection with a resulting high viral titre, suggesting the use of an 
internal ribosome entry site (IRES) to control translation. HCV and other 
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members of the Flaviviridae also use an IRES to initiate translation (Song et al., 
2019; Hercik et al., 2017). 
Furthermore, RNA stem-loop (SL) structures also modulate translation. A 
conserved 5' UTR SL structure within the capsid-coding region named capsid 
hairpin (cHP) is also involved in Flavivirus translation (Clyde and Harris, 2006; 
Li, P. et al., 2018) . Altering the structure of the cHP decreases initiation of the 
first AUG start codon, highlighting the role of cHP for correct translation initiation 
(Mazeaud et al., 2018). Moreover, other RNA structures are also involved in 
translation including two 3' UTR pseudoknots 5' Ψ and 3' Ψ (Manzano et al., 
2011); these have been identified in ZIKV, DENV, JEV and YFV  (Olsthoorn and 
Bol, 2001; Zhu, Z. et al., 2016). 
1.5.3 Polyprotein processing 
The ZIKV genome encodes fourteen functional subunits. Thus, during and after 
translation the ZIKV polyprotein needs to be processed and cleaved by viral and 
host proteases for the individual proteins to carry out their role during the virus 
life cycle. 
Viral protease NS3 and cofactor NS2B cleave seven of the 12 cleavage sites 
shown in   
Figure 1.5 (Assenberg et al., 2009). The viral protease cleaves the junctions 
between: C/Ci, pr/M, NS2A/NS2B, NS2B/NS3 (self-cleaved), NS3/NS4A, 
NS4A/2k, and NS4B/NS5. However, the host protease furin, present within the 
Golgi, is also capable of cleaving pr/M (Stadler et al., 1997). Four of the 
remaining cleavage sites Capsid/precursor, Membrane/Envelope, 
Envelope/NS1, and 2k/NS4B are presumed to be targets of one or more host 
proteases as they have high sequence conservation across the genus. The 
remaining cleavage site NS1/NS2A is also conserved across the genus, yet it is 
cleaved by an unknown protease (Sun, G. et al., 2017). It is important to 
consider that not all cleavage sites and proteases responsible have been tested 





1.5.4 Virus genome replication 
The viral RNA genome is a template for multiple functions: the formation of new 
replication complexes, production of viral proteins and packaging into new virus 
particles. 
Replication takes place in remodelled ER membranous replication factories, 
where the concentration of necessary components is increased, and a scaffold 
is constructed. Vesicle packets are linked to the cytoplasm by a 10 nm pore 
opening (Paul and Bartenschlager, 2013; Hamel et al., 2015). This pore could 
lead to release of positive stranded viral genomes to be translated for viral 
protein production and/or packaging into virus particles, also occurring in the ER 
(Cortese et al., 2017; Welsch et al., 2009). 
NS5 protein is essential for replication to take place due to its RNA-dependent 
RNA polymerase (RdRp) activity. NS5 binds to stem-loop A at the 5' of the viral 
genome to initiate synthesis (Filomatori et al., 2006). The first round of 
synthesis generates a negative stranded viral RNA intermediate, which is 
subsequently used as a template to generate multiple positive stranded viral 
genomes. This results in a higher number of positive stranded RNA molecules 
to negative stranded, in DENV this is observed to be 10 to 100 times greater 
(Guyatt et al., 2001; Cleaves et al., 1981). 
For synthesis of the viral negative strand RNA, the genome must circularise into 
a panhandle-shaped conformation via 5' and 3' UTR interactions. Circularisation 
allows NS5 to transfer for the SL A structure on the 5' UTR to the 3' SL at the 3' 
UTR (Hodge et al., 2016), allowing NS5 to polymerise multiple positive stranded 
RNA copies from the one negative stranded RNA intermediate. 
Similar to translation, RNA secondary structures play a role in RNA genome 
synthesis. Previously mentioned pseudoknots 5' Ψ and 3' Ψ additionally 
regulate replication and mutations disrupting the pseudoknots reduce viral 
genome replication (Olsthoorn and Bol, 2001; Manzano et al., 2011). 
Additionally, NS3 is known to be involved in viral replication through direct 
interactions with NS5 (Takahashi et al., 2012). The mechanism of NS3 helicase 
within genome replication is not known, however it is thought if viral replication 
involves dsRNA forming as an intermediate, NS3 helicase may be required to 
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unwind the strands, thereby allowing for nascent viral RNA to be synthesised 
(Mazeaud et al., 2018).  
1.5.5 Capping 
The majority of cellular mRNAs contain a cap structure at their 5’ end, which 
consists of a N-7 methylguanosine (m7G) moiety linked through a 5’-5’ inverted 
triphosphate bridge to the first nucleotide of the nascent mRNA. Cellular mRNA 
caps are important for splicing, transport, stability and recognition for 
translation (Banerjee, 1980; Furuichi & Shatkin, 2000; Ghosh & Lima, 2010). 
Similarly, most virus RNAs contain a similar cap, functioning to evade the host 
immune response through protecting the 5ˈ triphosphates from the innate 
immune system (Pichlmair et al., 2006). The cap also mimics cellular mRNA 
though 2’-O methylation (Daffis et al., 2010; Zust et al., 2011), in addition to 
aiding viral replication through translation enhancement mediated by N-7 
methylation (Ray et al., 2006).  
Flavivirus RNAs are capped via the same mechanism as host mRNA, involving 
RTPase, GTPase and methyltransferase (MTase). However, the process 
occurs in the cytoplasm rather than the nucleus, so viral proteins carry out 
capping. RTPase activity is retained by the NS3 C-terminal domain and NS5 
domains function as a GTPase and a MTase (Li, K. et al., 2014; Issur et al., 
2009). The process of capping involves removing a phosphate from the 5ˈ end 
of the nascent RNA, generating 5ˈ diphosphate RNA from 5ˈ triphosphate RNA 
RTPase, followed by transferring GMP moiety from GTP to the 5ˈ diphosphate 
RNA forming the core structure of the cap, finally methylation of the guanine at 
N-7 and ribose at 2ˈ-O forming a type-1 cap structure (Dong et al., 2014). 
1.5.6 Virus assembly, budding, maturation and release 
The newly synthesised RNA within replication complexes must exit and initiate 
virus assembly. Assembly begins as the viral RNA genome associates with the 
basic capsid protein, which has a high affinity to negatively charged viral RNA 
due to its acidic charge. The nucleoprotein complex must then be packaged one 
copy per virus particle, however no packaging signal has currently been 
identified (Pong et al., 2011).  
The nucleoprotein complex is then enveloped by an invagination into the ER 
membrane, which displays E and prM heterodimers on its lumenal surface, 
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anchored through their TMDs, potentially recruited by NS2A (Welsch et al., 
2009). The nucleoprotein buds through catalysed by the endosomal sorting 
complex required for transport (ESCRT) and membrane scission occurs 
(Tabata, K. et al., 2016), forming an immature virus particle (Welsch et al., 
2009; Junjhon et al., 2014). Additionally this area of the ER will display an array 
of lipids which have been recruited by viral proteins, such as NS4A, to be 
included in the virus membrane (Leier et al., 2020). The virus particles then bud 
away from the ER and enter the secretory pathway as immature virions, 
characterised by the spikey appearance of E trimers on the surface, and the 
presence of the prM precursor protein within the particle (Sirohi and Kuhn, 
2017; Tan et al., 2020; Prasad et al., 2017). 
Upon transportation through the secretory pathway the virus particles mature; 
the acidic environment in the TGN results in major conformational 
rearrangements of the spikey trimeric E into an antiparallel dimeric E 
herringbone organisation (Yu et al., 2008). This rearrangement reveals the furin 
cleavage site within prM, cleavage of which within the TGN matures the virus 
particle; the characteristic spikes are no longer present (Stadler et al., 1997; 
Sevvana et al., 2018). However, the cleaved pr peptide remains associated with 
the E protein, preventing the exposure of the E fusion loop. Once released from 
the cell, the neutral environment stabilises the E protein resulting in dissociation 
of pr from the mature particle (Yu et al., 2009). 
However, the maturation step is inefficient; ~40 % of particles are not fully 
mature and undergo varying degrees of pr cleavage, which in turn determines 
their infectivity (Dowd et al., 2014; Junjhon et al., 2008). Upon maturation, 
virions are trafficked via multivesicular bodies (MVBs) from the TGN to the cell 
surface. This section of the virus life cycle is not well studied, yet it is thought 
the majority of virions are released as individual particles (Burlaud-Gaillard et 
al., 2014). There is some evidence suggesting the virions present in the ER 
undergo repackaging into individual membrane bound vesicles (Sager et al., 
2018). Though vesicles containing virus particles have been observed enclosed 
within larger membrane bound structures too (Liu, J. et al., 2018). Once at the 
cell surface, membrane bound vesicles fuse with the cell membrane, releasing 




1.6 ZIKV model systems 
ZIKV is unable to replicate efficiently within immunocompetent mice. Commonly 
used model inbred mouse strains such as C57BL/6, CD-1 and BALB/c are not 
highly permissive hosts of ZIKV and detectable levels of viral RNA and/or 
infectious virions are very low (Lazear et al., 2016; Rossi et al., 2016). 
The resistance of mice becoming an efficient ZIKV host is likely due to the 
differences between human and mouse STAT2. In humans, the viral NS5 
protein degrades human STAT2, thereby inhibiting the type I IFN response 
(Grant et al., 2016). However, this same process does not occur in mice, as 
NS5 cannot degrade mouse STAT2, therefore the response to type I IFN is not 
interfered. 
Interferon receptor and STAT knockout mice models have been developed 
(Morrison and Diamond, 2017), however these models are not reliable for 
investigating the interactions of ZIKV with the host immune response. An 
alternative ZIKV mouse model has been developed with a knock-in human 
STAT2 replacing mouse STAT2, allowing mouse adapted ZIKV strains to 
replicate in the host and maintain the interferon responses (Gorman et al., 
2018). 
Non-human primates (NHPs) are an established animal model of disease 
pathogenesis and therapeutic research due to their relatedness to humans. 
NHPs are also thought to be part of the ZIKV sylvatic transmission cycle with 
mosquitos in the wild and are known to be permissive to the virus (Haddow et 
al., 2012). NHPs rhesus, cynomolgus, and pigtail macaques are infectable 
subcutaneously with the African MR 766 strain, or more recently adapted Asian 
ZIKV strains at doses comparable to those derived from infected mosquitos (Li, 
X.F. et al., 2016; Dudley et al., 2016). Moreover, the effect of ZIKV infection 
during pregnancy has been investigated utilising both mice and NHPs, with both 
displaying ZIKV associated pathological effects upon both the placenta and 
infected foetal brain, consistent with human disease (Mysorekar and Diamond, 
2016; Adams Waldorf et al., 2016). 
The in vivo experiment carried out herein comprised a model established by 
Marieke Pingen and Clive McKimmie. The model involves C57BL/6 mice 
injected with an anti-mouse IFNAR-1 antibody prior to virus inoculation, an 
effective Type I IFN receptor inhibitor (Lazear et al., 2016). Additionally 
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mosquito bites are included at the virus inoculation site, which is known to 
enhance virus infection (Pingen et al., 2016). 
1.7 Vaccines 
Vaccine development against ZIKV began after reports of microcephaly in 
babies of infected mothers in Brazil in late 2015. In 2017 there were forty ZIKV 
vaccines in development (Poland, 2018). The large number of vaccines 
included live-attenuated, inactivated whole viruses, peptide subunit vaccines, 
DNA and mRNA vaccines and viral vectored vaccines. The majority of these 
vaccines have been tested using non-human primates and/or 
immunosuppressed mice (Fragoso et al., 2018). 
In 2019 eight of the forty vaccines had reached Phase I studies, of which three 
are DNA vaccines and have advanced to human testing (Tebas et al., 2017; 
Gaudinski et al., 2018). Of these three vaccines one has reached phase II 
studies named ZKADNA085-00-VP, in development by VRC. ZKADNA085-00-
VP comprises of a DNA construct of full-length prM-Envelope from ZIKV strain 
H/PF/2013, with JEV stem and transmembrane regions, to enhance prM-Env 
protein expression and secretion (Dowd et al., 2016).  
As mentioned previously, due to the similarity between DENV and ZIKV, 
antibodies targeted at one virus may also recognise epitopes of the other. 
Although virus cross-reactivity could allow cross-protection, it can also cause 
antibody-mediated enhancement (ADE) of infection, which can prove fatal when 
patients are sequentially infected by different DENV serotypes. However, 
researchers designing vaccines investigate this throughout the process. 
Immunisation of mice with ZIKV E dimers resulted in dimer-specific antibodies 
protecting the host and its prospective foetus. The dimer lacks prM and contains 
a triple sulphide bond to keep the fusion loop epitope hidden, both of these 
features contribute to reducing cross-reactivity and ADE (Slon-Campos et al., 
2019). 
1.8 Antivirals and pharmacological disease management 
The current treatment for patients suffering from ZIKV involves rest, fluid and 
medication such as paracetamol to relieve symptoms. However, there is a need 
for targeted antivirals to prevent further spread of infection including across the 
placenta, and not just treatment of symptoms. 
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Direct-Acting Antivirals (DAA) directly target circulating virus particles or 
replicating virus within cells, to repress virus load to a point where the immune 
system can eliminate the virus-infected cells and prevent spread. Additionally, it 
is preferential for ZIKV antivirals to cross the blood-brain barrier due to the 
neurological symptoms associated with the ZIKV infection. Over recent years 
there have been many high-throughput screens and compound assays to help 
identify inhibitors of ZIKV infection. These have comprised potential inhibitors 
derived from small molecules and peptides, including both newly designed 
compounds and repurposed licenced/generic drugs. 
Peptide AH-D was engineered to be a brain penetrating antiviral that acts 
through disrupting the virus lipid envelope. AH-D is derived from the first 27 
amino acids of HCV NS5A, and has been shown to inhibit ZIKV infection in 
mice, and there is potential to translate this compound to other related 
enveloped viruses (Jackman et al., 2018). 
Another approach is to target host cell proteins involved in virus replication; 
abrogating infection by this method is less likely to result in resistance 
mutations. Hsp70 is thought to be required for several different stages of the 
virus life cycle and inhibiting its activity could therefore prevent virus replication. 
Additionally, use of the Hsp70 inhibitors including JG18 and JG40 in vitro have 
negligible toxic effects in human cells, although in clinical trials some Hsp 
inhibitors have shown adverse side effects (Taguwa et al., 2019; Pujhari et al., 
2019; Rajan et al., 2011). 
A popular route of antiviral identification is repurposing previously approved or 
identified compounds, due to the availability of clinical and toxicity data. Arbidol 
is a synthetic drug developed 30 years ago to target influenza A virus (IAV). 
However, Arbidol has shown potential to target viruses from a variety of 
families. Recently Arbidol was reported to have a dose dependent effect on 
ZIKV infection of both African and Asian lineages (Fink et al., 2018). The 
method by which Arbidol inhibits infection is not known, however it is thought it 
could target multiple stages of the virus lifecycle (Fink et al., 2018; 
Belokrinitskaya et al., 2012).  
A high throughput screen of almost 500 flavonoid derivatives, naturally found in 
plants and thought to have low toxicity, identified three hits which gave over 50 
% inhibition and positive cell viabilities (Lee, J.L. et al., 2019). Further screening 
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recognised that compound ST02393, known as pinocembrin, had the strongest 
inhibition and therefore was selected as the lead compound. Pinocembrin has 
previously been used for its antibacterial, anti-inflammatory, anti-fungal 
properties and cancer treatment (Rasul et al., 2013). Additionally, pinocembrin 
is reported to have neuroprotective effects, relevant due to the GBS and 
microcephaly symptoms of ZIKV. Phase I clinical trials showed pinocembrin 
given at 120 mg/day by IV is safe and tolerable in healthy adults (Lee, J.L. et 
al., 2019). However, its mechanism of action against ZIKV is not known. 
Moreover, a popular target for viruses is the polymerase through using 
nucleoside analogues/derivatives. BCX4430 (Galidesivir) and Sofosbuvir are 
both previously used analogues that additionally show activity against ZIKV. 
BCX4430 was originally derived from a HCV drug development programme, 
however it was developed as a potential treatment for Ebola and Marburg 
viruses (Filoviruses) (Julander et al., 2017). Similarly, Sofosbuvir inhibits HCV 
and was approved for a combination treatment by the FDA in April 2013 
(Ferreira et al., 2017). Other ZIKV targets, such as the methyltransferase 
activity of NS5 and NS2B/NS3 protease, have been targeted by potential small 
molecule inhibitors (Wang, L. et al., 2019) 
Since 2014 many antiviral candidates have shown to inhibit replication in vitro 
and some in vivo. The only therapeutic to have undergone clinical testing is 
monoclonal antibody Tyzivumab (ClinicalTrials.gov Identifier: NCT03443830, 
Sponsor: Tychan Pte Ltd). Thus far, no effective ZIKV antiviral has been 
licenced to date, indicating the difficulty of translating experimental results to the 
clinic (Saiz and Martin-Acebes, 2017). 
1.9 M protein as an antiviral target 
1.9.1 M protein structure and function 
Within the mature Flavivirus virion, M protein resides in the membrane forming 
heterodimers with E protein in a herringbone-like organisation forming a stable 
virus surface. Upon virus entry, the E proteins disassociate from M protein, 
forming E trimers and the M protein structure and stoichiometry is not known. 
Additionally, the role of M protein in this environment is not known.  
However, Flavivirus M protein shares characteristics with known viroporins, 
including small size and hydrophobicity. The C-terminus of DENV M was shown 
 
42 
to form a channel in vitro using lipid bilayers, with activity sensitive to 
hexamethylene amiloride (HMA), an ion channel inhibitor previously used to 
block HIV-1 Vpu viroporin activity, as well as by somewhat lower concentrations 
of amantadine, the classical inhibitor of IAV M2 proton channels (Premkumar et 
al., 2005). Accordingly, in the 1980’s it was also shown amantadine and its 
methylated derivative rimantadine were capable of suppressing DENV 
replication (Koff et al., 1981; Koff et al., 1980). Conversely, DENV M has been 
shown to be unable to form a channel when expressed in Xenopus laevis 
oocytes under acidified extracellular conditions (Wong et al., 2011). Our own 
collaborative studies (Dr Ian Tietjen, Simon Fraser University, CA) showed full 
length DENV M protein displayed channel activity within a surrogate cell culture 
model monitoring vesicular acidity using a pH-dependent fluorophore, 
“Lysotracker Red DND-99” (Invitrogen) (Wozniak et al., 2010). It was shown 
vesicular pH increased within M-transfected cells, is reversed by the addition of 
viroporin inhibitor rimantadine (unpublished, personal communication, Ian 
Tietjen, Wistar Institute, Philadelphia).  
1.10 Viroporins 
Viroporins are small hydrophobic membrane proteins encoded by numerous 
viruses, which form oligomeric channels within cellular membranes via 
hydrophobic interactions, allowing passage of ions and small molecules 
(Carrasco, 1995; Gonzalez and Carrasco, 2003; Scott and Griffin, 2015). 
Viroporin monomers are usually shorter than 120 amino acids in length, and 
play roles during various parts of the virus life cycle, namely virion 
morphogenesis and release, however others have distinct mechanisms in virus 
entry and genome replication. 
Many clinically relevant RNA and DNA viruses encode viroporins including 
hepatitis C virus (HCV) p7, Influenza A virus (IAV) M2, Human 
Immunodeficiency virus 1 (HIV-1) Vpu, Picornavirus VP4, and Human 
Papilloma virus type 16/18 (HPV) E5 (Clarke et al., 2006; Ewart et al., 1996; 
Pinto et al., 1992; Holsinger and Lamb, 1991; Sugrue and Hay, 1991; Wetherill 
et al., 2012; Danthi et al., 2003; Panjwani et al., 2014; Kalko et al., 1992). 
However, proteins encoded by other viruses also show potential to form 
viroporins, including Flavivirus M protein (Premkumar et al., 2005), Alphavirus 
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6k (Sanz et al., 1994; Melton et al., 2002) and Coronavirus (CoV) E protein 
(Wilson et al., 2004).  
Although viroporins vary in their structure and functions their simplicity often 
means they lack the same level of regulatory behaviour as cellular ion channel 
gating. Furthermore, the compact nature of virus genomes, results in functional 
redundancy making investigations into these proteins more difficult as they 
commonly have multiple functions additionally to their role as an ion channel. 
Despite their simplicity, many viroporins display weak ion selectivity and specific 
gating behaviour (Shimbo et al., 1996; Grice et al., 1997). For example, the 
well-characterised viroporin IAV M2 is a proton channel, which acidifies the 
virion interior. The M2 channel is gated via HIS37 which when neutral the 
channel is open to the external environment of the virus but closed to the 
interior of the virus. Upon diffusion of protons into the channel it becomes open 
to the virus interior, however closed to the external environment. Indicating a 
transporter-like mechanism which alternates between the two conformations 
(Figure 1.13)(Okada et al., 2001; Khurana et al., 2009).  
Ion channels are known to be highly effective drug targets. For example, 
Amlodipine, a calcium channel blocker, is used to treat hypertension and 
Zolpidem, a GABAA receptor antagonist, is used to treat insomnia. Therefore, 
channels encoded by viruses could also be an ideal drug target, to stop viral 
replication and prevent viral infection spreading. M2 was the first viroporin to be 
targeted by a licensed adamantyl drug, amantadine, in the 1960s (Baker et al., 
1969; Davies et al., 1964; Sabin, 1967; Togo et al., 1968; Wingfield et al., 
1969). However, the mode of action for amantadine was unknown until the 
1980s (Hay et al., 1985). Amantadine and amino-adamantane derivatives 
including rimantadine not only target M2, they can also inhibit HCV p7, E5 and 
CoV E and other viroporins, and have shown activity against dengue virus 
replication (Griffin, S.D. et al., 2003; Torres et al., 2007; Lin, C.C. and Chen, 
2016; Wetherill et al., 2012). However, amantadine and Rimantadine are no 
longer used to treat IAV due to mutations arising within the M2 sequence, 
rendering them unusable. Due to the failings of amantadine in the treatment of 





Figure 1.13 IAV M2 as a proton transporter 
Schematic of transporter-like mechanism of proton conductance through the IAV M2 
channel. M2-TM exists in two conformations. At high pH the VAL27 region opens while 
the HIS37 region narrows, and the opposite is found at low pH  (Khurana et al., 2009). 
 
1.10.1 Influenza A Virus (IAV) M2 
IAV encodes M2 a short transmembrane protein of 97 amino acids. M2 is a 
well-characterised viroporin oligomerising into a tetrameric proton selective 
channel (Lamb et al., 1985; Sugrue and Hay, 1991; Hay et al., 1985). M2 
comprises three domains, the N-terminal domain, a signal anchor TMD and a 
cytoplasmic domain, each playing roles during the virus life cycle.  The M2 
ectodomain is necessary for incorporation of M2 into virions (Park et al., 1998). 
The TMD mediates oligomerisation of four M2 monomers into a proton-selective 
homotetrameric ion channel (Duff and Ashley, 1992), driven by stabilising 
disulphide bridges and non-covalent bonds (Holsinger and Lamb, 1991; 
Castrucci et al., 1997). Lastly, the cytoplasmic tail is reported to be involved in 
genome packaging, virus budding, membrane scission and undergoes acylation 
and phosphorylation post-transcriptional modifications of three serine residues 
(McCown and Pekosz, 2005; Holsinger et al., 1995; Rossman and Lamb, 2013). 
In the life cycle of certain strains of IAV, the M2 homotetramer is responsible for 
modulating pH in the TGN during transport of the HA to the cell surface for 
virion assembly. IAV virions have two major surface glycoproteins 
hemagglutinin (HA) and neuraminidase (NA). HA is required to bind sialic acid 
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on the target cell, however if exposed to a low pH HA undergoes conformational 
changes preventing this binding, hence M2 must prevent pH lowering to 
maintain HA conformation (Cross et al., 2001; Ciampor et al., 1992; Grambas 
and Hay, 1992). Secondly, the M2 homotetramer present in the virion is 
involved in IAV entry, allowing protons into the virion interior leading to 
uncoating and dissociating viral ribonucleoproteins (RNPs) from M1 protein 
(Pinto et al., 1992; Zoueva et al., 2002; Helenius, 1992) 
Additionally M2 has minor roles during the life cycle including stabilising virus 
budding on the cell surface and alters the membrane curvature (Rossman et al., 
2010). The C-terminal of M2 contains a highly conserved region of 54 amino 
acids which had little impact on the M2 proton channel activity (Tobler et al., 
1999). It is reported this C-terminal region is vital for vRNPs being incorporated 
into budding particles (McCown and Pekosz, 2006; Grantham et al., 2010). 
The pore lining residues of the M2 homotetramer channel were investigated 
using cys scanning and oxidative disulphide cross-linking which showed 
SER22, SER23, VAL27, ALA30, SER31, GLY34, HIS37 and TRP41 lining the 
pore (Pinto et al., 1997; Bauer et al., 1999; Shuck et al., 2000). VAL27 and 
HIS37 both cause restrictions in the channel lumen, however HIS37 is a pH 
sensor, becoming protonated in an acidified environment and TRP41 acts as 
the gate (Stouffer et al., 2008; Wang, C. et al., 1995).  
Early studies investigating the channel activity of M2 involved patch clamping 
Xenopus laevis oocytes confirming M2 channel activity and its sensitivity to 
amantadine (Pinto et al., 1992). Additionally, TMD M2 peptides showed proton 
selective channel activity in vitro using planar lipid bilayers (Duff & Ashley, 
1992). Further studies identified acidic pH activation focussing on the conserved 
HIS37 residue (Shimbo et al., 1996; Wang, C. et al., 1993; Wang, C. et al., 
1994; Wang, C. et al., 1995). 
Structural information has been used to investigate the potential of alternative 
antiviral compounds targeting S31N, identifying compounds to be taken forward 
to in vivo testing (Drakopoulos et al., 2018; Li, F. et al., 2017; Li, F. et al., 
2016a; Li, F. et al., 2016b; Musharrafieh et al., 2019; Thomaston and DeGrado, 
2016; Wang, J. et al., 2013; Wang, Y. et al., 2018; Wu, Y. et al., 2014; Scott et 
al., 2020). There are over twenty M2 structures available, however all of these 
are of truncated proteins, either derived from the transmembrane region or C-
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terminally extended conductance domain peptides due to their role in channel 
formation. However TM and conductance domain (CD) amantadine binding 
varies from structure to structure (Schnell and Chou, 2008; Stouffer et al., 
2008). Structures of the TM region report a single amantadine molecule 
occluding the lumen, conversely too CD structures showing four rimantadine 
molecules binding to the channel periphery. This binding controversy has not 
been resolved due to a lack of comparative studies (Andreas et al., 2010; Cady, 
S. et al., 2011; Cady et al., 2010; Cady, S.D. et al., 2011; Du et al., 2009; Hu et 
al., 2011; Kozakov et al., 2010; Ohigashi et al., 2009; Pielak et al., 2011; Pielak 
et al., 2009; Rosenberg and Casarotto, 2010). 
1.10.2 Hepatitis C Virus (HCV) p7 
HCV p7 is a small hydrophobic protein of 63 amino acids, predicted to have two 
TMDs separated by a short cytosolic loop consisting of conserved basic 
residues (Carrere-Kremer et al., 2002). HCV p7 was discovered during 
characterisation of HCV polyprotein cleavage, which revealed the cleavage of 
E2-p7-NS2 and E2-p7 are inefficient processes (Lin, C. et al., 1994; Mizushima 
et al., 1994; Carrere-Kremer et al., 2004). 
HCV p7 is predominantly found in the endoplasmic reticulum membrane (Lin, C. 
et al., 1994; Griffin, S. et al., 2005; Bentham et al., 2013). Monomeric p7 is 
reported to form a hairpin structure in membranes (Montserret et al., 2010; 
Foster et al., 2014; Luik et al., 2009), although this has been debated (OuYang 
et al., 2013). Two monomeric NMR structures have been published (PDB 2MTS 
and 3ZD0) (Foster et al., 2014; Cook et al., 2013). However, there are 
variations potentially due to varying pH (PDB 2MTS, pH 4.0 and PDB 3ZD0, pH 
7.0) and varying conditions (detergent or Methanol).  Monomeric p7 
oligomerises into both hexameric and heptameric higher order structures 
(Clarke et al., 2006; Griffin, S.D. et al., 2003; Luik et al., 2009). p7 has been 
shown to exhibit channel activity in various in vitro assays including: Black lipid 
membranes (Premkumar et al., 2004; Griffin, S.D. et al., 2003; Pavlovic et al., 
2003; Saint et al., 2009; Whitfield et al., 2011; Clarke et al., 2006), patch-
clamping (Breitinger et al., 2016; OuYang et al., 2013) and liposome-based 
assays (Antoine et al., 2007; Madan et al., 2007; Montserret et al., 2010; 
StGelais et al., 2007). 
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To further investigate the structure of oligomeric p7, molecular dynamic 
techniques were used to construct an in silico heptameric channel  model 
(Foster et al., 2014). Conversely two hexameric structures have been 
published, firstly an electron microscopy structure of genotype 2a p7 with similar 
monomeric conformations to previous structures (Luik et al., 2009), secondly an 
NMR structure of genotype 5a (PDB 2M6X). However the structure of the 
monomers in 2M6X differ (OuYang et al., 2013). PDB 2M6X monomers have a 
staple-like conformation, whereas all other monomers exhibit hairpin like 
conformations. This dissimilarity could be due to the varying genotypes, 
however this structure has been queried due to potential artefacts from alkyl-
phosphocholine detergents (Oestringer et al., 2018), disputed by the authors 
(Chen, W. et al., 2018). 
Previous NMR studies using synthetic peptides determined the secondary 
structure elements and along with molecular dynamic simulations identified the 
pore lining helix and residues (Montserret et al., 2010; Chew et al., 2009). 
Similarly to M2, acidic pH enhances activity of some p7 proteins, which is 
hypothesised to be due to HIS17 protonation. However, for M2 this protonation 
leads to a conformational change in gating residue TRP41, whereas protonation 
of p7 HIS17 is reported to cause protomers to rotate. This protonation 
mechanism aligns with data suggesting p7 is stimulated by lower pH and can 
conduct protons (StGelais et al., 2007; Wozniak et al., 2010). However, HIS17 
are not well conserved between p7 proteins. Consequently, HCV genotypes 
respond to pH with varying levels of sensitivity (Atkins et al., 2014; Li, H. et al., 
2012). Mutation of HIS17 had little effect on HCV virion production of genotype 
2a isolate JFH-1 (StGelais et al., 2009). Additionally PHE25 is hypothesised to 
act as a gate of heptameric p7 channels, mutation resulted in a hyperactive 
channel in liposome assays (Foster et al., 2011). 
The HCV p7 channel is selective for positively charged ions in vitro (Griffin, S.D. 
et al., 2003; Premkumar et al., 2004; Pavlovic et al., 2003) and proton channel 
activity is seen within HCV infected cells (Wozniak et al., 2010). Thus, p7 can 
be substituted by IAV M2 in a cell-based assay transporting aforementioned pH 
sensitive HA (Griffin, S.D. et al., 2004). Additionally viral genomes containing 
mutant p7 cannot support infectious virus production, however can be restored 
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by trans-complementing with IAV M2 (Wozniak et al., 2010; Bentham et al., 
2013).  
Although p7 is not essential for viral replication, it is critical for efficient egress of 
virus particles, leading to identification as a HCV drug target (Steinmann et al., 
2007a; Yi, M. et al., 2007; Jones et al., 2007). Previously studied M2 inhibitors 
such as adamantanes and imino sugars can block some p7 genotypes channel 
function and virion production in cell culture (Griffin, S. et al., 2008; Steinmann 
et al., 2007b) however resistance mutations to rimantadine and imino sugars 
have been identified (Foster et al., 2011; Mihm et al., 2006).  
pH maturation happens at a late stage in HCV particle production either before 
or during particle release, directly influenced by p7 (Atkins et al., 2014; Wozniak 
et al., 2010). The majority of HCV particles reside in the ER at neutral pH 
(Gastaminza et al., 2008), p7 may play a role controlling and restricting 
secretion of the HCV particle, by increasing the pH of the secretory pathway. 
However, HCV cell-cell spread is less sensitive to p7 inhibitors (Meredith et al., 
2013) suggesting the pathway is less dependent upon channel activity 
(genotype dependent). 
Additionally p7 is suggested to have channel activity during the virus entry stage 
of the virus life cycle due to improved hepatocyte uptake of p7 containing HCV 
like-particles (Saunier et al., 2003) and infectious HCV was inhibited by p7 
channel inhibitors during entry (Griffin, S. et al., 2008), however p7 has not 
been detected in infectious particles (Vieyres et al., 2013; Catanese et al., 
2013).  
Furthermore, p7 interacts with both non-structural protein 2 (NS2) and NS5A 
and P7-NS5A co-localisation is required for virus assembly. Targeted mutations 
of p7, NS2 and E2 has suggested they contain signals, which act synergistically 
to direct NS2 towards an interaction with NS5A positive membrane lipid droplets 
(Jirasko et al., 2008; Jirasko et al., 2010; Boson et al., 2011). 
1.10.3 Human immunodeficiency Virus type-1 (HIV-1) Vpu 
HIV-1 Vpu protein is 81 amino acids long and contains three domains, a short 
endoplasmic domain and a TMD followed by a longer cytoplasmic domain. 
Unlike some other viroporins, Vpu is not found within HIV-1 virions and is 
translated late in the viral replication cycle along with Env from the same mRNA 
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(Cohen et al., 1988; Strebel et al., 1988). Vpu exhibits multiple roles including 
inducing CD4 degradation, preventing detection by the immune system (Willey 
et al., 1992a; Willey et al., 1992b), antagonising tetherin, promoting virion 
budding from the cell surface (Neil et al., 2008) and ability to form a viroporin 
(Schubert et al., 1996; Ewart et al., 1996) 
Vpu has shown channel activity when present in Xenopus oocytes (Schubert et 
al., 1996), planar lipid bilayers permeable to sodium and potassium ions and 
sodium-permeable E.coli membranes (Ewart et al., 1996).   
Inhibition studies of Vpu channels have reported amiloride derivatives can 
successfully inhibit Vpu peptide channels in vitro,  and inhibit budding of HIV-1 
VLP in cell culture (Ewart et al., 2002). Mutagenesis studies show an Ala18His 
substitution generates an amantadine-sensitive HIV-1, further supporting its role 
as a channel protein (Hout et al., 2006). The mechanism behind this sensitivity 
is the formation of a HxxxW tetrad in the Vpu sequence, which is present in the 
IAV M2 sequence (Sharma et al., 2011).  
Conversely Vpu is proposed to not exhibit channel activity itself, but by 
interfering with cellular channel Twik-related acid sensitive K+ (TASK) channel 
TMDs (Coady et al., 1998). Vpu is suggested to degrade the aforementioned 
channels, therefore preventing the flow of potassium ions (Hsu et al., 2004).  
1.10.4 Human Respiratory Syncytial Virus (hRSV) SH 
The SH protein encoded by hRSV is a small hydrophobic protein of 64-65 
amino acids predicted to have only one TMD and form higher order oligomeric 
channels (Gan et al., 2012; Perez et al., 1997; Carter et al., 2010). SH protein 
forms part of the virion, although in cell culture deletant viruses have shown 
RSV can replicate without SH. However, levels of IL-1B significantly increased 
suggesting a role of SH in immune evasion similarly to other viroporins (Russell 
et al., 2015). In vivo studies have shown using chimpanzees and small animals 
hRSV can replicate in the absence of SH, however leading to 40 and 10-fold 
lower virus titres respectively (Bukreyev et al., 1997; Jin et al., 2000; Whitehead 
et al., 1999). SH is therefore an important virulence factor. Furthermore, SH is 
thought to have roles in preventing infected cell death by preventing TNF-α 
signalling which leads to apoptosis (Fuentes et al., 2007). 
 
50 
SH has been shown to form pentameric and hexameric complexes with a 
predicted single TMD. Sedimenting SH protein using sucrose gradients, cross-
linking SH and using PFO-PAGE have all shown SH in a pentameric 
conformation (Collins and Mottet, 1993; Gan et al., 2008). Additionally using 
electron microscopy SH showed both five-fold and six-fold symmetry suggestive 
of pentameric and hexameric pores formed in detergent (Carter et al., 2010). 
SH channel activity has been shown in liposome-based assays used to study 
activity of many viroporins (Carter et al., 2010), as well as bacterial membrane 
permeability assays (Perez et al., 1997). Surprisingly, cation selectivity in vitro 
and cation transport is reduced when pH drops, conversely to the reaction of 
other viroporins including M2 (Carter et al., 2010; Gan et al., 2012). However 
deletion of conserved gating residues HIS22 and HIS51 results in non-
functional SH by patch clamping (Gan et al., 2012). Additionally, residues ARG 
59 and 61 in the C-terminal domain potentially play a role stabilising the 
oligomeric channel through protein-membrane interactions. 
Inhibition of SH has been reported using Pyronin B, which was identified using 
liposome-based assays. Upon further testing in cell culture the 250 nM of 
Pyronin B prevented RSV infection of Vero cells, however there have been no 
reports of other inhibitors since (Li, Y. et al., 2014) 
1.10.5 Human Papillomavirus type 16 (HPV-16) E5 
HPV’s are small dsDNA viruses and a subgroup of these including HPV-16 and 
18 are known to be oncogenic.  HPV-16 E5 is an 83 amino acid protein and is 
highly hydrophobic (Halbert and Galloway, 1988). E5 monomers consist of 
three TMDs and are known to oligomerise (Gieswein et al., 2003), however the 
only published structure model was constructed in silico and there is no 
confirmed structure of the monomer or oligomer (Wetherill et al., 2012). 
Moreover, expression of recombinant E5 formed an oligomeric species in a 
membrane-like environment, thought to be hexameric and showed channel 
activity of a defined lumen diameter (Wetherill et al., 2012). 
Additionally, E5 exhibited further viroporin characteristics. Channel activity was 
enhanced at lower pH when recombinant protein was expressed in a liposome-
based channel activity assay (Wetherill et al., 2012). Similarly channel activity 
was inhibited by the presence of rimantadine (Wetherill et al., 2012). 
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Furthermore, the in silico oligomeric model led to drug screening which 
highlighted compound MV006 as a potential compound. MV006 was found to 
inhibit E5 in the liposome based assay and reduced the E5-mediated EGFR 
signalling effects in cell culture (Wetherill et al., 2012; Suprynowicz et al., 2010; 
Pim et al., 1992). This implies that MV006 targets E5 oncogenic function. More 
recently further oncogenic properties of E5 channel activity within the HPV life 
cycle have been determined, increased ERK-MAPK activation and cyclin B1 
expression (Wetherill et al., 2018). 
1.10.6 Enterovirus VP4 
VP4 protein along with VP1, VP2 and VP3 comprise the icosahedral virus 
capsid. VP4 is found internally, however the capsid is dynamic and ‘breathes’, 
exposing internal components of the capsid on the surface of the non-
enveloped virus. During this process the N-terminus of VP4 is transiently 
present at the surface (Lin, J. et al., 2012; Li, Q. et al., 1994). Upon virus entry 
into the host cell VP4 is irreversibly externalised triggered by receptor binding or 
endosomal acidification (Tuthill et al., 2010). Localisation of VP4 on the virus 
surface has been shown to interact with cellular membranes, leading to viral 
RNA release (Davis et al., 2008; Fricks and Hogle, 1990; Panjwani et al., 2014; 
Strauss et al., 2013; Tuthill et al., 2006). However, VP4 does not arbitrarily 
disrupt membranes, it has been shown to induce discreet channel formation in 
vitro (Danthi et al., 2003). Similarly to many other viroporins, recombinant VP4 
protein also displays activity in liposome dye-release assays (Davis et al., 
2008). Furthermore, pentameric and hexameric complexes have been observed 
in DHPC and liposome membranes, and activity enhanced by reduced pH and 
myristoylation, consistent with the environment during virus endocytosis 
(Panjwani et al., 2014). VP4 N-terminus can form multimeric structures in a lipid 
bilayer (Panjwani et al., 2016), however VP1 is also thought to be involved in 
the release of viral genome into the host cell, forming an ‘umbilicus’, linking the 
virus particle to the membrane (Strauss et al., 2013). VP4 is thought to be 
suitable antiviral target for enteroviruses and the wider picornavirus family. Anti-
VP4 antibodies have shown to neutralise the virus in addition to antiviral 
compound WIN 52084, thought to lock VP4 inside the capsid, preventing virus 





We hypothesise that ZIKV M protein (as well as M from other Flaviviruses) is 
able to form an ion channel within the acid-exposed mature virion that serves to 
promote virion uncoating during virus entry. This activity should be sensitive to 
inhibition using small molecules, providing not only an opportunity to target this 
process for therapy but also tools with which to further examine M protein 
function.  
Our approach combines medicinal chemistry, molecular dynamics and structure 
modelling with molecular virology and techniques for examining ion channel 
activity. First using computer modelling to assess the potential structure of a 
channel and its response to altered pH, followed by in vitro laboratory work 
investigating the oligomerisation of M through cryo-EM, and its role during the 
virus life cycle in cell culture and its potential as a drug target in vitro. 
1. Use Molecular Dynamics to understand the potential formation of 
an M protein viroporin 
2. To investigate whether M forms channels in vitro, in cell culture, 
and their potential function during the virus life cycle 
3. To identify M protein inhibitors utilising a Molecular Dynamic 




Chapter 2 Materials and Methods 
Vero and baby hamster kidney (BHK-21) cells were kindly provided by Dr 
Victoria Jennings and Dr Clive McKimmie, respectively. Both were originally 
sourced from ATCC and checked regularly for mycoplasma infection. 
2.1.1 Zika Virus 
ZIKV/H. sapiens/Brazil/PE243/2015 (PE243) Zika virus was kindly provided by 
Prof Alain Kohl, MRC Centre for Virus Research and University of Glasgow as a 
frozen viral stock derived from C6/36 cells at 6 x106 PFU/mL. A new stock was 
generated in house at 1.6 x10^6 PFU/mL (section 2.3.1). 
2.2 Mammalian Cell Culture 
2.2.1 Recovery of frozen cells 
Vero and BHK-21 cells were taken from liquid nitrogen and quickly thawed in a 
water bath at 37 °C. Cells were then diluted in 10 mL cell culture media 
(Appendix A.1 and A.2) in a 15 mL falcon tube. Cells were centrifuged at 1500 x 
g for 5 min at RT, separating the cells from the freezing media (Appendix). Cells 
were resuspended in 10 mL of cell culture media, prior to transferring to a T75 
tissue culture flask (Corning). Cells were cultured at 37 °C in 5 % CO2. 
2.2.2 Maintenance and Passage of Cells 
Vero and BHK-21 cells were cultured in complete Dulbecco’s modified essential 
cell culture media (Appendix A.1 and A.2) at 37 °C in 5 % CO2 in a humidified 
culture incubator. Every 2-3 days cells were passaged by washing in phosphate 
buffered saline (PBS) (Sigma), followed by incubation with trypsin (Sigma) to 
detach cells from the flask surface for 2-5 min at RT. Trypsin was then 
inactivated using an equal volume of serum-containing complete cell culture 
media. Vero and BHK-21 cells were sub-divided using ratios between 1:5 and 
1:10. 
2.2.3 Freezing cells 
Vero & BHK-21 cells were centrifuged at 1500 x g for 5 min. The cell pellet was 
resuspended in freezing media (Appendix A.3) at a density of 1x10^6 cells/mL. 
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Cells were frozen slowly, wrapped in tissue and placed in polystyrene box at -80 
°C, after 24 hr cells were transferred to liquid nitrogen for long-term storage. 
2.2.4 MTT Assay 
Vero cells were seeded at 3x103 cells/well into 96 well plates and left to adhere 
overnight. Cells were incubated with increasing concentrations of compounds 
(0-220 µM), or a DMSO solvent control, for 24 hr. Following incubation 20 µL of 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 5 mg/mL 
was added to each well and incubated at 37 °C for 4 hr. Post-incubation the 
MTT & media was removed from the wells, washed with PBS twice and 150 µL 
DMSO was added and shaken for 10 min at RT. The OD550 absorbance was 
measured using a plate reader (Multiskan Ex, Thermo Scientific). Data was 
normalised to the appropriate DMSO solvent control. 
2.2.5 EGF Uptake Assay 
Vero cells were seeded at 1x106 per well in 6-well plates (Corning). After 4 hr 
Rimantadine was added to the cell culture media (Appendix A.1) and incubated 
overnight at 37 °C and 5 % CO2. Cells were then washed and treated with 
Epidermal growth factor complexed with Alexa Fluor™ 488 (ThermoFischer) for 
20 min. Fluorescence was quantified using flow cytometry, using the 488 laser 
and FITC channel (Cytoflex S), FITC positive cells were calculated as a 
percentage of total cells.  
2.2.6 Immunofluorescence 
Cells were plated onto sterile glass cover slips in a 12 well plate or directly in to 
a 96-well plate and cultured under normal cell culture conditions for 4 hr. Cells 
were infected with ZIKV for 1 hr, after which virus containing supernatant was 
replaced with fresh media. Cells were fixed with 4 % v/v paraformaldehyde for 
10 min and permeabilised using 0.1 % v/v Triton X-100 in PBS. Cells were 
washed with PBS and probed for Zika Envelope protein (1:500, mouse 
monoclonal, Aalto Bio Reagents #AZ1176), prM/M protein (1:200, rabbit 
polyclonal, Genetex #GTX133305), NS3 (1:500, rabbit polyclonal, Andres 
Merits) and NS5 (1:500, rabbit polyclonal, Andres Merits) in 10 % v/v FCS in 
PBS overnight at 4 °C. Cells were washed with PBS three times prior to adding 
the secondary Alexa Fluor-labelled antibody (Invitrogen) in 10 % v/v FCS in 
PBS. Cells were incubated in the secondary antibody for one hr at RT.  
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ProLong Gold (ThermoFisher) was placed on microscope slides and the 
coverslips mounted on top facing the solution. The edges of the coverslip were 
sealed using transparent nail varnish. Cells in 96 well plates were stored in 
PBS.  Stained cells on coverslips were viewed on an Eclipse Ti-E widefield 
microscope (Nikon) at 40x magnification. Cells in 96 well plates were imaged 
and quantified using an IncuCyte Zoom (Essen Bioscience) microscope using 
10x objective. Four images per well were taken to calculate the number of total 
cells and infected cells per well. Parameters for optimal detection of cells and 
fluorescent cells were setup using an image collection of positive and negative 
control wells allowing for alteration of the processing definition (Stewart et al., 
2015). 
2.3 Virus production and storage 
2.3.1 Virus stock propagation 
Vero cells were seeded at 4-6x106 per T75 flask and left to adhere for over 4 hr. 
Cells were washed once in PBS, prior to addition of PE243 virus in complete 
DMEM media + 10mM HEPES (Gibco), at a multiplicity of infection (MOI) of 
0.001 PFU/cell. After infection for 1 hr at 37 °C, 5 % CO2, media was replaced 
with fresh complete DMEM. Once cytopathic effect (CPE) was observed for 
~60% of the cells, virus containing media was clarified and stored 
2.3.2 Freezing virus 
Virus-containing supernatants were clarified by centrifugation (3184 x g, 20 min, 
4 °C) in an Eppendorf 5810 R centrifuge, supernatants were transferred to 0.5 
mL eppendorf tubes, and 1.0 mL cryovial tubes. Virus was snap frozen using 
liquid nitrogen. Once frozen virus was either kept at -80 °C for shorter term 
storage or liquid nitrogen for long term storage. 
2.3.3 Determination of Virus Titre 
For quantification of virus titre, both plaque assays and focus forming assays 
were performed. For plaque assays both Vero and BHK-21 cells were used at a 
confluency of 80 % in a 12-well plate with 10-fold virus serial dilutions in 0.75 % 
PBSA (PBS containing 0.75 % bovine serum albumin). 200 µL of serial dilutions 
was added to each well for 1 hr with rocking every 15 min. After 1 hr 2 mL 
overlay media of 2X MEM medium (Gibco) containing 4 % FCS (Gibco), 200 
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units/mL penicillin and 0.2 mg/ mL streptomycin, mixed with viscous 1.2 % 
Avicell (FMC Biopolymer). Vero and BHK-21 cells were incubated for 5 and 3 
days respectively at 5 % CO2 and 37 °C. After incubation, supernatant was 
removed and cells were fixed in 10 % PFA for one hr at 4 °C prior to staining 
with 0.1 % Toludine Blue (Sigma) for 30 min. Virus PFU titre was calculated 




average number of plaques
amount of inoculum x dilution factor
 
 
2.3.4 Virus assays 
2.3.4.1 Focus Forming assay 
Vero cells were seeded at 2000 cells per well in a 96 wells cell culture dish 
(Greiner Bio-one), after 4 hr cells were incubated with virus at an MOI of 1 
PFU/cell for one hour. Following a 1 hr infection, virus containing media was 
removed, cells were washed with PBS and replaced with fresh cell culture 
media (Appendix A.1). Cells were incubated at 37 °C and 5 % CO2 for 48 hr.  
Cells were fixed using 4 % PFA for 10 min at RT and permeabilised with 0.1 % 
Triton X-100.  For quantification, cells were stained using a primary ZIKV E 
antibody and a secondary AlexaFluor 488 anti-mouse antibody (section 2.2.6). 
IncuCyte Zoom was used to quantify infected cells. 
2.3.4.2 Plaque reduction assay 
Effectivity of compounds against ZIKV infection was determined using plaque 
assays (section 2.3.3). The number of plaques was compared between 
duplicate compound treated cells and DMSO negative control treated cells. 
Cells were incubated with the compound throughout the assay, or for 
combinations of the experiment as described in time of addition assays (section 
4.5.3).  
2.4 Preclinical in vivo models of ZIKV replication 
In vivo experiments, up to the point of sacrifice, were kindly carried out by 
Daniella Lefteri and Clive McKimmie (Leeds). Mice were dosed with 1.5 mg 
InVivoMAb anti-mouse IFNAR-1, a day prior to virus inoculation. The mice were 
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then anaesthetized using 0.1mL/10g of Sedator/Ketavet via intraperitoneal (I.P.) 
injection. Once anesthetized the mice were placed on top of mosquito cages 
using foil to expose only the dorsal side of one hind foot to the mosquitos. No 
more than 5 mosquitoes were allowed to feed on each mouse. 2000 PFU of 
C6/36 derived ZIKV was injected directly to the bite site using a 5 µL 75N 
syringe, 26ga (Hamilton) using small RN ga33/25mm needles (Hamilton). 
Mice were observed 4 times throughout the 24-hr experiment and weighed 
once. Mice were culled 24 hr post infection. Skin from the bitten foot and the 
spleen were dissected and placed in 0.5mL RNAlater (Sigma Aldrich, USA) in 
1.5mL tubes. I then took over the experiment and stored the tissues in RNAlater 
at 4 °C for a minimum of 16 hr preventing RNA degradation. Blood samples 
were also collected from the ventricles and centrifuged to isolate serum which 
was stored at -80 °C until used. 
2.5 Protein Biochemistry  
2.5.1 Western blot  
To analyse cellular protein levels, lysates were made using an appropriate 
volume of Enriched Broth Culture(EBC) lysis buffer (Appendix A.4). To lyse the 
cells growth media was removed, and cells were washed three times using 
PBS. After washing, cells were scraped off into PBS and the cells were pelleted 
by centrifugation at 2000 x g then resuspended in EBC lysis buffer (Appendix 
A.4) and kept on ice for 20 min. Lysates were normalised for protein 
concentration using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). 
Then diluted with an equal volume of 2x Laemmli Buffer (Appendix A.5). 
Lysates were denatured by heating for 5 to 10 min at 95 0C. Lysates were 
normalised for concentration and run on hand-cast Tris-Glycine polyacrylamide 
gels with 5-15 µL of lysate per well; the polyacrylamide percentage of the gel 
depended on the protein of interest, either 8, 10, 12 or 15 %. Proteins were 
resolved by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis) at 120-160 V for 1-2 hr using Tris glycine running buffer 
(Appendix A.6). 
Proteins were transferred from the polyacrylamide gels to PVDF (Polyvinylide 
fluoride- Immunoblot-FL Merck Millipore) membrane by semi-dry blot transfer 
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(Hoefer). PVDF membrane was activated with methanol for 30 s and placed 
along with the gel between thick blotting paper soaked in Towbin buffer 
(Appendix A.7). Transfer of proteins was performed at a constant current of 
120-240 mA for 1-2 hr depending on the number of gels and the molecular 
weight of the protein of interest. Membranes were blocked for non-specific 
binding using 5 % w/v fat-free milk in TBS-T (Tris buffered saline (Appendix A.9) 
with 0.1 % v/v Tween 20, Sigma-Aldrich) for 1 hr at RT. Membranes were 
probed with primary antibody for protein of interest (Zika Envelope protein 
(1:10000, mouse monoclonal, Aalto Bio Reagents #AZ1176), prM/M protein 
(1:5000, rabbit polyclonal, Genetex #GTX133305), NS3 (1:10000, rabbit 
polyclonal, Andres Merits) and NS5 (1:10000, rabbit polyclonal, Andres Merits)  
in either 5 % w/v fat-free milk in TBS-T or 5 % w/v BSA (Bovine Serum 
Antibody, Fisher Scientific) in TBS-T shaking at 4 °C overnight. Secondary 
antibodies (Goat anti-mouse IgG-Horseradish peroxidase (HRP) conjugate, 
#A4416, Sigma and Goat anti-rabbit IgG-HRP, #A6154, Sigma) were diluted 
1:5000 in either 5 % fat-free milk in TBS-T or 5 % BSA in TBS-T were incubated 
with the membranes shaking at RT for 1-2 hr. Membranes were washed for 3 x 
10 min in TBS-T, with shaking, between each step. Immunoblots were 
visualised using either prepared Enhanced ChemiLuminescence (ECL) 
substrate solution (A.9) or ECL prime western blotting detection reagent (GE 
Healthcare Life Sciences) on X-ray film using a Medical fil processor (SRX-
101A, Konica Minolta Medical & Graphic, Inc.). Protein sample sizes were 
compared with prestained molecular weight markers (prestained Seeblue® 
Plus2, Invitrogen). 
2.5.2 Native PAGE 
Protein was solubilised at 37 °C for 10 min in 300 mM detergent (1,2-
dihexanoyl-sn-glycero-3-phosphocholine (DH(6)PC), 1,2-diheptanoyl-sn-
glycero-3-phosphocholine (DH(7)PC), 1-palmitoyl-2-hydroxy-sn-glycero-3-
phospho-(1'-rac-glycerol) (LPPG) and 1-myristoyl-2-hydroxy-sn-glycero-3-
phospho-(1'-rac-glycerol) (LMPG)) in Liposome Assay Buffer (Appendix A.11). 
Native-PAGE loading dye (Appendix A.12) was added to samples, which were 
loaded onto gradient precast gels (4-20%) (Bio-Rad) and run using Native-
PAGE running buffer (Appendix A.13) at 140 V for 1 hr. Gels were stained with 
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Coomassie Brilliant Blue as described in section 2.5.3. Unstained SDS-free 
molecular weight marker (Sigma-Aldrich) was used to estimate protein size. 
2.5.3 Coomassie-blue staining 
Polyacrylamide gels were incubated in Coomassie Brilliant Blue stain (Appendix 
A.14) overnight at RT with continuous rocking. Gels were destained to visualise 
protein using Coomassie Blue destain solution (Appendix A.15). 
2.5.4 M peptide 
M peptide was purchased from Alta Bioscience and was provided lyophilised 
(Appendix). The peptide comprised the two TMDs and a truncated N-terminal 
helix. Details of the sequence are noted below: 
Ac – 
ESREYTKHLIKVENWIFRNPGFALVAVAIAWLLGSSTSQKVIYLVMILLIAPAYS 
2.6 In vitro liposome assay 
2.6.1 Liposome preparation 
Lipids (Avanti Polar Lipids) were kept on ice, combined in a glass tube and 
handled under non-oxygen gas (Nitrogen). 50 µL PA, 50 µL PC & 5 µL PE were 
mixed together to give 1 mg of lipid. The PE lipid head groups were labelled 
with lissamine rhodamine, giving a final concentration of 0.5 % w/w. Lipids were 
stored in chloroform, this was evaporated from the mixture overnight using a 
vacuum at room temperature (RT). Lipids were rehydrated to 2 mg/mL, at a 
self-quenching concentration of carboxyfluorescein (CF) buffer (Appendix A.16) 
and vigorously shaken overnight at RT. 
A 3 µL pre-extrusion sample was taken, followed by 15 passes through an 
Avanti extruder containing a 0.4 µM filter (Whatmann), at 37 °C. Unilamellar 
liposomes were washed three times with liposome assay buffer (Appendix A.11) 
to remove the remaining CF and purified via centrifugation at 35,000 rpm 
(100,000 x g) for 15 min at RT, using a MLS-50 rotor in a Beckman Coulter TLX 
ultracentrifuge. The last liposome pellet was resuspended in liposome assay 
buffer (500 µl). 
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Liposome concentration was determined by measuring the rhodamine 
absorbance (OD570) using a spectrophotometer (Jenway) of the pre-extrusion 
sample (3 µL diluted 1:20) and the post-extrusion samples (3 µL neat 
liposomes). The absorbance values were then entered into the following 
equation: 
𝐿𝑖𝑝𝑜𝑠𝑜𝑚𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑚𝑀) =  
2.75 𝑚𝑀 (𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑖𝑝𝑖𝑑 𝑚𝑜𝑙𝑎𝑟𝑖𝑡𝑦)
𝑂𝐷570𝑝𝑟𝑒 𝑒𝑥𝑡𝑟𝑢𝑠𝑖𝑜𝑛 ×𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 (20)
 × 𝑂𝐷570 𝑝𝑜𝑠𝑡 𝑒𝑥𝑡𝑟𝑢𝑠𝑖𝑜𝑛  
 
2.6.2 End-point in vitro M protein liposome dye release assay 
M peptides were reconstituted to 1 mM in Dimethyl Sulfoxide (DMSO). Further 
stock dilutions were made in DMSO; which was added to a maximum of 5 % 
w/w DMSO per well.  
End-point dye release assays were carried out using flat-bottomed, black 96 
well plates (Greiner Bio One). Each reaction comprised 50 µM liposomes and 
up to 800 nM peptide (780 nM for normal use) in liposome assay buffer 
(Appendix A.11) to 100 µl. FLUOstar Optima plate-reader (BMG Labtech) was 
used to measure CF release every after 30 min at 37 °C. All reactions were 
repeated in triplicate alongside 50 µM liposomes plus 5% (v/v) DMSO to 
calculate background fluorescence and 0.5 % v/v Triton X-100 to set gain 
adjustment of 90 % fluorescence.  
An increase of CF release and fluorescence indicated permeabilisation of 
liposomes induced by the addition of peptide. Assays were carried out at RT 
and kept on ice until inserted into the machine. End-point values were used to 
measure the level of permeability induced by the peptide. 
2.6.3 Inhibitor assays 
Inhibitors were added to reaction wells maintaining the 5 % v/v DMSO as 
mentioned in 1.8.2. Compounds were incubated with peptides for 5 min at RT 
prior to the addition of chilled liposomes and assay buffer.  End point values 
were taken and negative control (DMSO only) values were subtracted for each 
condition. Each biological replicate contained three technical repeats. 
2.6.4 pH Liposome assay 
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Determining the effect of pH on M peptide activity in liposomes was carried out 
using end-point measurement due to the quenching effect of acidic pH on CF 
fluorescence. Liposomes containing 50 µM CF were resuspended in Liposome 
assay buffer at different pH (6.2, 6.7 and 7.4). Liposome reactions were made 
as previously described (section 2.6.1), however after 30 min at 37 °C the 
samples were centrifuged at 100,000 x g for 15 min using a TLA45 rotor 
(Beckman) and a TL Ultracentrifuge (Beckman). The liposome-free supernatant 
was transferred to a 96-well plate and adjusted to pH 7.4 by the addition the 
same volume of 1M Tris-HCl pH 8.0. The endpoint CF fluorescence was then 
measured using a FLUOstar Optima plate-reader (BMG Labtech) at ex 485/ em 
520 nm.  
2.6.5 Lipids 
L-α-phosphatidic acid (α-PA), L-α-phosphatidyl choline (α-PC) and L-α-
phosphatidyl ethanolamine with lissamine rhodamine b labelled head groups (α-
PE), were purchased from Avanti Polar Lipids. All were derived from chicken 
eggs and supplied in chloroform as 10 mg/ml stock solutions, these were 
aliquoted using Hamilton glass syringes into glass vials, stored at -80 ˚C. 
2.6.6 Transmission Electron Microscopy 
5 µg of M peptide was incubated in 10 mM HEPES, 107 mM NaCl and varying 
concentrations of DHPC for 10 min at RT, this was added to copper grids, 
before washing with water and negatively stained with 2 % uranyl acetate and 
examined using a Tecnai F20 at 120 kV on a FEI CETA camera at a nominal 
magnification of 125000 providing a pixel sampling of 4.18 Å per pixel. Particle 
picking and 2D class averaging was carried out using RELION software, 2D 
class averaging was carried out with 25 iterations. 
2.7 Molecular Dynamics 
2.7.1 Coarse-grained simulations 
Coarse-grained (CG) Molecular Dynamic simulations of Monomeric and Dimeric 
M proteins were performed using Martini v2.2 force field (de Jong et al., 2013) 
and GROMACS (Abraham et al., 2015). The cryo-EM structure of ZIKV M 
protein structure (PDB: 5IRE) (Sirohi et al., 2016) was converted to coarse-grain 
resolution. An elastic network was only used in the monomer and dimer 
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simulations to maintain the secondary structure, however not the tertiary 
structure. Additionally, an elastic network was used when restraining the Cα 
during dimirising simulations as this would maintain the secondary and tertiary 
structure. The cryo-EM structure was used to simulate Model-1, however 
Modeller was used to generate Model-2 straightening the linker region between 
the two TMDs into a longer TMD (Fiser and Sali, 2003). 
A POPC bilayer or WNV emulated bilayer (POPC(57%): POPS(25%): 
POPE(3%): SM (15%) was built using INSANE (INSert membrANE) CG tool 
(Wassenaar et al., 2015). Systems were solvated with CG water particles and 
ions were added to neutralize the system to a final concentration of 150 nM 
NaCl. 
Prior to simulation, systems were energy minimised using the steepest descent 
algorithm for 500 steps in GROMACS and equilibrated for 10 ns with the protein 
backbone restrained. 
The temperature was set at 323 K and controlled by V-rescale thermostat 
(coupling constant of 1.0) (Bussi et al., 2007). Pressure was controlled by 
Parrinello-Rahman barostat (coupling constant of 1.0 and a reference pressure 
of 1 bar) (Parrinello and Rahman, 1981). Integration step in 20 fs Lennard-
Jones interactions were shifted to zero between 9 and 12 Å and Coulombic 
interactions between 0 and 12 Å respectively. 
2.7.2 Atomistic Simulations  
The all-atom hexameric and heptameric M protein oligomers were first energy 
minimised prior to conversion into CG using Martini and as above inserted into 
the bilayer system using INSANE, the systems were then equilibrated in CG 
restraining the protein. The systems were then converted back into atomistic 
resolution using the martini backward tool (Wassenaar et al., 2014). Simulations 
were then energy minimised, equilibrated for 20 ns with the protein Cα atoms 
restrained and run in CHARMM36 force field (Huang and MacKerell, 2013). 
Simulations ran for 200 ns. Temperature and pressure were controlled using the 
v-rescale thermostat (Bussi et al., 2007) and Parrinello-Rahman barostat 
(Parrinello and Rahman, 1981) respectively. Bond lengths were kept constant 
using the LINCS algorithm (Hess et al., 1997). The time-step was 2 fs and the 
temperature set to 323 K.  
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2.7.3 Design of Hexamer and Heptamers 
A python script was used to calculate the co-ordinates of each monomer within 
the oligomeric structure, a radii of 1.3 nm was used for hexamer. 
import math 
  
n = 6           # Number of sides 
x = 0           # Origin on x axis 
y = 0           # Origin on y axis 
r = 1.3      # Radius of Circle polygon is in 
  
for i in range (0, n): 
        posx = x + (r * math.cos (2 * math.pi * i / n)) 
        posy = y + (r * math.sin (2 * math.pi * i / n)) 
  
        print ("% 2d : %2.4f : %2.4f" % (i, posx, posy))  
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Chapter 3 In silico modelling of M protein 
3.1 Introduction 
Flavivirus M proteins are 75 amino acids in length, regions of which are highly 
conserved throughout the genus (Figure 3.1). M protein, known to play a role 
during assembly as a chaperone for the virus envelope protein, is first produced 
as part of the pr-M-E fusion peptide. However, after cleavage by furin or other 
trans-Golgi resident proteases (Stadler et al., 1997), the mature form of M 
resides within the virus membrane (Sirohi et al., 2016), where its role remains 
unknown. 
The function of mature M protein is poorly understood amongst the entire 
Flavivirus genus. All M proteins are highly hydrophobic, making them difficult to 
synthesise, express as recombinant proteins and purify; however, its presence 
within the virion is suggestive of a role during virus entry. 
The structure of M protein inside the virion has been resolved as dimeric across 
multiple examples within the genus by cryo-EM (Figure 3.2 and Figure 3.3) 
(Nieva et al., 2003; Melton et al., 2002; Raghava et al., 2011; Clarke et al., 
2006; Carter et al., 2010). However, as the virus enters the cell via clathrin-
mediated endocytosis (Persaud et al., 2018), the endosome containing the 
virion matures from early to late and acidifies, resulting in a harsh environment 
of around pH 5 (van der Schaar et al., 2008; Chu and Ng, 2004). At this stage, 
envelope glycoproteins re-arrange their conformation from dimeric to trimeric, 
providing dimeric M, which resides beneath envelope, a similar opportunity to 
change conformation. However, the structure of M protein in this environment is 
partially disordered, therefore has not been resolved, and so remains unknown 
(Zhang, W. et al., 2003; Klein et al., 2013; Zhang, X. et al., 2015). 
We hypothesised that M protein within this dynamic acidified environment may 
behave similarly to IAV M2 by playing a role during virus uncoating (Pinto et al., 
1992). As M is capable of dimerising, it could further oligomerise into a virus-
encoded channel, or “viroporin”. An M protein viroporin allowing H+ into the virus 
capsid may destabilise the interactions between these proteins and the viral 
genome, expediting the release of RNA into the host cell cytoplasm. Previous 
work with DENV-2 M protein C-terminal peptides has supported cation channel 
activity in vitro that was sensitive to the prototypic viroporin inhibitors, 
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amantadine and hexamethylene amiloride. Additionally, amantadine and its 
methylated derivative, rimantadine, inhibited DENV infection in vitro (Koff et al., 
1980; Koff et al., 1981). Conversely, the ability of M to act as a proton channel 
has been disputed in electrophysiology studies using Xenopus oocytes 
(Premkumar et al., 2005; Wong et al., 2011).  
Expression of viroporins by classic overexpression systems is challenging due 
to their hydrophobicity and small size. Previously, viroporins have been 
expressed using prokaryotic expression systems, either by targeting them to 
inclusion bodies, or in a soluble form with the addition of a tag (Nieva et al., 
2003; Melton et al., 2002; Raghava et al., 2011; Clarke et al., 2006; Carter et 
al., 2010) However, this requires large amounts of optimisation and yields are 
generally low. Once expressed, the proteins require extraction using detergents, 
which can be problematic following subsequent purification, and when 
introduced into membrane-containing systems. Accordingly, our own attempts 
at expressing M in bacteria using previously successful viroporin strategies 
yielded only minimal amounts of soluble protein with poor purity. Thus, we 
moved on from expressing M protein in the laboratory and instead undertook 
the modelling of M protein in silico using molecular dynamics (MD) simulations.  
MD simulations have been used previously with many other viroporins to 
complement wet laboratory techniques and provide molecular insights into 
structures, including generating models for monomeric and oligomeric p7 
(Chandler et al., 2012; Montserret et al., 2010; Saint et al., 2009) and 
highlighting the protonation states of HIS37 as a conductance mechanism of the 
M2 viroporin, (Khurana et al., 2009). This chapter describes the study of M 
protein structure and oligomeric interactions in different membrane 




Figure 3.1 Amino acid sequence alignment of Flavivirus M proteins 
Flavivirus M proteins are 75 amino acids in length and contain highly conserved residues and regions, shown aligned here. Residues 35-
44, indicated above by parentheses, are particularly well conserved. This region contains the last 3 residues of the N-terminal helix (helix 
1) and the first residues of the N-terminal TMD helix (helix 2). The alignment was produced using Clustal Omega 




Figure 3.2 Cryo-EM structure of ZIKV E and M protein within the virion membrane 
Side view of E-M dimer. E proteins shown in black and white with the E ectodomains on the surface of the virion and the E 
transmembrane. M protein loop and transmembrane domains shown in green and blue with the linker region indicated by the arrow.   The 




Figure 3.3 M protein dimer structure 
M protein dimeric structure taken from cryo-EM ZIKV E-M heterodimer, one monomer shown in green, one shown in blue. A. Side view of 
dimeric M. B. Top down view of dimeric M.  
 
69 
3.2 In silico predictions of M protein secondary structure  
Flavivirus M protein within the mature virion cryo-EM structure has very short 
transmembrane domains of 13-14 amino acids, ~2.4 nm in length, whereas a 
typical lipid bilayer spans 3 nm (Ding et al., 2015). Therefore, we postulated the 
M linker region between the two TMDs highlighted in Figure 3.2 may be under 
high conformational stress and could change conformation upon virus 
acidification. When the virus arrives in the acidic endosome environment the E 
proteins change from dimeric to trimeric, potentially releasing M protein from 
underneath (Bressanelli et al., 2004). 
Using computational protein secondary structure prediction tools, we obtained 
conflicting results for the TM domains of monomeric M protein. The ‘TMHMM’ 
server uses a hidden Markov model (HMM) to predict the likelihood for each 
residue to be part of a TMD, incorporating hydrophobicity, charge bias and helix 
length. TMHMM inferred a strong probability for M protein to have a single TMD 
(Figure 3.4A). It predicted residues 1-34 to be cytoplasmic (probability of ~0.65, 
blue line), followed by one TMD from residue 35-54 (probability of  ~0.7, red 
lines) and residues 55-75 to be non-cytoplasmic (probability of ~0.6, pink line) 
(Moller et al., 2001). Additionally we used two other computational tools that 
predicted M protein to have one TMD, Phobius and TOPCONS (Figure 3.4) 
(Bernsel et al., 2009; Kall et al., 2007). Phobius, similarly to TMHMM, uses a 
HMM but is more reliable for proteins containing both a signal peptide as well as 
TMDs (Kall et al., 2004; Zhang, Xiaohui et al., 2009). Phobius (Figure 3.4C) 
predicted residues 1-41 to be non-cytoplasmic, (probability of ~0.6, blue line), 
followed by a single TMD spanning residues 42-71, (probability of ~0.8, grey 
lines), and residues 72-75 were predicted to be cytoplasmic (probability of 
~0.55, displayed by the green line).    
TOPCONS server uses a fundamental algorithm utilising BLAST and a 
consensus prediction to predict topology and measures this in reliability. 
TOPCONS (Figure 3.4B) predicted residues 1-40 to be cytoplasmic as 
displayed by the red line, followed by a TM-helix (in → out) from residue 41-62 
as displayed by the grey box, and residues 63-75 to be non-cytoplasmic as 
displayed by the blue line all with a reliability of over 0.9.  
Conversely, we also used MEMSAT and SPLIT, which predicted the presence 
of two TMDs (Figure 3.5). SPLIT (Figure 3.5A) predicts the two TMDs to be 39-
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56 and 58 to 75 by using method of preference functions. MEMSAT-SVM 
(Figure 3.5B) predicts the two TMDs to be from 37-52 and 56-72. MEMSAT-
SVM uses multiple support vector machines (SVM) to identify the many residue 
presences before combining these into a probability output (Nugent and Jones, 
2009),  
Thus, upon release from dimeric E it may be possible for the two TMD helices 
of M to flip, forming a single TMD spanning the membrane prior to oligomerising 
into a channel.  
The disparate results from TMD predictions led us to construct models based 
on both one TMD and two TMD conformations for analysis by MD. We also 
considered the composition of the virion membrane (Martin-Acebes et al., 
2014), and how this might influence the M protein properties; phospholipids with 
shorter chains may allow the linker region between the two TMDs to interact 




Figure 3.4 Single TMD predictions of the ZIKV M protein structure from 
TMHMM, TOPCONS and Phobius servers.  
A. TMHMM predicts ZIKV M residues 1-34 to be cytoplasmic with a probability 
of ~0.65 as displayed as a blue line, followed by one TMD from residue 35-54 
with a probability of ~0.7 as displayed by the red vertical lines and residues 55-
75 to be non-cytoplasmic with a probability of ~0.6 as displayed by the pink line. 
B. TOPCONS tool predicts ZIKV M residues 1-40 to be cytoplasmic as 
displayed by the red line, followed by a TM-helix (in→out) from residue 41-62 as 
displayed by the grey box, and residues 63-75 to be non-cytoplasmic as 
displayed by the blue line all with a reliability of over 0.9. C. Phobius tool 
predicts ZIKV M residues 1-41 to be non-cytoplasmic with a probability of ~0.6 
as displayed by the blue line, followed by one TMD from residue 42-71 with a 
probability of ~0.8 as displayed by the grey vertical lines and residues 72-75 to 






Figure 3.5 Two TMD predictions of the ZIKV M protein structure from 
SPLIT and MEMSAT-SVM servers. 
A. SPLIT v4.0 tool predicts ZIKV M to have two TMD from residue 39-56 and 
58-75 as displayed by the violet boxes, the red line indicates the 
transmembrane helix preference, which aligns with the prediction shown in the 
violet boxes. The beta preference shown in blue indicates a low probability of 
beta sheet presence.  B. MEMSAT-SVM   predicts ZIKV M to have two TMDs 







3.3 Modelling M protein monomers in silico  
M protein is dimeric in the mature virion, yet if the protein is capable of forming 
higher order oligomers then it is likely to be stable, maintaining its’ secondary 
and tertiary structure within a bilayer in its monomeric form. Additionally, as E-M 
heterotetramers dissociate during entry into E trimers, some M dimers are likely 
to also rearrange from dimers to monomers.  All simulations conducted 
throughout this chapter use an amino-terminally truncated M protein. The native 
75 amino acid protein was truncated to 58 amino acids for computational 
efficiency, removing a region of the N-terminal domain that was predicted to be 
unstructured, as seen in the cryo-EM structure (Figure 3.2) (Sirohi et al., 2016) 
and the TMD predictions (Figure 3.4 and Figure 3.5). The structure of the 
truncated protein is shown in Figure 3.6.   
The monomeric simulations described in this section assessed whether M 
protein may change conformation and membrane topology after dimer release 
from E during endosome acidification, based upon the stability of either single 
or double TMD M conformers. Initially, we generated a long single TMD protein 
comprising both helices present within the cryoEM structure, reflecting the 
prediction results of TMHMM, TOPCONS and Phobius shown in Figure 3.4. 
Secondly, M was simulated as a two TMD protein to assess whether the two M 
protein helices are long enough to span a membrane bilayer individually, 
reflecting the cryo-EM structure (Sirohi et al., 2016) and prediction results from 
SPLIT and MEMSAT shown in Figure 3.5. Finally, we generated a further 
truncated protein with the C-terminal TMD absent to determine whether the 
linker region between the two proposed TMDs can interact sufficiently with the 
inner leaflet to remain stably anchored or if the second TMD is required 
(Appendix B.1). Table 3.2 lists coarse-grained MD simulations performed for 
this chapter and atomistic MD simulations are listed in Table 3.3. Coarse-
grained MD simulations were run for 3 or 6 μs using martini 2.2 force field (de 
Jong et al., 2013) and atomistic MD simulations were run for 200 ns using 
CHARMM36 force field (Huang and MacKerell, 2013). A simulation snapshot of 
the coarse-grained MD simulation system containing protein, lipids, water and 




Figure 3.6 Structure and protein sequence of ZIKV M protein truncation  





Figure 3.7 Simulation system of coarse-grained MD simulations of the M protein monomer  
Simulation system showing M protein backbone in pink, phospholipid heads in orange, lipid tails represented by grey dots and 
water and ions represented by blue dots. 
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3.3.1 Is M protein stable as a one or two transmembrane domain M 
protein in a POPC bilayer? 
To simulate monomeric M, the structure of the protein in the mature ZIKV 
particle cryo-EM was taken from PDB: 5IRE (Sirohi et al., 2016). However, to 
convert the two TMD protein with short helices into a single TMD protein with 
one long helix, the structure of the hairpin linker region highlighted in Figure 3.6 
between the TMDs was straightened using Modeller software (Webb and Sali, 
2016). The protein was then inserted into a POPC model membrane with the N-
terminal helix outside the membrane bilayer as shown in  
Figure 3.8A. After simulating for 3 μs, the single TMD protein had surprisingly 
markedly changed conformation ( 
Figure 3.8B), partially reverting to a structure comparable to that of the mature 
virion two TMD cryo-EM structure and the same region can be seen forming the 
linker region, indicated by the blue arrow ( 
Figure 3.8C). During repeated simulations, it took 2 ns on average for the 
protein to adopt this revertant conformation. The conversion of the 1 TMD 
protein back into a 2 TMD protein results in the linker region between the two 
TMD helices interacting with the inner leaflet of the bilayer ( 
Figure 3.8B), thereby narrowing the membrane due to the short TMDs, and the 
second TMD (H3) residing within the bilayer, although without outer leaflet 
interaction. Root mean square deviation (RMSD) analysis of the simulation 
shows the structure changed a lot over the first few ns as the RMSD rapidly 
increased from 0 to 1 nm ( 
Figure 3.8D & E), where it became more stable in the altered TMD structure 
and stayed similar throughout the simulation.  
We then carried out a set of double TMD M protein simulations to compare with 
results for single TMD simulations. The input conformation for these comprised 
a double TMD protomer derived from the dimeric structure reported in the ZIKV 
virion cryo-EM structure (PDB: 5IRE), (Sirohi et al., 2016) with TMDs from 
residue 40-52 and 58-72 as this approximately reflected predictions from SPLIT 
(residues 39-56 and 58-75) and MEMSAT-SVM (residues 37-52 and 56-72). 
The two TMD species was inserted into a POPC membrane with the N-terminal 
helix outside the membrane bilayer, with the two TMDs resident within the 
 
77 
membrane. However, the helices were not long enough to span the POPC 
bilayer at the start of the simulation (Figure 3.9A).  
After the 3 μs of coarse-grained MD simulation, unexpectedly both TMDs 
remained within the membrane and were largely structurally unchanged 
throughout the simulation, although the bilayer had rearranged allowing for the 
shorter TMDs (Figure 3.9A and B). However, the N-terminal helix appeared very 
flexible throughout. Subsequent analysis of the distance between the tip of the  
N-terminal helix and the tip of C-terminal TMD (blue arrows) shows the N-
terminal helix was very flexible and often faced in the opposite direction to the 
starting conformation (Figure 3.9C). Additionally, the root mean square 
deviation (RMSD) plot (Figure 3.9D) shows an increase from 0 to 0.5 nm at the 
start of the simulation, as the monomer becomes established within the 
membrane. The RMSD then increases, aligning with the altered positioning of 
the N-terminal helix seen in fig Figure 3.9B. Overall the two TMD monomers 




Figure 3.8 Monomeric M protein is not stable as a single TMD protein in a POPC lipid bilayer 
Conformations of M protein before and after 3 μs of simulation. Protein backbone shown in pink and phospholipid bilayer heads shown in 
orange. A. Monomeric single TMD M protein simulation starting conformation, shown side on with and without phospholipid bilayer 
heads, with the linker region position indicated. B. Monomeric single TMD M protein simulation after 3 μs, shown side on with and without 
phospholipid bilayer heads, with the linker region position indicated. C. Alignment of M 1TMD simulation next to the cryo-EM 2TMD 
structure with corresponding regions highlighted with arrows. D. Root mean square deviation over time (RMSD) of one representative 




Figure 3.9 Monomeric M protein with two TMDs is stable in a POPC bilayer 
A & B Conformations of M protein before and after the 3 μs simulation. Protein backbone shown in pink and phospholipid bilayer heads 
shown in orange. Shown side on with and without phospholipid bilayer heads. C. The distance between the two blue arrows in A, 
throughout the simulation. Showing the N-terminal helix is flexible and moves to face the opposite direction during the simulation. D. Root 
mean square deviation over time (RMSD) of one representative simulation. 
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3.3.2 Is M protein stable as a two transmembrane domain protein 
(Model-1) in a representative Flavivirus virion bilayer? 
In previous simulations the lipid bilayer simulated surrounding M protein has 
been entirely composed of POPC phospholipids. Although the majority of 
Flavivirus membranes contain a high proportion of POPC lipids (Martin-Acebes 
et al., 2014; de Oliveira Dos Santos Soares et al., 2017; Zhang, Q. et al., 2012), 
bilayers solely comprised of this fatty acid are neither representative of cellular 
membranes, nor, more importantly, a virus particle (Mackenzie et al., 2007; 
Welsch et al., 2009). Virion membranes are derived from the host cell lipid 
bilayers, yet their composition varies due to the recruitment of different lipids at 
varying compositions by non-structural proteins or the glycoproteins themselves 
(Aktepe and Mackenzie, 2018; Wewer and Khandelia, 2018).  
Thus, to determine whether lipid composition affects M protein behaviour the 
model membrane was altered to that of WNV, due to the absence of related 
data for ZIKV; specifically: POPC(57%): POPS(25%): POPE(3%): SM (15%) 
(Martin-Acebes et al., 2014).  
After 3 μs simulations of the two TMD M conformer (PDB: 5IRE) within a WNV 
composed membrane, the structure was the same as those when simulating M 
protein within a POPC membrane (Figure 3.9 and Figure 3.10). The change in 
lipids surprisingly appears to have little effect on the flexibility or final 
conformations of M protein as a monomer within the Flavivirus lipid bilayer in 





Figure 3.10 Monomeric M protein with two TMDs is stable in a WNV derived lipid bilayer 
A + B Conformations of M protein before and after the 3 μs simulation. Protein backbone shown in pink and phospholipid bilayer heads 
shown in orange. Shown side on with and without phospholipid bilayer heads. C. The distance between the two blue arrows in A, 
throughout the simulation. Showing the N-terminal helix is flexible and moves to face the opposite direction during the simulation. D. Root 
mean square deviation over time (RMSD) of one representative simulation. 
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3.4 Dimerisation of M protein in silico 
Section 0 supports that M protein is stable as a two TMD monomer within 
membranes in silico, yet the protein is known to be stable as a dimer within 
mature virions as seen by cryo-EM (Figure 3.2 and Figure 3.3) (Sirohi et al., 
2016). Within the virion, M protomers appear to interact through the two C-
terminal TMD helices (H3) with the N-terminal TMD helices (H2) on the 
periphery, adjacent to the E TMD anchors (Figure 3.3). Additionally, E subunits 
I-III reside on the surface of the virion and interact with M protein H1 and the 
unstructured region from above (Figure 3.2). Therefore, dimerisation of M may 
require the presence of E for stabilisation, or M dimers may form alone but may 
be less stable in the absence of E.  
If M protein is to oligomerise into a higher order structure, monomers and 
dimers of M protein must interact intermediately during the formation of the 
oligomer from dimers. M protein may oligomerise similarly to M2, which forms a 
tetramer starting from a dimeric conformation, creating a ‘dimer of dimers’ 
(Sharma et al., 2010), or the rearrangement of E dimers to trimers during 
acidification may result in the dissociation and rearrangement of M dimers into 
higher order oligomers. 
This section investigates whether two M protein monomers can interact to form 
dimers and the subsequent conformations thereof. All the coarse-grained 
simulations in section 3.4 were run for 6 µs each and 10 repeats were carried 
out. M proteins were situated 6 nm apart within the described lipid bilayer, using 
coarse-grained force field martini v2.2. 
3.4.1 M protein forms stable dimers in standard POPC bilayers 
Two M proteins were simulated at distance in a 100 % POPC bilayer to 
determine whether they could interact and dimerise. Ten simulations were run 
under the same conditions and dimerisation did indeed occur during each 
simulation. However, interestingly, dimeric interactions were not identical in 
each case (Figure 3.11). Dimers formed as one of four different classes; Class 
I: as per ZIKV virion cryo-EM dimers (Sirohi et al., 2016), where interactions 
occur between H3, and H2 is present upon the periphery; Class II: interactions 
occurring at H2 with H3 on the periphery; Class III: interactions occurring at 
both H2 and H3; Class IV: interactions at both H2 and H3 regions, yet 
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alternating in direction. In this set of ten simulations only one formed a Class I 
conformation, two formed Class II conformations, five formed Class III 
conformations and two formed Class IV conformations. Interestingly, class III 
adopted a conformation that might enable orientation of further protomers into a 
circular channel-like structure with H3 lining an aqueous pore based on the 
MEMSAT-SVM prediction (Figure 3.5) (see section 3.5). Representative graphs 
of which residues form the most interactions during simulations are shown 
under the corresponding classes. The residues forming the highest number of 
interactions for class III dimers are SER58, ILE49, ALA46, ALA45, ALA43, 
ASN34, VAL32, ARG31, HIS28, TYR25, GLU24, ARG23 and SER22. 
Moreover, classes did not correlate with the time taken for the dimers to come 
together; the average time taken was 1.46 µs, although times varied from 320 
ns to 4.64 µs due to randomisation of the simulation and the absence of 





Figure 3.11. M protein dimerises in a POPC bilayer 
Dimerisation conformations of M protein monomers within a POPC bilayer after 
a 6 μs coarse-grained simulation. M protein shown in pink, side on and above. 
Representative protein-protein interaction graphs show one monomer in black 
and the other in red. Interactions are normalised to the largest number of 
contacts of a residue, with 1 equating to maximum interactions and 0 being no 
interactions. A. Dimeric M protein in a Class I conformation, with H3s forming 
interactions. C. Dimeric M protein in a Class II conformation with H2s 
interacting. D. Dimeric M protein in a Class III conformation with H3s interacting 





Figure 3.12 Dimerisation analysis of monomers in a POPC bilayer 
Time taken for monomers to dimerise in the ten repeat 3 μs simulations carried 
out in a POPC composed membrane.
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3.4.2 Dimerisation of M protein in WNV virion composition bilayer 
differs to a POPC bilayer 
Flavivirus virion membrane phospholipid composition, as described in section 0, 
is distinct from cellular organelles, although the precise composition of the ZIKV 
particle membrane has not yet been defined. Virion membranes are primarily 
formed from the ER membrane at the site of virus assembly, where viral 
proteins recruit and attract certain lipids for composition into the virus 
membrane (Mukhopadhyay et al., 2005; Gillespie et al., 2010). After this work 
was undertaken a study using MD techniques was published showing Zika E 
and M proteins specifically enrich the surrounding membrane with PS lipids 
(Wewer and Khandelia, 2018). The activity and interactions of M protein may 
therefore vary based on the surrounding lipids. The lipid bilayer composition for 
these simulations are the same as used in simulations in section 0, which 
recapitulated a Flavivirus WNV virion membrane (Martin-Acebes et al., 2014).  
Dimerisation of M proteins in a WNV lipid derived bilayer occurred within a 
similar timeframe, on average 1.49 µs compared to 1.46 µs in POPC bilayers, 
and time taken for dimerisation ranged from 140 ns to 3.34 µs (Figure 3.13). 
However, surprisingly two simulations did not result in M protein dimerization. 
Again, dimers formed were categorised into the aforementioned classes, 
however with an addition (Figure 3.14). Two dimers were classified as class I, 
similar to cryo-EM, four were class II and one class III. Additionally, one dimer 
class did not resemble the four previous POPC derived conformations as one 
H3 interacted with H2 from the other protomer, whilst the other TMD helices 
were adjacent (Figure 3.14). Furthermore, the classifications did not correlate 
with time taken to dimerise (Figure 3.13). The reduced number of dimer 




Figure 3.13  Dimerisation analysis of monomers in a Flavivirus derived 
lipid bilayer 
A. Time taken for monomers to dimerise in ten repeat 3 μs simulations, in a 






Figure 3.14 M protein dimerises in a Flavivirus composed lipid bilayer  
Additional dimerisation conformation of M protein monomers within a WNV derived lipid bilayer after a 6 μs coarse-grained simulation. A. 
M protein shown in pink and phospholipid heads shown in orange, protein shown with and without bilayer side on. Dimeric M protein in a 
Class V conformation with a H3-H2 interaction. B. Graph displaying the residues with the normalised highest number of interactions. 
Monomers coloured black and red.
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3.4.3 Restraining M protein conformation during dimerisation alters 
dimer class preferences  
MD allows experimentation with protein dynamics not currently possible in the 
laboratory. We can simulate proteins with conformational restraints to observe 
the resulting difference of their interactions. In previous simulations (section 
3.4.1 and 3.4.2) it was noticed the N-terminal hydrophilic helix (H1) was very 
flexible and sometimes was the first point of interaction between dimers. 
Therefore, we questioned whether this H1 flexibility was required for M 
protomers to come together. In addition, the presence of E protein within the 
immature and mature virion prior to acidification may restrain M, favouring the 
formation of specific dimer conformations (Bressanelli et al., 2004; Sirohi et al., 
2016). To assess these factors we restrained the movement of all C-alpha 
atoms within M protein during the simulation, effectively preventing the dynamic 
structural variations observed in other systems by rigidifying the protein 
backbone. 
When M protein C-alpha (Cα) atoms were restrained and simulated within a 
POPC bilayer, dimerisation occurred on average within 2.74 µs (Figure 3.15), 
compared to 1.46 µs for unrestrained dynamic protein. However, one of the 10 
simulations did not dimerise within the 6 µs timeframe. Although the Cα 
restraints resulted in a slower dimerisation, the frequency of conformations also 
differed. Unlike the unrestrained protein forming class III conformations, the 
class I dimer which has a conformation similar to that found in the virion 
occurred most frequently, with four of the ten simulations adopting this H2-H2 
H3-H3 interacting conformation compared to just one when M was not 
restrained. Logically, this might therefore reflect the influence E protein has on 
M protein dimers forming within the virion, whereby the glycoprotein exerts 
structural restraints upon M, favouring the formation of class I dimers, as seen 
in the cryo-EM structure. No dimers formed a class II conformation, suggesting 
flexibility is required for this conformation to form. Only two dimers formed the 
class III conformation, which could form a higher order oligomer with a predicted 
aqueous channel due to the adjacently aligned protomers, in comparison to five 
dimers when not restrained. Additionally, no dimers formed the class IV 
conformation and three dimers formed the class V conformation in comparison 
to two and zero respectively when the Cα atoms were not restrained.  
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Similar results were seen when dimerization simulations were run with a WNV 
lipid composed bilayer and the Cα atoms of M proteins were restrained. The 
results of these ten simulations showed dimerisation happened in every 
simulation and occurred on average after 1.64 µs (Figure 3.16), which is quicker 
than when Cα atoms were restrained in a POPC bilayer (2.74 µs), however 
somewhat slower than when M was not restrained and simulated in a WNV 
virion derived membrane (1.49 µs). Moreover, the mean time to dimerization for 
each of the scenarios ranges from 1.46-2.74 µs, in this course-grained 
simulation the difference in time does not lend itself to any conclusions, except, 
the addition of Cα restraints appears to increase the time taken. 
The restrained dimers simulated in a WNV composed bilayer see similar 
proportions of classes to the restrained dimer in POPC bilayer and the patterns 
from not restrained to restrained are also comparable. The dimers formed five 
class I conformations, an increase from two when not restrained, again 
potentially reflecting the influence of E proteins on the dimers formed. One class 
II, one class III, no class IV and three class V conformations were also formed, 
compared to three class II, one class III, one class IV and one class V when not 
restrained.  
These changes in dimeric conformations do not seem to be influenced by the 
lipid membrane composition, however the changes may be due to the reduction 
of H1 structural flexibility. The dimers formed may provide an insight into the 
interactions that occur when E protein is acidified, oligomerises and no longer 




Simulation set Dimeric classes as a % of all simulations 
 I II III IV V N/A 
POPC membrane 10 20 50 20 0 0 
WNV membrane 20 40 10 0 10 20 
POPC membrane 
restrained 
40 0 20 0 30 10 
WNV membrane 
restrained 
30 10 10 0 30 20 
Table 3.1 Dimeric classes formed across simulation sets 
The number of dimers which formed the differing class conformations across 
the simulations carried out in POPC membranes and WNV comprised 





Figure 3.15 Dimerisation analysis of restrained monomers in a POPC lipid 
bilayer 
A. Time taken for monomers to dimerise, in ten repeat 3 μs simulations, with a 
POPC membrane and the Ca atoms of the protein restrained. X denotes a 




Figure 3.16 Dimerisation analysis of restrained monomers in a Flavivirus 
derived lipid bilayer 
Time taken for monomers to dimerise, in a WNV composed membrane with Ca 
atoms of the protein restrained. X denotes a simulation where monomers did 
not dimerise. B. RMSF plot of dimers forming class III and IV conformations and 





3.5 Simulating M protein channels in silico  
We hypothesised that M protein is capable of forming a higher order oligomeric 
channel during virus entry once acidic pH promotes E protein conformational 
changes from dimeric to trimeric (Dai et al., 2016). This change in conformation 
would no longer restrain M protein in proximity to dimeric E, potentially allowing 
M protein to oligomerise further. Applying the data from section 3.4 we sought 
to identify possible prior interactions between monomers that might promote 
channel formation.  
Applying Cα restraints to M protein monomers during simulations in section 
3.4.3, caused an increase in the formation of class I dimers, reflecting the 
mature M protein dimeric structure, therefore these are potentially similar to the 
restraints applied by the presence of E dimers. However, M protein monomers 
simulated without restraints formed a higher percentage of dimers in 
orientations that favour forming an oligomeric channel, i.e. where helix 3 is in 
close apposition and aligned (class III), favouring the pore lining helix predicted 
by MEM-SAT SVM (Figure 3.5). 
Viroporins are typically small membrane proteins of 100 residues or less, 
comprising up to three TMDs, which subsequently oligomerise into a 
membranous pore, ranging from tetrameric, IAV M2 (Sakaguchi et al., 1997) to 
heptameric, HCV p7 (Clarke et al., 2006) with a single helix lining the pore. The 
aforementioned viroporin properties led to the generation of the schematic in 
Figure 3.17. As previously mentioned, known viroporins range from being 
tetrameric to heptameric, however when generating M protein oligomeric 
models, it became apparent the pore is lined by a minimum of five helices to 
ensure the radius for a water permeable channel to form, as pentameric 
channels had a narrow pore diameter of less than 3 Å (data not shown). 
Additionally, the presence of dimeric M within the virion, and the stable dimers 
formed in section 3.4 indicate that it is more likely for M protein monomers to 
remain closely associated in pairs. Consequently, we assumed M protein 
channels would form from a minimum of six pore-lining helices, in line with the 
stoichiometry of other viroporins such as p7, E5 and SH. In addition, ZIKV 
virions contain 180 M proteins and the presence of M at the point of 3-fold 
symmetry, where six M proteins are present, is suggestive of hexameric 
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channels. Therefore, we hypothesise M protein oligomers are unlikely to form 
channels from class I, II or V dimers, which require 12 monomers and are 
unlikely to form from class IV dimers due to both helix 2 and 3 lining the pore, 
which has not been seen with any previously identified viroporins.  
This highlights class III dimers may comprise the starting conformation of higher 
order oligomers leading to the formation of a channel. However, this would 
require the class I (cryo-EM) dimers to alter their interacting surface, to change 
to a class III dimeric conformation, the class III conformation may be more 
favourable once the restraints from envelope protein dimers have been 
released as discussed in section as discussed in section 3.4.3. If time had 
allowed, removing Cα restraints from class I cryo-EM dimers at a defined point 
during simulations, then observing whether dimers altered conformation, would 
have investigated this possibility.   
We began modelling hexameric channels using MD software GROMACS. 
GROMACS, as mentioned in chapter 1, is widely used and allows use of many 
different force fields and water models. Additionally, GROMACS has been used 
to successfully study ion channels or viroporins previously (Ulmschneider et al., 
2013; Bagneris et al., 2014; Shukla et al., 2015; Araujo et al., 2016; Shaw et al., 
2019).  Hexamers were constructed using class III dimers in different 
orientations with either helix 2 or helix 3 lining the pore. In addition, for both 
hexamer structures, monomers were further rotated from a ‘radial’ structure to a 
‘compact’ structure to increase inter-monomer interactions and investigate how 
this influenced the channel stability and activity, creating four different structures 
to simulate. Furthermore, structures were simulated at neutral pH, either with or 
without protonated HIS28 residues, reflecting the acidified endosome 
environment, which is known to activate or enhance activity of other viroporins 
(Wang, C. et al., 1995; Chizhmakov et al., 1996; Wetherill et al., 2012; StGelais 
et al., 2007; Wozniak et al., 2010; Atkins et al., 2014).  
Due to the complexity of the predicted interactions between monomers in 
channel conformations, atomistic simulations were carried out, allowing us to 
study the proteins’ conformational dynamics. Simulations were run three times 
for 200 ns using the all-atom CHARMM36 force field (Huang and MacKerell, 




Figure 3.17 Hexameric channel conformations based on dimeric classes 
Schematic displaying how dimeric classes I-V would fit together in a hexameric 
channel conformation, N-terminal TMD (H2) shown in light blue, C-terminal 





Figure 3.18 Simulation system visualisation of M protein channel  
Simulation system of an all-atom simulation. A. Cut away system side view 
showing protein as ribbons in black, water shown in red and lipids shown in blue 
as van der waals, Cl- and Na+ ions are not shown. B. System from above 
showing lipids present in white by a surface representation, and protein 




3.5.1 Which TMD helix lines the M protein pore? 
Pore-lining helices do not have readily definable characteristics. However, they 
usually contain a mixture of hydrophobic and polar residues compared with lipid 
facing helices.  Helix 2 is comprised wholly of non-polar residues (Figure 3.19). 
In this regard, helix 3 contains one polar and charged residue (Figure 3.19) and 
was predicted by MEMSAT-SVM to be the pore-lining helix of M protein 
viroporin channels (Figure 3.5).  
3.5.2 Are hexameric channels with pores lined by Helix 3 stable? 
MD simulations of M protein channels were run with helix 3 pore-lining in two 
different conformations, named ‘radial’ and ‘compact’. Channels were 
constructed with hexameric stoichiometry. Six monomers were packed and 
each rotated 60 or 80 degrees for the radial and compact conformations 
respectively (see section 2.7.3 for coordinates), producing two structures with 
different inter-monomer interactions without steric clashes. Next, all-atom 
simulations of the two conformations were run in a neutral pH environment, with 
and without protonation of the six HIS28 residues. This protonation imitates 
placing the protein in an acidic endosomal environment, where we hypothesise 
M protein channels are likely to form during virus entry. 
3.5.2.1 Simulating channels with pores lined by helix 3, within a neutral 
pH environment. 
The ‘radial’ conformation with helix 3 lining the pore was constructed with the N-
terminal helix protruding away perpendicular to the channel pore (Figure 3.20). 
The starting conformation of the channel exhibited a lumen radius of 4.137 Å 
with pore lining residues LYS60, TYR63, LEU64, ILE67 and LEU69 (Figure 
3.21). These residues are predominantly hydrophobic with the exception of the 
positively charged lysine residue, often found within Na+ channel lumens (Li, Y. 
et al., 2016). Lysine is regarded as an amphipathic residue, with its long 
hydrophobic carbon tail and a positively charged residue both found on its side 
chain. Due to the charge of the lysine, it may repel and destabilise the oligomer, 
although the lysine residue is found at the channel base, allowing it to interact 
with the lipids phosphate atoms, potentially neutralising its charge, stabilising 
the channel complex. 
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The start ‘radial’ conformation of the 200 ns atomistic simulations is shown in 
Figure 3.20. Helix 1 does not interact with the adjacent monomers, so the only 
interacting residues are found in the TMDs. Figure 3.22 shows a representative 
channel conformation at the end of one of the simulations, including a surface 
plot of pore radius generated using the HOLE programme. Out of three 200 ns 
simulations, all oligomers maintained their association to adjacent protomers, 
one channel retained a pore radius of 3.342 Å (Figure 3.22D), whereas the 
others closed after 6 and 40 ns, respectively (Figure 3.22A, C).  
In Figure 3.22B the orientation of the channels that closed during simulation is 
shown in more detail, with hydrophobic residues LEU64, ILE67 and LEU68 
playing major roles during channel closure. ILE67 occludes both channels with 
the addition of LEU68 in simulation one. However, LEU64 also restricts both 





Figure 3.19 M protein amino acid properties determined by EMBOSS Pepinfo 
Properties of the 75 residues of M protein, aligned to the two TMDs helix 2 (H2) and 3 (H3). Properties shown are non-polarity, 





Figure 3.20 Starting conformations of hexameric ‘radial’ channel with pore lined by Helix 3  
A. Ribbon representation side on and from above with HIS28 residues highlighted in red with helices indicated. B. Surface 
representation side on and from above with one protomer highlighted in orange. C. Ribbon and Surface overlay representation 




Figure 3.21 Hexameric helix 3 pore-lining ‘radial’ channel lumenal 
residues 
Pore lining residues of a Hexameric M protein channel in a ‘radial’ conformation 
with the C-terminal TMD (helix 3) lining the pore. Pore lining residues LEU68 in 




Figure 3.22 200 ns conformation of hexameric 'radial' channel with pore lined by helix 3 
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A. Surface and Ribbon representation of simulation three at 200ns from above and side with one helix cut away and HOLE surface 
plot displayed. Areas inaccessible to water with a pore radius < 1.15 Å in red, referred to as a closed channel, areas that will allow 
passage of one water molecule 1.15 Å > pore radius < 2.30 Å in green, and areas accessible to greater than one water molecule 
pore radius > 2.30 Å in blue. B. Simulation three channel zoomed in with HOLE surface plot displayed and residues closing the 
channel shown with sticks. LEU64 in yellow, ILE67 in purple and LEU68 in orange.  C. Overlay of starting conformation in black and 
representative end conformation in white, with HIS28 in red. D. HOLE profile plot of pore radius, starting conformation shown in 
blue, simulation one, two and three in black, red and green respectively, with positions of residues LEU64 in yellow, ILE67 in purple 




Figure 3.23 Helix 3 pore lining radial start and end conformation overlay 
Overlay from above of helix 3 pore lining radial start and representative end 





‘Radial’ structures, whilst remaining intact through the simulations, retained poor 
packing between protomers resulting in a low number of potentially stabilising 
interactions. However, rotation of the protomers by an additional 20 degrees in 
a clockwise direction, observed from the top of the channel complex, greatly 
increased the proportion of surface interactions between protomers (Figure 
3.25C). The more ‘compact’ hexameric structure (Figure 3.24) in comparison 
with the ‘radial’ structure (Figure 3.20), has a visibly increased number of 
interactions between monomers, including interactions of the N terminal helix 
with adjacent protomers similarly to those seen in class III dimers. We therefore 
hypothesised the N-terminal helices (helix 1) interactions would reduce the 
overall flexibility of the channel complex. In addition, this region contains a HIS 
at position 28 on helix 1 (Figure 3.24), which is likely to become protonated in 
the acidifying endosomes, and therefore could influence the overall structure. 
These interactions may influence the activity of the channel, especially due to 
the presence of HIS28 on helix 1, which would be protonated in an acidic 
environment, such as within an internalised endosome. HPV E5 also possesses 
a peripheral HIS residue, using a liposome-based assay, indirect E5 channel 
activity is enhanced at acidic pH (Wetherill et al., 2012). Moreover, DENV M 
HIS39 present on the N terminal helix was shown to be important for particle 
production (Pryor et al., 2004). 
The helix 3 pore-lining compact channel lumen has a radius of 5.233 Å at the 
start of the simulation compared to 4.137 Å when ‘radial’ due to protruding side 
chains, with pore lining residues THR57, VAL61, ILE62, VAL65, MET66, LEU68 
and LEU69 (Figure 3.25), very different from the ‘radial’ pore lining residues 
(Figure 3.21) with only LEU68 present in both channels. However, both channel 
lumens contain a high percentage of residues with hydrophobic side chains, the 
exceptions being positively charged amino acid lysine for radial channels and 
polar amino acid threonine for compact channels. 
Helix 3 pore lining compact oligomers also all maintained their interactions 
between protomers, not becoming dissociated. The compact channels closed in 
70, 80 and 176 ns, compared to 6, 40 and >200 ns for helix 3 pore lining radial 
channels. Therefore, compact channels are open for a greater time period on 
average, irrespective of a single radial channel remaining open for >200 ns, due 
 
107 
to the short periods of time the remaining channels were open for. Thus the 
helix 3 pore lining compact oligomer is more likely to be representative of those 
found in the virion as it remains open for a greater period of time.  
A representative closed conformation is shown in Figure 3.26A with the lower 
part of the channel closed, as seen across all three final channel conformations. 
However, upon closer inspection of the simulation one channel also closes in 
the middle and the closure of simulation two channel extends upwards to the 
middle of the channel. These closures involve LEU64 and LEU68 similarly to 
the radial conformations, despite LEU64 not being a pore-lining residue in the 
compact conformation at the start of simulations. Additionally, pore-lining 
residues VAL61 and VAL65 also cause channel closure in these conformations 
(Figure 3.26B, C). 
These differences in closures may be a consequence of the compact 
conformation, which retains a greater number of pore-lining residues compared 
to radial models. However, interestingly LEU64, a residue not pore-lining at the 
start, was involved in the closure and restriction of the channels. An overlay of 




Figure 3.24 Hexameric Helix 3 pore-lining 'compact' channel, starting conformations 
A. Ribbon representation side on and from above with HIS28 residues highlighted in red. B. Surface representation side on 
and from above with one protomer highlighted in orange. C. Ribbon and Surface representation overlay with HOLE profile 
through the centre displaying the space inside the pore.
 




Figure 3.25 Hexameric helix 3 pore-lining ‘compact’ channel lumenal 
residues 
Pore lining residues of a Hexameric M protein channel in a ‘compact’ 
conformation with the C-terminal TMD (helix 3) lining the pore. Pore lining 
residues LEU69 in grey, LEU68 in grey, MET66 in purple, VAL65 in black, 
ILE62 in white, VAL61 in black and THR57 in green are shown from side on 




Figure 3.26 Hexameric Helix 3 pore-lining 'compact' channel conformations after 200 ns simulation 
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A. Surface and Ribbon representation of simulation three at 200ns from above and side with one helix cut away and HOLE surface 
plot displayed. Areas inaccessible to water with a pore radius < 1.15 Å in red, referred to as a closed channel, areas that will allow 
passage of one water molecule 1.15 Å > pore radius < 2.30 Å in green, and areas accessible to greater than one water molecule 
pore radius > 2.30 Å in blue. B. Simulation two channel zoomed in with HOLE surface plot displayed and residues closing the 
channel shown with sticks. LEU64 in yellow, LEU68 in orange, VAL61 in mauve and VAL65 in cyan. C.  Overlay of starting 
conformation in black and representative end conformation in white, with HIS28 in red. D. HOLE profile plot of pore radius, starting 
conformation shown in blue, simulation one, two and three in black, red and green respectively, with residues LEU64 in yellow, 




Figure 3.27 Helix 3 pore lining compact start and end conformation 
overlay 
Overlay from above of helix 3 pore lining compact start and representative end 




3.5.2.2 Does protonation of HIS28 change the structure of the hexameric 
helix 3 pore lining channels and their rate of closure? 
Simulations of hexameric M protein channels with helix 3 pore-lining in neutral 
pH showed stability by not disassociating upon equilibration, and have shown 
potential for channel activity by staying open for over 200 ns in one simulation. 
However, M protein channels are expected to form in an acidic environment 
within an endosome. Thus, we chose to mimic this environment by protonation 
of HIS28, located within the N-terminal helix 1, and to examine ensuing effects 
upon predicted channel structure and resultant switching between open and 
closed conformations.  
Interestingly, protonation of the ‘radial’ structure reduced the pore radius from 
4.137 to 3.8 Å (Figure 3.29 and Figure 3.22). However, protonated complexes 
displayed a similar propensity to close as did non-protonated radial structures 
during simulations (25, 27 and 172 ns), although direct comparison is 
challenging given that one of the non-protonated channels remained open for 
the duration (6, 40 and >200 ns) (Figure 3.22 and Figure 3.29). Had time 
permitted, an extended series of simulations may have yielded a more definitive 
measure of how HIS28 protonation affected the helical bundle. Similarly to non-
protonated simulations, channel closure involved LEU64, ILE67 and LEU68, 
with the addition of SER58 in one simulation (Figure 3.29). Despite the 
reduction in pore radius, the differences between protonated and non-
protonated HIS28 radial simulations are minimal, potentially due to the greater 
molecular distances separating HIS28 from the remainder of the channel in 
comparison to compact channels, resulting in the diminished influence of the 
associated positive charge. Measurement of the distance between the pore 
centre and HIS28 was found to be 31.28 Å. 
Conversely, protonation of the histidines on ‘compact’ helix 3 pore-lining 
channels had a greater impact upon channel behaviour. HIS28 protonation had 
minimal effect upon the channel radius, the narrowest point which remained 
virtually identical to non-protonated complexes: 5.233 compared with 5.207 Å 
(Figure 3.26D and Figure 3.31D). However, compared to non-protonated 
complexes, the presence of positive charge upon HIS28 led to an increase in 
the time taken for channels to close during three 200 ns simulations: 100, 130 
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and >200 ns compared with 70, 80 and 176 ns. Whilst again the lack of closure 
during one of the simulations makes it difficult to compare directly, the extended 
channel opening supports that M protein channels in this conformation are 
capable of responding to acidified environments. In comparison to radial 
channels, the distance between HIS28 and the pore centre in compact channels 
was reduced considerably to 16.8 Å, as opposed to 31.28 Å. This proximity may 
influence channel activity when HIS is protonated in an acidified environment. 
Furthermore, the remaining open channel exhibited a lumen radius of 2.533 Å 
at 200 ns, reducing by around half from 5.233 Å, yet still retaining a water 
column, providing an insight into the potential structure of an M protein viroporin 
(Figure 3.31). The conformation of a representative channel after 200 ns can be 
seen in Figure 3.31A, and in detail in Figure 3.23B, showing similarities 
between the protonated and not-protonated channels (Figure 3.26). Both sets of 
channels close similarly with residues VAL61, LEU64, VAL65 and LEU68 
occluding the pore, with the addition of residue ILE62 when channels are 
protonated.  
It is apparent from analysing the helix 3 pore-lining simulation sets that compact 
protonated channels remain open for the longest time periods, demonstrating 
that the compact channels respond as we would expect a channel to in a 
protonated environment, opening favourably in the acidic environment, 
mimicking the acidified endosome. Whereas the ‘radial’ structures did not 




Figure 3.28 Hexameric Helix 3 pore-lining ‘radial’ protonated channel starting conformations 
A. Ribbon representation side on and from above with histidine residues highlighted in red. B. Surface representation side on and 
from above with one protomer highlighted in orange. C. Ribbon and Surface overlay representation with HOLE profile through the 





Figure 3.29 Hexameric Helix 3 pore-lining 'radial' protonated channel conformation after 200 ns simulation 
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A.Surface and Ribbon representation of simulation three at 200ns from above and side with one helix cut away and HOLE surface 
plot displayed. Areas inaccessible to water with a pore radius < 1.15 Å in red, referred to as a closed channel, areas that will allow 
passage of one water molecule 1.15 Å > pore radius < 2.30 Å in green, and areas accessible to greater than one water molecule 
pore radius > 2.30 Å in blue. B. Representative channel zoomed in with HOLE surface plot displayed and residues closing the 
channel shown with sticks. LEU64 in yellow, ILE67 in purple and LEU68 in orange.  C. HOLE profile plot of pore radius, starting 
conformation shown in blue, simulation one, two and three in black, red and green respectively. D. Representative final 




 Figure 3.30 Hexameric Helix 3 pore-lining 'compact' protonated channel starting conformations  
A. Ribbon representation side on and from above with histidine residues highlighted in red. B. Surface representation side on 
and from above with one protomer highlighted in orange. C. Ribbon and Surface overlay representation with HOLE profile 





Figure 3.31 Hexameric Helix 3 pore-lining 'compact' protonated channel conformation after 200 ns simulation  
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A. Surface and Ribbon representation of simulation three at 200ns from above and side with one helix cut away and HOLE surface 
plot displayed. Areas inaccessible to water with a pore radius < 1.15 Å in red, referred to as a closed channel, areas that will allow 
passage of one water molecule 1.15 Å > pore radius < 2.30 Å in green, and areas accessible to greater than one water molecule 
pore radius > 2.30 Å in blue. B. Simulation two channel zoomed in with HOLE surface plot displayed and residues closing the 
channel shown with sticks. LEU64 in yellow, VAL61 in mauve and VAL65 in cyan and ILE62 in red.  C. HOLE profile plot of pore 
radius, starting conformation shown in blue, simulation one, two and three in black, red and green respectively. D. Representative 
final conformation of the compact not protonated simulation previously shown in Figure 3.25.
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3.5.2.3 Helix 1 truncation destabilises M protein channels 
M protein oligomers have shown stability with either Helix 2 or 3 pore lining, 
however Helix 3 channels retain a water permeable pore for extended periods 
of time in comparison. The role of Helix 1 in M protein channel stability has not 
been investigated. Through simulations of M protein channels with Helix 3 pore 
lining and a truncated Helix 1 we observed channels do not retain their pore. Of 
three repeat simulations, channels closed within 50 ns in each occurrence, 
suggesting Helix 1 plays a role in stabilising the open pore. Helix 1 may make 
vital interactions between monomers forming a more stable structure, or its 
residues may respond to the acidifying endosomal environment due to the 
presence of a HIS residue. 
 
Figure 3.32 Hexameric helix 3 pore lining channel simulations with 
truncated helix 1 
Ribbon representations of M protein channels with helix 3 pore lining and helix 1 




3.5.3 Are channels with Helix 2 lining the pore stable? 
Helix 2 was not predicted to be a channel pore-lining helix using MEM-SAT 
SVM software (Figure 3.5). However, to control for whether these predictions 
would apply during simulations, additional experiments were performed using 
radial and compact models where helix 2 lines the pore, including the simulation 
of HIS28 protonation. MD simulations were run with either helix 3 (section 3.5.2) 
or helix 2 in the centre of the pore for comparison. Similarly to the helix 3 pore 
lining channels, simulations were run in differing conformations, either ‘radial’ or 
‘compact’ and both were simulated in a neutral and a protonated environment, 
as previously run for helix 3 pore-lining to determine activity in an acidic 
environment.  
3.5.3.1 Simulating channels with helix 2 lining the pore, in a neutral pH  
The radial conformation of M protein hexamer with the helix 2 lining the pore 
was constructed with the N-terminal helix protruding away from the channel, 
resulting in helix 3 wrapping around the outside of the channel (Figure 3.33). 
The channel has a pore radius of 3.2 Å at its narrowest point, wider than the 
radius of a water molecule at 1.375 Å, the residues lining the pore start with 
PRO40 at the neck followed by LEU44, ALA47 and TRP51 prior to simulation 
(Figure 3.34). 
Channels were simulated for 200 ns using atomistic resolution. The channels 
remained open for just 6 ns in each of the three simulations. In Figure 3.33 the 
channel formed through the hexamer is obvious at the start of the simulation, 
after 200 ns the conformation of the closed channels can be seen in Figure 
3.35A, B. The channels closed in different ways, however all channels were 
occluded at the bottom by TRP51.  
As seen in section 0 rotation of individual protomers of the helix 3 pore-lining 
channels into the compact conformation results in more interactions between 
them, potentially stabilising the channel in comparison to the ‘radial’ 
conformation. The same rotation was applied to helix 2 pore-lining radial 
channel protomers. However, due to the position of the connecting helix 3, 





Figure 3.33 Hexameric Helix 2 pore-lining ‘radial’ channel starting conformations 
A. Ribbon representation side on and from above with histidine residues highlighted in red. B. Surface representation side on 
and from above with one protomer highlighted in orange. C. Ribbon and Surface overlay representation with HOLE profile 





Figure 3.34 Hexameric helix 2 pore-lining ‘radial’ channel lumenal 
residues and comparison of radial and compact conformations. 
Pore lining residues of a hexameric M protein channel in a ‘radial’ conformation 
with the N-terminal TMD (helix 2) lining the pore. Pore lining residues PRO40 in 
white, LEU44 in black, ALA47 in pink and TRP51 in blue are shown from side 
on with two protomers hidden and from below. B. Comparison of radial and 






Figure 3.35 Hexameric Helix 2 pore-lining 'radial' channel conformation after 200 ns simulation 
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A.Surface and Ribbon representation of simulation three at 200ns from above and side with one helix cut away and HOLE surface 
plot displayed. Areas inaccessible to water with a pore radius < 1.15 Å in red, referred to as a closed channel, areas that will allow 
passage of one water molecule 1.15 Å > pore radius < 2.30 Å in green, and areas accessible to greater than one water molecule 
pore radius > 2.30 Å in blue. B. Representative channel zoomed in with HOLE surface plot displayed and residues closing the 
channel shown with sticks. PRO40 in orange, LEU44 in purple, ALA45 in yellow close the channel at the top and TRP51 in cyan at 




the monomers overlapping. Therefore, the protomers were rotated anti-
clockwise for maximum interactions between protomers (Figure 3.33C).  
Starting conformations of the compact channels shown in Figure 3.36 had a 
radius of 4.236 Å, compared to the 3.2 Å of the radial conformation, explained 
by the different pore lining residues of PHE42, ALA45, ILE49 and LEU52 
(Figure 3.37). These compact channels also closed very quickly after 12 ns 
compared to 6 ns when radial, suggesting these channels are not a 
physiological representation of channel structure formed by M protein. 
A closed representative structure is shown in Figure 3.38A, and the pore-lining 
residues closing the structures are highlighted in Figure 3.38B. As seen with 
radial structures, all simulations close at the lower end of the channel by residue 
TRP51, for the compact structures the residues closing this region are TRP51, 
LEU52 and LEU53. Additionally, all channels are occluded at the top by 
residues GLY41, PHE42 and LEU44 (Figure 3.38B) in comparison to residues 
PRO40, LEU44 and ALA45 of the radial channels (Figure 3.35) These minor 
changes in pore closures demonstrate the change in structure due to rotation. 
3.5.3.2 Does protonation change the activity and structure of the 
hexameric helix 2 pore lining channels? 
Previously helix 2 pore-lining channels remained open for a very short period of 
time, 6 ns for ‘radial’ and 12 ns for ‘compact’ on average. However, upon 
protonation of HIS28 on the ‘radial’ structures the pore radius reduces to 3.0 
from 3.2 Å and the channels remain open longer, for 33 ns on average. By 
contrast, the same effect was not observed for ‘compact’ channels, where the 
pore radius reduced from 4.236 to 4.040 Å, but the channels only remained 
open for 5 ns on average. Determining protonation of HIS28 only improved the 
channel stability of ‘radial’ channels, potentially due to the direction of protomer 
rotation. The HIS28 residue is found on helix 1, which when highlighted on the 
radial structure (Figure 3.39A) is shown to be close to the adjacent protomer in 
a clockwise direction, however the location of HIS28 on the helix 1 on ‘compact’ 
channels this is found close to the adjacent protomer in an anti-clockwise 




Figure 3.36 Hexameric Helix 2 pore-lining ‘compact’ channel starting conformations 
A. Ribbon representation side on and from above with histidine residues highlighted in red. B. Surface representation side on 
and from above with one protomer highlighted in orange. C. Ribbon and Surface overlay representation with HOLE profile 
through the centre displaying the space inside the pore 




Figure 3.37 Hexameric helix 2 pore-lining ‘compact’ channel lumenal 
residues. 
A. Pore lining residues of a Hexameric M protein channel in a ‘compact’ 
conformation with the C-terminal TMD (H3) lining the pore. Pore lining residues 
PHE42 in blue, ALA45 in pink, ILE49 in white and LEU52 in grey are shown 




Figure 3.38 Hexameric Helix 2 pore-lining 'compact' channel conformation after 200 ns simulation 
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A. Surface and Ribbon representation of simulation three at 200 ns from above and side with one helix cut away and HOLE surface 
plot displayed. Areas inaccessible to water with a pore radius < 1.15 Å in red, referred to as a closed channel, areas that will allow 
passage of one water molecule 1.15 Å > pore radius < 2.30 Å in green, and areas accessible to greater than one water molecule 
pore radius > 2.30 Å in blue. B. Simulation two channel zoomed in with HOLE surface plot displayed and residues closing the 
channel shown with sticks. PHE42 closes the top, TRP51 and LEU52 close the bottom. C. HOLE profile plot of pore radius, starting 
conformation shown in blue, simulation one, two and three in black, red and green respectively. D. Simulation one of helix 2 pore 
lining radial conformation, previously shown in Figure 3.35.  
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Additionally, the pore-lining residues involved with channel closures are altered 
in the radial structures. Residue TRP51 still plays a role in closing channels, 
however this appears more of a restriction which leads to combinations of 
residues PRO40, GLY41, LEU44, ALA48 and LEU53 to close the channels 
(Figure 3.40). Residues PRO40, LEU44 also close the non-protonated channels 
with the addition of residue ALA45. Compact channels also observe similar 
closings, prior to protonation all channels were obstructed at both the top and 
bottom by combinations of GLY41, PHE42, LEU44 and TRP51, LEU52, LEU53 
respectively (Figure 3.38). However, after protonation only two channels were 
obstructed at the top, involving combinations of residues ASN39, GLY41 and 
PHE42 and only two channels were closed lower down by residues TRP51 and 
LEU52 (Figure 3.42). 
The subtle differences of residues involved in channel closure likely reflect the 
interactions induced by HIS28 protonation, the increase in time the helix 2 pore 
lining ‘radial’ protonated channels remained open could highlight the importance 
of the location of the HIS28 in relation to the channel. Furthermore the helix two 
pore-lining channel remained open for a much shorter average time than the 
helix 3 pore lining channels, and did not respond as positively to protonation, 
demonstrating they are unlikely to represent the structure of M protein 
viroporins within the acidified virion during entry and uncoating. Conversely 
helix 3 pore-lining channels remained open for over 100 ns on average, and the 
compact conformations responded positively to being protonated, taking the 
channels longer to close, or in some cases not close within the 200 ns 
simulations. The simulation data shown in this section indicates helix 2 is not 
likely to line the pore of the channel, in comparison to helix 3 simulation data 




Figure 3.39 Hexameric Helix 2 pore-lining ‘radial’ protonated channel starting conformations 
A. Ribbon representation side on and from above with histidine residues highlighted in red. B. Surface representation side on 
and from above with one protomer highlighted in orange. C. Ribbon and Surface overlay representation with HOLE profile 




Figure 3.40 Hexameric Helix 2 pore-lining 'radial' protonated channel conformation after 200 ns simulation 
 
135 
A.Surface and Ribbon representation of simulation three at 200ns from above and side with one helix cut away and HOLE surface 
plot displayed. Areas inaccessible to water with a pore radius < 1.15 Å in red, referred to as a closed channel, areas that will allow 
passage of one water molecule 1.15 Å > pore radius < 2.30 Å in green, and areas accessible to greater than one water molecule 
pore radius > 2.30 Å in blue. B. Simulation three channel zoomed in with HOLE surface plot displayed and residues closing the 
channel shown with sticks. PHE42 closes the top, TRP51 and LEU52 close the bottom. C. HOLE profile plot of pore radius, starting 
conformation shown in blue, simulation one, two and three in black, red and green respectively. D. Simulation one of helix 2 pore 




Figure 3.41 Hexameric Helix 2 pore-lining ‘compact’ protonated channel starting conformations 
A. Ribbon representation side on and from above with histidine residues highlighted in red. B. Surface representation side on 
and from above with one protomer highlighted in orange. C. Ribbon and Surface overlay representation with HOLE profile 
through the centre displaying the space inside the pore 








A. Surface and Ribbon representation of representative channel at 200ns from above and side with one helix cut away and HOLE 
surface plot displayed. Areas inaccessible to water with a pore radius < 1.15 Å in red, referred to as a closed channel, areas that 
will allow passage of one water molecule 1.15 Å > pore radius < 2.30 Å in green, and areas accessible to greater than one water 
molecule pore radius > 2.30 Å in blue. B. Representative channel zoomed in with HOLE surface plot displayed and residues 
closing the channel shown with sticks. ILE49 in green and PHE42 in grey close the top, ILE49 in purple occludes the middle and 
LEU52 in pink restricts the bottom. C. HOLE profile plot of pore radius, starting conformation shown in blue, simulation one, two 





Using MD simulation, we have predicted that M is capable of forming a stable 
two TMD monomer within a POPC lipid bilayer, as well as in a more complex 
membrane present within WNV virions (Figure 3.9 and Figure 3.10). The short 
TMD’s of the cryo-EM M protein structure raised questions regarding its 
capability to span a lipid bilayer, and potentially the need for a variety of lipids 
with different length hydrophobic tails for the protein to remain within the 
membrane. However, as a one TMD M protein, E would reside on the incorrect 
side of the virion membrane. Furthermore, our simulations in Figure 3.9, have 
shown M protein is stable within a more simple POPC bilayer. Although during 
simulations phospholipid heads of the lipid bilayer are seen pinching into the 
leaflets to meet the short TMDs maintaining the protein within the membrane.  
This feature is known as hydrophobic mismatching, a result of the difference in 
thickness of the lipid membrane and the proteins’ hydrophobic domain (Jensen 
and Mouritsen, 2004). Hydrophobic mismatching is seen with other viral and 
non-viral proteins, where hydrophobic TMDs are shorter (negative hydrophobic 
mismatch) or longer (positive hydrophobic mismatch) than the lipid bilayer. 
Appropriately hydrophobic mismatching is observed during MD simulations of 
HCV p7 viroporin channels, causing membrane pinching and straightening of 
the TMDs, reducing their tilt angle (Chandler et al., 2012). Conversely, HIV-1 
Vpu monomers undergo tilting of TMD helices due to a positive hydrophobic 
mismatch (Yeagle et al., 2007). M protein helices do not appear to change their 
tilt angle, however the mismatching is maintained by phospholipid tails tilting 
instead.  
The overall morphology of Flavivirus particles is stabilised by the icosahedral 
surface of E/M in the mature virions and through their anchoring into the virus 
membrane (Figure 3.2). The membrane underneath each region of the 
icosahedral surface exhibits either a concave, planar, convex or saddle shape, 
which together result in spherical membrane formation (Zhang, W. et al., 2013). 
The herringbone arrangement of E/M proteins on the surface of the ZIKV virion 
(Sirohi et al., 2016), is formed by units of three Envelope dimers and three M 
protein dimers. MD coarse-grained simulations of each of  these hexamers has 
a visible effect on the membrane curvature, particularly M protein which results 
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in a positive curvature of the lower leaflet, thought to be important in assembly 
of the virus particle into the icosahedral shape (Wewer and Khandelia, 2018).  
Additionally, we consistently observed the inner leaflet of the lipid bilayer where 
the linker region resides to be the area with most pronounced lipid 
rearrangements, in line with virion membrane curvature for vesicle formation. 
Furthermore, the M protein TMDs diverge from the linker region, resulting in a 
gap between them at the outer bilayer leaflet. This structure forms a wedge-like 
conformation, which along with hair-pin regions lends themselves to membrane 
curvature and ultimately vesicle formation (Jarsch et al., 2016). 
More recently, a variety of coarse-grained and all atom MD simulations of a 
DENV E/M homotetramer resulted in the same membrane pinching indentation 
on the lower leaflet as seen in the dimers in section 1.4, reducing membrane 
thickness (Wewer and Khandelia, 2018). Further simulations of 5 
homotetramers were arranged as seen at the five-fold axis however on a planar 
DENV derived lipid membrane, similar in shape to a square wafer. After 440 ns 
of simulation the E/M homotetramers caused the membrane to curve 
extensively resulting in a complete vesicle formed of 17.3 nm (de Oliveira Dos 
Santos Soares et al., 2017). 
Our monomeric and dimeric simulations were conducted in more simplistic 
POPC bilayers and bilayers emulating the composition of a WNV virion. 
However, the differences in stability observed for monomers and interactions 
between dimers were not obviously different between these lipid bilayers. Thus, 
we simulated higher order oligomeric structures in simple POPC bilayers, due to 
time restraints. However, a recent study simulating ZIKV and DENV E & M 
glycoproteins reported differential interactions between glycoproteins and 
certain phospholipids (Wewer and Khandelia, 2018). The simulated membranes 
consisted of PC : PS : PE : SM at the respective ratios of 57 : 25 : 3 : 15. ZIKV and 
DENV both enriched the surrounding membranes with PS and PE lipids in 
comparison to PC and SM, however PE localised closer to DENV proteins and 
conversely PS lipids localised closer to ZIKV proteins, hotspots on these 
proteins for the lipids were identified (Wewer and Khandelia, 2018). If time 
allowed, it would be interesting to analyse the lipid-protein interactions of the 
previously run simulations, to observe if similar interactions are seen with our 
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minimally different PC : PS : PE : SM lipid bilayer composition of 57 : 21 : 5 : 17 
(Martin-Acebes et al., 2014).  
As mentioned previously the class proportions of final dimer conformations did 
not vary widely between the lipid environments, however restraining C atoms 
resulted in a shift of the classes seen. Restraints saw an increase of the cyro-
EM dimeric M conformation (Sirohi et al., 2016) from 1 and 2 instances for 
POPC and WNV membranes to 4 and 3 when restrained. This dimeric 
conformation occurs in viruses due to the bringing together of two prM-E 
heterodimers, which upon pr cleavage by furin go on to form two E and M 
homodimers, therefore forming in a restrained environment. C restraints may 
partially mimic this physiological restraint on M protein held by E protein in the 
virion. Additionally, reductions in class II, III and IV dimers were observed upon 
restraining; this change in dimer class formation may reflect the need for helix 1 
flexibility for these dimer classes II, III and IV to form. As observed in Figure 
3.17 we expect dimers of Class III conformation to form higher order oligomers, 
these form more frequently when restraints are not applied. We hypothesise M 
channels form once the virion is acidified and dimeric M is released from 
underneath dimeric E; at this point, the restraints upon the dimers would be 
released. Therefore, future work could focus on simulating unrestrained M 
protein class I dimers in an acidic environment, or by histidine protonation 
observing if there are conformational changes from class I to class III dimers. 
M protein channel simulations uncovered a potential insight into the structure 
and activity of an M protein viroporin. Hexameric M channels closed within 
varying timeframes dependent on the pore-lining helix and the protonation state 
of the channels. M protein appears capable of functioning as a hexameric ion 
channel, however radial conformations with helix 2 lining the pore did not result 
in a stable open channel in a neutral environment, all channels closed their 
pores after only 5 or 6 ns. On the other hand, helix 3 lining the pore resulted in a 
water column remaining intact for much longer (6, 40 and over 200 ns) with one 
channel not closing within the 200 ns. These results align with the pore-lining 
helix prediction results mentioned in section 3.2 from MEMSAT SVM. The 
prediction software used in Figure 3.4 and Figure 3.5 were all the currently 
available online prediction tools, and MEMSAT-SVM was the only pore-lining 
helix predictor. Furthermore, the prediction of DENV M to be a single TMD 
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protein from the Phobius prediction tool was published (Tomar et al., 2019). 
However, the research suggests DENV M may also be a viroporin. 
Moreover, rotation of protomers results in both helix 2 and helix 3 pore-lining 
channels remaining open for longer, helix 2 pore-lining channels increased 
slightly from an average of 6 to 12 ns of channel activity and helix 3 pore-lining 
channels increased from an average of 82 to 108 ns. Rotation of the individual 
protomers increases the interactions between adjacent protomers, particularly 
with the N-terminal helix for helix 3 pore-lining channels (Figure 3.21 and Figure 
3.24) Furthermore, comparison of Figure 3.23 and Figure 3.27 shows the 
changes in structure are greater for the radial structure than the compact, 
possibly due to the more favourable conformation and the increase in inter-
monomer interactions. However, rotation also changed the pore-lining residues, 
which largely influences the stability of the water column. Helix 2 pore lining 
channel ‘radial’ conformation has a pore containing a proline, leucine, alanine 
and tryptophan (Figure 3.34). After rotation, the pore changes slightly to contain 
a phenylalanine, alanine, isoleucine and leucine (Figure 3.37). Both of these 
pores contain residues with similar properties of hydrophobic side chains. 
Helix 3 pore lining ‘radial’ conformation starts simulations with two leucines, an 
isoleucine, tyrosine and lysine lining the pore (Figure 3.21), however with 
rotation of protomers the channel is lined with two leucines, a methionine, two 
valines, an isoleucine and threonine (Figure 3.25). Both the ‘radial’ and 
‘compact’ helix 3 pore-lining channels are lined predominantly by hydrophobic 
amino acids with the addition of one or two polar of charged residues. The 
addition of an amphipathic or hydrophilic residue may increase the stability of 
the pore in comparison to helix 2, which does not have a hydrophilic residue in 
the pore lining.  
In comparison to other viroporin lumens, M2 contains a valine, alanine, glycine 
(Pinto et al., 1997) and the multiple computational p7 structures contain 
alanines, valines, leucines and isoleucines (Chandler et al., 2012). 
Comparatively M protein is also largely lined with hydrophobic residues, 
however the radial channel conformation contains a polar tyrosine and a 
positively charged lysine, or in a compact channel conformation a polar 
threonine, capable of being charged.  
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Moreover, protonation of the N-terminal histidine affected the closing of the 
channel lumens as well. Helix 2 ‘radial’ channels stayed open for 33 ns when 
protonated as opposed to 6 ns when not protonated, however their final HOLE 
conformations are comparable. Protonated helix 2 ‘compact’ channels remained 
open for 5 ns on average and 12 ns when not. Repeatedly the final 
conformations of the channel closures appear comparable. The opposing 
nature of these results could be due to the location of the protonated histidine 
and its proximity to the channel lumen. 
In contrast, helix 3 pore-lining ‘radial’ channel conformations remained open for 
72 ns with protonation and 82 ns without, with one non-protonated channel 
remaining open for the whole simulation. Helix 3 compact channels take 108 ns 
on average to close and this is lengthened to 137 ns when protonated. As 
mentioned previously the change in time taken for the channels to close is likely 
due to the location of the histidine, its proximity to the channel and which 
residues it interacts with. In Figure 3.29 the histidine is highlighted and can be 
seen much closer to the channel lumen at 16.8 Å and potentially interacting with 
adjacent protomers comparatively to Figure 3.32, showing the ‘radial’ 
conformation with the highlighted histidine much further away from adjacent 
protomers and the channel lumen than seen in the compact conformation at 
31.28 Å. Acid sensitive viroporin M2 and some genotypes of p7, both have a 
HIS residue present within the channel lumen (Ito et al., 1991; Oestringer et al., 
2019). However, viroporin E5 has two HIS residues present at the C-terminal 
tail of each monomer, similarly to the presence of the two M protein HIS 
residues found at the N-terminus leading to pH activation (DiMaio and Petti, 
2013), moreover both HIS residues of E5 are present in the unstructured C 
terminal region, whereas M protein contains one in both the structured and 
unstructured N terminal regions. Simulations of M2, compared to protonated M2 
showed differences in structure, comparable to the previously resolved 
structures in both environments (Khurana et al., 2009). 
As noted earlier, M protein channels are only likely to form within the endocytic 
pathway during virus entry. Endosomal pH is less than 6.5, and so will cause 
protonation of histidines present on the exposed N-terminal region of M, 
including helix 1 from our simulation that contains HIS28. MD simulations in this 
protonated environment contribute to simulating a more physiologically relevant 
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environment. Additionally, other viroporins contain conserved histidines, 
including IAV M2 and some HCV p7 genotypes. Protonation of M2 histidine 37 
causes channel activation and proton-selective conductance of the channel 
(Pinto et al., 1997; Betakova and Kollerova, 2006), p7 pore-lining HIS17 is 
conserved and is important for genotype 1b p7 channel activity (StGelais et al., 
2009; Chew et al., 2009). 
Evidence supporting that helix 3 may represent a pore-lining helix was first 
obtained through the MEMSAT-SVM prediction. However, its longer channel 
opening and positive reaction to protonation further supports that helix 3 
comprises the lining of the pore. Two channels simulated with helix 3 pore-lining 
remain open after 200 ns. However, upon closure of the remaining channels it 
appears ILE64 is involved in closure of all channel simulations regardless of 
protomer rotation and LEU68 is also involved in the majority of these. LEU68 as 
seen in Figure 3.1 is conserved in YFV and WNV however not in DENV, 
although ILE64 is not a conserved residue. Compact channels also are closed 
by VAL61 and 65 and again these are not conserved residues. As ILE64 and 
LEU68 cause the closure of most of these channels, they may be identified as 
gating residues.  
Conversely helix 2 pore-lining channels all close relatively quickly, indicative of 
an unfavourable channel. In radial channel simulations a non-conserved 
TRP51, and a conserved PRO40 and LEU44 are responsible for channels 
closing. Upon protonation an additional residue GLY41, found to be highly 
conserved throughout the Flavivirus genus, closes all channels alongside 
previously mentioned TRP51, PRO40 and GLY41. When helix 2 pore-lining 
channels are compact the residues lining the pore and closing the channels 
change, a conserved PHE42 closes all channels run in the absence of 
protonation alongside previously mentioned TRP51 and an additional LEU52. 
When protonated these channels remain closing by PHE42 and LEU52. The 
involvement of highly conserved residues in closure of channels is likely due to 
these channels being highly involved in maintaining the structure of the channel, 
however from a membrane-facing role as a peripheral helix, as opposed to a 
pore-lining helix. 
The four hexameric structures simulated suggest that helix 3 pore-lining 
compact oligomers are the most representative of those found in the virion, as 
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they remain open for the longest period of time. However, it is not clear how 
long channels would remain open during infection. p7 channels in DOPC rich 
bilayers remain open for ~500 ms by patch clamping, far longer than our 
simulations (Hyser, 2015), however Rotavirus non-structural protein 4 (NSP4) 
channels formed in planar lipid membranes remained open for just 65 ps (Pham 
et al., 2017). Additionally, compact helix 3 pore-lining channels do respond 
positively to being HIS-protonated indicating the model is the most accurate in a 
physiologically relevant environment. 
Heptameric M protein channels also formed stable oligomers which remained 
interacting throughout simulations. Helix 2 pore lining radial and compact 
conformations remained open for far longer than corresponding hexameric 
channels. However, upon protonation helix 2 pore lining heptamers closed more 
quickly, whereas protonated hexameric channels remained open for longer.  
With helix 3 pore lining, the majority of heptameric channels remained open 
throughout the simulation with many ‘compact’ conformations retaining a water 
column for almost 200 ns regardless of protonation. These channels take longer 
to close due to the high number of interactions between adjacent protomers, 
forming a highly stable structure. When protomers with pores lined by helix 3 
are radial, channels show an increased propensity to close, however both these 
averages reflect two out of three channels remaining open with one channel 
closing sooner.  
Although we are able to simulate heptameric channels, it is unlikely channels of 
seven would form due to the virion stoichiometry. Additionally, M protein is 
present within the virion as a dimer, and simulations of two M protein monomers 
(section 3.4) consistently show dimerisation in the vast majority. Disassociation 
of dimers has not been observed in the MD simulations, however, when the E-
M heterotetramers dissociate during entry, allowing E trimers to form, it could be 
possible for M dimers to also dissociate.  
Our MD simulations and analysis suggest hexameric channels with helix 3 pore-
lining are the most likely viroporin structure, due to these channels remaining 
open for longer periods of time and when protonated this time is extended. 
Conversely, heptameric channels remain open for long time periods regardless 
of the helix lining the pore, this lack of specificity highlights heptameric channels 
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CG-simulation Membrane Composition  Duration 
Monomer 
1 TMD POPC POPC (100) 3 µs 
2 TMD POPC POPC (100) 3 µs 
2 TMD WNV POPC:POPS:POPE:SM 
(57:25:3:15) 
3 µs 
1 TMD truncated POPC POPC (100) 3 µs 
Dimer 




Restrained - POPC POPC (100) 6 µs 




Table 3.2 Coarse-grained Simulation Overview   
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AA-simulation Membrane Composition  Duration 
Hexamer 
H2 Radial  POPC (100) 200 ns 
H2 Radial protonated POPC (100) 200 ns 
H2 Compact POPC (100) 200 ns 
H2 Compact Protonated  POPC (100) 200 ns 
H3 Radial  POPC (100) 200 ns 
H3 Radial protonated POPC (100) 200 ns 
H3 Compact POPC (100) 200 ns 
H3 Compact Protonated  POPC (100) 200 ns 
Heptamer 
H2 Radial  POPC (100) 200 ns 
H2 Radial protonated POPC (100) 200 ns 
H2 Compact POPC (100) 200 ns 
H2 Compact Protonated  POPC (100) 200 ns 
H3 Radial  POPC (100) 200 ns 
H3 Radial protonated POPC (100) 200 ns 
H3 Compact POPC (100) 200 ns 
H3 Compact Protonated  POPC (100) 200 ns 




Chapter 4 M protein displays pH activated, rimantadine-
sensitive, channel activity with a role during ZIKV entry 
4.1 Introduction 
Increasing numbers of small (60-100 amino acids), hydrophobic viral membrane 
proteins are being recognised to form oligomeric complexes that exert channel 
activity. Such proteins, termed “viroporins”, play often-essential roles during 
virus life cycles, with many of them acting to expedite virus egress and/or entry 
(Scott and Griffin, 2015). Hence, based upon molecular dynamics simulations 
(Chapter 3) combined with its primary structure and studies on related M 
proteins (Premkumar et al., 2005), we hypothesised that ZIKV M bore the 
characteristic hallmarks of a viroporin and so should both oligomerise and 
display channel activity in vitro.  
Formation of higher-order viroporin structures can be induced using non-ionic, 
membrane-mimetic detergents (e.g. 1,2-dihexanoyl-sn-glycero-3-
phosphocholine (DH(6)PC) or 1,2-diheptanoyl-sn-glycero-3-phosphocholine 
(DH(7)PC)) at concentrations above the critical micellar concentration (CMC). 
These micelles stabilise membrane protein complexes (Wetherill et al., 2012; 
StGelais et al., 2009; Schnell and Chou, 2008; Luik et al., 2009; OuYang et al., 
2013; Panjwani et al., 2014), substituting for lipids such as POPC, which form 
vesicles and are more technically challenging for structural studies (Figure 4.1). 
Biochemical analysis of viroporin oligomerisation has previously comprised 
multiple techniques, including visualisation using native-PAGE and transmission 
electron microscopy (TEM).  
However, visualisation of oligomers is not sufficient to ascribe viroporin function 
to a given protein. We required an assay adaptable to the use of a truncated M 
protein peptide (section 2.5.4), to provide evidence of channel activity and to 
enable screening of potential inhibitors. Thus, we adapted a previously used, 
liposome-based, dye release assay as a robust indirect method (StGelais et al., 
2007; Tuthill et al., 2006; Davis et al., 2008) for assessing viroporin activity.  
This liposome-based assay is most suitable for observing channel activity and 
identifying potential inhibitors, as other systems struggle with scaling up, 
including BLMs and single cell patch clamping. We have shown the assay 
works routinely in a 96 well plate, furthermore, the liposome-based assay has 
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been used to screen compounds against HCV p7 channels, in a 384 well plate 
format, achieving a satisfactory z score (Gervais et al., 2011). 
Liposome-based systems have previously been used to investigate channel 
activity of viroporins including M2, alphavirus 6k, poliovirus 2B and HCV p7 
(Scott and Griffin, 2015; Antoine et al., 2007; Madan et al., 2007; Montserret et 
al., 2010; StGelais et al., 2007). Use of this assay has been disputed on one 
occasion (Gan et al., 2014), however many reports mentioned above support its 
indirect measurement of channel activity. Dye release assays can also identify 
other properties, including the use of fluorescent dextrans to determine pore 
size, the effect of pH on channel activity and viroporin inhibitors such as 
Rimantadine (Wetherill et al., 2012; Panjwani et al., 2014; Shukla et al., 2015; 
StGelais et al., 2007). The effect of pH was of considerable interest as we 
hypothesised that M protein forms channels during virion endocytosis. However, 
identification of inhibitors can also support proof of M protein oligomerisation, in 
addition to development of a potential antiviral compound. 
In vitro methods have been used successfully to identify inhibitors previously, 
however evidence of their activity in cell culture is further convincing. Incubating 
host cells and virus with potential antivirals throughout infection can show their 
effect of reducing virus titre. Furthermore, time of addition (TOA) assays 
determine the virus life cycle stage at which a virus inhibitor is active. TOA 
assays are carried out by adding an antiviral compound to the virus and host 
cells at different times in the virus life cycle. The distinct stages are: pre-treating 
host cells or the virus prior to inoculation, co-treatment of cell and virus during 
inoculation and treatment of virus-infected cells during the post-inoculation 
period. The stages can also be combined to see the effects of the compound 
when present in multiple stages of the virus life cycle (Pauwels et al., 1990; 
Kato et al., 2016; Daelemans et al., 2011; Chen, M. et al., 2017). Observing the 
lifecycle stage where a previously screened inhibitor has the greatest effect is of 
great interest to help identify the viral target.  
Additionally, successful inhibitors in cell culture can be translated into an in vivo 
model system to further investigate the effect an identified compound may have 
on a whole organism when infected, and whether the effects of the compound 
are comparable to those seen in cell culture.  
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This chapter presents evidence for M protein oligomerisation in a membrane 
mimetic environment and channel activity is demonstrated using liposome dye 
release assays. Additionally, M protein channels are found to be sensitive to the 
channel-blocking compound, rimantadine, in vitro, and the corresponding 
antiviral activity of this compound in cell culture supports a role for M protein 
channels during virus entry. Lastly, we demonstrate that rimantadine prevents 







Figure 4.1 Schematic comparing phospholipid structures 




4.2 ZIKV M protein forms oligomers in detergent micelles 
4.2.1 M protein oligomerises in DHPC detergent 
To explore whether M protein can oligomerise in a membrane mimetic 
environment, a truncated M peptide of 55 amino acids, lacking 20 N-terminal 
residues (Figure 4.2), was diluted in various non-ionic detergents which have 
previously been used in viroporin studies: 1,2-dihexanoyl-sn-glycero-3-
phosphocholine DH(6)PC, DH(7)PC, 1-palmitoyl-2-hydroxy-sn-glycero-3-
phospho-(1'-rac-glycerol) (LPPG) and 1-myristoyl-2-hydroxy-sn-glycero-3-
phospho-(1'-rac-glycerol) (LMPG). Other viroporins including p7, SH and E5 
have previously been shown to form higher order structures in detergent 
environments by both native PAGE and transmission electron microscopy 
(TEM) (StGelais et al., 2007; Carter et al., 2010; Wetherill et al., 2012; Li, Y. et 
al., 2014; Luik et al., 2009).    
M was insoluble in aqueous solution, therefore dissolved in DMSO prior to 
dilution in detergent. DH(6)PC, DH(7)PC, LMPG and LPPG were selected to 
stabilise M protein and characterise its oligomerising capabilities based on 
previous viroporin studies (Griffin, S.D. et al., 2003; Clarke et al., 2006; Carter 
et al., 2010; Luik et al., 2009). All detergents were used above their respective 
CMC’s and protein was diluted into each at 500 ng/µL. After 10 min at 37 °C, 
samples were separated by native PAGE and stained with Coomassie brilliant 
blue reagent (section 2.5.2 and 2.5.3) (Figure 4.3A).  
M peptide oligomerisation occurred in the presence of DH(6)PC, but not for the 
other detergents. Monomeric truncated M peptide is 6.3 kDa in molecular 
weight and the M-DH(6)PC detergent complexes migrated at a similar rate to 
the ~45 and ~66 kDa molecular weight markers. However, native PAGE 
separates proteins by net charge, molecular weight, and conformation; thus, 
protein migration cannot be accurately related to molecular weight using this 
technique. 
To gain an insight of the tertiary arrangements of oligomeric M protein in the 
detergent environment we chose to employ negative TEM to investigate 
whether this oligomer represents a channel-like structure, based upon previous 




Figure 4.2 M peptide of 55 amino acids with an N terminal truncation 
Protein shaded with sections corresponding to the structural regions of the protein sequence shown below. The site of the peptide 




Figure 4.3 Oligomerisation of M protein in detergent environment by 
native PAGE 
Native PAGE analysis of M protein 5 μg in differing membrane mimetic 
detergents (300 mM), DH(6)PC, DH(7)PC, LPPG and LMPG. Gel stained using 




4.2.2  Visualisation of ZIKV M peptide oligomers by Transmission 
Electron Microscopy (TEM) 
Structural information for ZIKV M protein hails from the mature virion cryo-EM 
structures, where it resides as a dimer within the virion membrane (Sirohi et al., 
2016; Sevvana et al., 2018). M protein has not been visualised in isolation, or in 
the context of an acidified virus particle mimicking the entry process. Hence, the 
structure of M in the absence of adjacent E protein TM regions remains 
unknown (section 3.2). In section 3.4.3 M protein simulations gave insight into 
the potential influence of the presence of E protein on M protein dimers through 
N-terminal restraints, potentially causing preferential formation of ‘class III’ 
dimers which may represent a dimeric structure which leads to the formation of 
oligomers.  
Based upon native PAGE data (section 4.2.1), truncated M peptide was 
reconstituted across a range of DH(6)PC concentrations, deposited onto carbon 
coated grids and analysed using negative stain TEM. Ring-like structures with 
an electron-dense central pore were readily observable at all DH(6)PC 
concentrations (125-175 mM) (section 2.6.6 & Figure 4.4). Additionally, 
channels were seen at 300 mM, the concentration used in the native PAGE, but 
at far lower frequency. These structures resembled those observed for other 
viroporins under similar conditions, including HCV p7 (Clarke et al., 2006; Luik 
et al., 2009).  
Consistent with the presence of M protein oligomers, many channel structures 
with an average oligomer diameter of 8.6 nm were present at 150 mM 
DH(6)PC, which was the optimal in terms of the lowest signal noise ratio and 
particle heterogeneity (Figure 4.4B).  Particles seemingly aligned in a single 
plane relative to the grid surface displaying the presence of the electron-dense 
pore.  
The favourably aligned orientations of M protein channels appeared ideal for 
two-dimensional class averaging to determine channel stoichiometry. 9907 
particles were picked at 150 mM DH(6)PC (Figure 4.6B), yet the resolution of 
the images did not allow the stoichiometry to be determined. The issues with 
resolution may be due to the thickness of 2 % uranyl acetate stain and/or 
potential heterogeneity of the oligomers.  
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Additionally, the 125, 150 and 175 mM concentrations of DH(6)PC displayed 
seemingly different channel configurations (Figure 4.4).  Channels observed in 
150 mM DH(6)PC were chosen for further analysis due to their high levels of 
homogeneity and frequency. The average diameter of oligomers was 
determined by measuring all channels from two fields of view. Channels present 
in 150 mM DH(6)PC averaged 8.8 nm, comparatively oligomers in 125 mM 
DH(6)PC had an average diameter of 7.6 nm, with more smaller oligomers and 
an electron dense pore not being present (Figure 4.4A), furthermore at 175 mM 
DH(6)PC channels averaged 10.5 nm and the background noise had increased 
(Figure 4.5). 
This analysis represents the first visualisation of oligomeric channels for any 
Flavivirus M protein. The ZIKV M protein oligomers exhibiting electron dense 
pores, reminiscent of other viroporins is highly supportive of our ZIKV M 
viroporin hypothesis. To determine whether the channels seen by TEM can 
form membrane-permeabilising pores, we introduced the M peptide into a dye-







Figure 4.4 M oligomerisation at varying DH(6)PC concentrations, visualised by TEM 
M protein diluted in DH(6)PC prior to staining with 2 % uranyl acetate and visualisation at 125 000 x magnification by transmission 
electron microscopy. A. M protein added to 125 mM DH(6)PC B. M protein added to 150 mM DH(6)PC C. M protein added to 175 
mM DH(6)PC. TEM images kindly generated by Dr Daniel Maskell and Dr Rebecca Thompson. 
 







Figure 4.5 Pore diameter of M protein oligomers in a detergent 
environment 
M protein channels in the presence of 125, 150 and 175 mM DH(6)PC were 
imaged using transmission electron microscopy and the channels formed were 




Figure 4.6 Oligomerisation of M protein in detergent environment by 
Transmission Electron Microscopy 
A. A selection of M protein channels in the presence of 150 mM DH(6)PC 
stained with 2 % uranyl acetate, on average ~8.6 nm in diameter. B. 2D class 
averaging of 9907 channels with 25 iterations in 150mM DH(6)PC. TEM images 






















4.3  M peptides mediate dose-dependent release of 
carboxyfluorescein from liposomes 
Visualisation of M protein by TEM in a detergent environment showed M 
peptide oligomerised to form a ring-like structure indicative of a channel. To 
determine whether this channel is functional in vitro, a published liposome-
based dye release assay was optimised for use with M peptides (StGelais et al., 
2007; Tuthill et al., 2006; Davis et al., 2008). 
Liposomes were made by extrusion using commercially available phospholipids: 
l-α-phosphatidic acid (PA), l-α-phosphatidylcholine acid (PC) and N-lissamine 
rhodamine labelled l-α-phosphatidylethanolamine (PE), and contain 
carboxyfluorescein (CF) at a self-quenching concentration (section 2.6.1). 
Positive controls comprising rimantadine resistant M2 derived peptides (channel 
activity) or Triton X-100 (maximal dye release) (Atkins et al., 2014; Scott et al., 
2020) (Figure 4.6A and B) were added to the liposomes releasing CF, diluting 
CF from its self-quenching concentration within the liposomes and into the 
surrounding buffer. The resulting fluorescence was monitored by fluorimetry 
over a 30 min period. Baseline levels were calculated from solvent controls (5 % 
DMSO or 5 % MeOH) (section 2.6.2).  
Increasing concentrations of M protein resuspended in DMSO were added to 
CF containing liposomes, resulting in a concentration-dependent increase in 
total CF released from liposomes (Figure 4.7C). However, reconstitution of M 
protein up to 50 nM in MeOH showed no activity (Figure 4.7B), and this applied 
up to 250 nM (data not shown). Therefore, M protein was resuspended in 
DMSO at a concentration of 780 nM in subsequent experiments. 
The indirect measurement of ZIKV M channel activity described in this section is 
the first case of in vitro quantified activity for ZIKV M protein, and results are 
comparable with those of well-characterised IAV M2, HCV p7 and HPV E5 in 
the same assay (Carter et al., 2010; Wetherill et al., 2012; StGelais et al., 2007; 





Figure 4.7 M peptide displays channel activity in the liposome-based 
assay when reconstituted in DMSO. 
M2 shows a concentration-dependent effect of CF released from liposomes 
when reconstituted in methanol (MeOH). B. ZIKV M protein does not show 
activity when reconstituted in DMSO. C. ZIKV M protein displays concentration-
dependent channel activity when titrated in the liposome assay between 97.5 
and 1590 nM. Released CF fluorescence was analysed by fluorimetry (ʎex 485 
nm/ʎem 520 nm). All data shown, n=3 biological repeats, Error bars represent 
standard deviation of the mean 
M2 in MeOH 
M in MeOH 




4.3.1 ZIKV M protein channel activity is enhanced at acidic pH 
We hypothesise that M protein will oligomerise within endosomal 
compartments. During endosomal maturation pH decreases from 6.8-5.9 in 
early endosomes to 6.0-4.9 in late endosomes (Maxfield and Yamashiro, 1987; 
Huotari and Helenius, 2011), therefore it was important to determine whether 
pH affected the activity of M protein channels. 
The archetypical M2 viroporin is pH gated via HIS37 protonation (Wang, C. et 
al., 1995; Chizhmakov et al., 1996). M2 activity aids the entry and uncoating of 
IAV by allowing protons from the acidified endosome into the virus core, 
resulting in virion destabilisation. Additionally, other viroporins have displayed 
pH-dependent activity including E5 and p7, although p7 pH sensitivity is 
genotype specific (Wetherill et al., 2012; StGelais et al., 2007; Wozniak et al., 
2010; Atkins et al., 2014). 
The liposome-based assay was adapted to assess the effect of pH on M 
channel activity, as performed for p7 and E5 (StGelais et al., 2007; Wetherill et 
al., 2012). This published endpoint assay employed external buffers at differing 
pH, with liposome-depleted supernatants re-buffered prior to measurement of 
fluorescence due to acid quenching of CF. Additionally, Triton-X100 and DMSO 
controls were included to validate the reliability of the liposomes in each pH 
buffer (section 2.6.4). 
Figure 4.8 shows a statistically significant increase in levels of M-mediated CF 
release corresponding to decreasing pH between 6.2 and 7.4. Thus, these 
experiments suggest that M protein channel activity increases in response to 
acidic pH in vitro. The acidic buffer pH in this assay reflects the pH found within 
the endosomal pathway environment, corresponding to early endosomes (pH 
6.5-6.0). This suggests that M protein channels are potentially activated in  
endosomal compartments, consistent with studies on DENV entry (Cruz-














































Figure 4.8 The effect of pH titration on M protein channel activity 
Levels of CF release mediated by M protein was enhanced by acidic pH. M 
peptide (1 µM) and Triton x-100 were added to CF liposomes resuspended in 
liposome assay buffer adjusted to pH 6.2, 6.7 and 7.4. Liposome-free 
supernatants were quantified by fluorimetry and the pH was adjusted to pH 7.4 
by the addition of 20 µL 1 M Tris-HCl pH 8.0 per 100uL of supernatant. Triton X-
100 (T) lysed controls were used to determine maximum fluorescence. Error 
bars represent standard deviation of three repeat experiments individually 
background subtracted. Data was normalised to pH 7.4. Statistical significance 
was determined using an unpaired t test, p value pH 7.4 to 6.8 = 0.14, *p value 






4.4 M peptide channel activity displays sensitivity to 
Rimantadine in vitro 
Rimantadine (Rimantadine hydrochloride ((RS)-1-(1-adamantyl)ethanamine) 
Maybridge), was originally licensed in the 1980s to treat influenza A virus (IAV) 
infection, along with its related compound, amantadine, which was licensed in 
the 1960s. Whilst originally targeted against the prototypic IAV viroporin M2 
(Hay et al., 1985; Schnell and Chou, 2008), Rimantadine is now also known to 
block HCV p7 (Clarke et al., 2006; Griffin, S.D. et al., 2003; Griffin, S.D. et al., 
2004; Hay et al., 1985; Schnell and Chou, 2008; StGelais et al., 2007), HPV E5 
(Wetherill et al., 2012), and evidence also suggests that it blocks channels 
formed by C-terminal peptides from DENV M protein (Koff et al., 1981; Koff et 
al., 1980; Premkumar et al., 2005). Rimantadine and its derivatives are 
promiscuous compounds due to their small size, 3-dimensional hydrophobic 
adamantyl-cage and polar amine group, which help it occupy a wide variety of 
diverse binding cavities with greater or lesser avidity. Previously, rimantadine 
has been used in our lab to identify druggable binding sites via low potency 
interactions, which can be further explored via rational drug discovery methods 
(Foster et al., 2011; Foster et al., 2014; Griffin, S. et al., 2008).   
M peptide was used in liposomes at a final concentration of 780 nM, as 
determined by previous M peptide titrations (Figure 4.7). Rimantadine was 
titrated from 1.95 µM to 4 mM. Inhibition of M protein channel activity was 
classified by a decrease in the endpoint fluorescence when compared to 
vehicle-only control (section 2.6.3).  
Rimantadine concentrations at or lower than 500 µM inhibited M protein activity 
(Figure 4.9). However, at higher concentrations rimantadine caused artefactual 
higher levels of CF release from liposomes. At the lowest concentration tested, 
390 nM of rimantadine displayed inhibition levels of around 40 % (Figure 4.9), 
moreover 1 µM gave the most consistent inhibition (Figure 4.10).Although 
rimantadine has previously shown inhibitory effects on DENV M peptide 
channels in vitro and DENV in cell culture, the drug has not been tested against 
ZIKV or ZIKV M protein. Inhibition of ZIKV M channels by rimantadine in vitro 




rimantadine consistently inhibits ZIKV in cell culture and in vivo, the compound 
and its respective binding site could be used for drug development.  
 
Figure 4.9 Rimantadine has a dose-dependent effect on M protein-
mediated CF release 
A. Titration of rimantadine from 4 mM to 1.95 µM and in the presence of M 
protein, rimantadine was added to 780 nM of M protein 5 min prior to addition to 
CF containing liposomes. B. Titration of rimantadine from 3.125 µM to 390 nM 
in the presence of 7.6 µM M protein. C. Titration of rimantadine in the absence 
of M protein. Released CF fluorescence was analysed by fluorimetry (ʎex 485 
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Figure 4.10 Rimantadine at 1 µM reproducibly reduces M protein-mediated 
CF release 
Addition of rimantadine at 1 µM in the presence of M protein (780 nM) was 
added to CF containing liposomes. Background fluorescence was subtracted 
from final values and channel activity was calculated relative to M alone. 
Rimantadine reduced the fluorescence released from 100 % to 52 % on 
average from 3 biological repeats of a single well. Error bars represent standard 
deviation of the mean and statistical significance of channel activity was 





4.5 Rimantadine mediates dose-dependent inhibition of ZIKV 
in cell culture 
Previous identification of rimantadine inhibition of viroporins in dye release 
assays has been translatable to virus inhibition in cell culture (StGelais et al., 
2007; Griffin, S. et al., 2008). Therefore, if rimantadine could inhibit ZIKV 
replication in cell culture, it could suggest the presence of M protein channel 
formation. It has previously been published rimantadine has a dose-dependent 
effect on the replication of closely related DENV in cell culture (Koff et al., 
1981). However, its activity against ZIKV has not previously been reported. 
Vero cells were infected with ZIKV at a multiplicity of infection (MOI) of 0.1 
plaque forming units per cell (pfu/cell). Ensuing virus replication was assessed 
using immunofluorescence and western blotting 48 hours post infection, using 
αNS3, αNS5, αE and αM antibodies with Hoechst co-staining for αNS3 and 
αNS5 antibodies (Figure 4.12) (section 2.2.6, 2.5.1, αNS3, αNS5 gifted from 
Andres Merits, Tartu). However due to the lack of Hoechst staining, non-
infected stained cells and primary-only and secondary-only antibody staining, 
there are limitations of the staining, in particular the specificity of the antibodies. 
Optimisation of Immunofluorescence (Figure 4.11) revealed the likely 
localisation of NS3 and E to be cytoplasmic, whereas NS5 appeared to localise 
to the nucleus. Of note ZIKV M shown in the bottom panel, stained for using 
AlexaFluor 594 suggests M co-localises with Envelope in AlexaFluor 488. 
However, further controls would be needed to confirm the aforementioned 
findings. 
Western blot data in Figure 4.12 shows the sizes of probed ZIKV proteins, 
interestingly the blot probed the using αM antibody shows two bands at ~10 and 
25 kDa, suggesting both mature M and prM were present in the infected cell 
lysate. Downstream analysis for cell imaging and automated cell counting was 
carried out using the IncucyteZOOM determining titre represented as the 
number of infectious units per µL at 48 hpi, adapted from protocols developed 





Figure 4.11 Optimisation of ZIKV specific antibodies for we/stern blot and 
immunofluorescence 
A. Immunofluorescence staining of cells treated with ZIKV at an MOI of 0.1 
PFU/cell. Cells were fixed and stained with anti-NS3 antibody, anti-NS5 
antibody or anti-E antibody with AlexaFluor 488 and Hoecsht, or anti-E and anti-
M antibody with AlexaFluor 488 and 594 respectively, then imaged at 40x 






Figure 4.12 Optimisation of ZIKV antibodies by western blot  
Detection of ZIKV positive cell lysate, by anti-E antibody, anti-NS3 antibody, 





4.5.1 Rimantadine does not affect cell cytotoxicity or endocytic 
uptake of EGF 
Prior to testing rimantadine in virus culture, we conducted a cell viability assay 
using a proxy measure of metabolic activity to determine the range of 
rimantadine concentrations to use for experiments upon vero cells. We tested 
the effect of rimantadine using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) for assays. Previous use of rimantadine in cell 
culture has been widely reported over a range of concentrations (Koff et al., 
1981; Black et al., 1993; Govorkova et al., 2004; Koff and Knight, 1979).  
Rimantadine was tested between 5 and 120 µM for cell toxicity effects over a 48 
hr incubation period using MTT assays, results show rimantadine does not 
induce cell toxicity when added at concentrations below 100 µM. MTT levels 
were quantified by absorbance at 590 nm (Figure 4.13) (section 2.2.4).  
Additionally, the effect of rimantadine on the clathrin-dependent endocytic 
pathway, used by Flaviviruses for cell entry (Chu and Ng, 2004; Sorkin and 
Waters, 1993), was investigated using uptake of fluorescently labelled EGF 
(section 2.2.5). Rimantadine at 80 µM and below had no effect upon clathrin 
dependent endocytic uptake of fluorescent EGF, when measured and quantified 
by flow cytometry. Moreover, Bafilomycin A1, which is known to inhibit 
endocytosis through targeting the V-ATPASE proton pump, was used as a 
positive control (Figure 4.14). There are no error bars in Figure 4.14 as this was 
not repeated due to time constraints, however 25000 cells were counted for 
each condition. 
4.5.2 Rimantadine suppresses ZIKV replication in cell culture  
To investigate the effects of rimantadine on ZIKV replication, cells were 
incubated with rimantadine at non-cytotoxic concentrations (section 4.5.1). 
Rimantadine and ZIKV at an MOI of 0.1 pfu/cell were added to cells in standard 
cell culture medium. After 1 hr of incubation allowing for uptake of the virus, the 
media was removed and replaced by rimantadine containing media (Figure 
4.15A) (section 2.3.4.1). Multicycle virus replication was measured 48 hours 
post-infection, by both western blot and quantification of infected cells using 




Rimantadine exerted a concentration-dependent inhibition of ZIKV infection, 
evidenced by both reduced numbers of infected cells by IF (IncucyteZOOM) 
and diminished levels of ZIKV E protein by western blot. The presence of 10 µM 
rimantadine or above had a significant effect on ZIKV infection (Figure 4.15). 
Translating inhibition of ZIKV M protein channels in vitro to inhibition of ZIKV 
infection in cell culture, is a significant step in proving M protein forms 
oligomeric channels which can be targeted by therapeutics and subsequently 
reduce virus infection. Furthermore, rimantadine has the potential to inhibit ZIKV 




Figure 4.13 The effect of Rimantadine on cell viability 
Vero cells were treated for 48 hr with increasing concentrations of rimantadine 
and were compared to DMSO treated cells. The cell viability was measured 
using an MTT assay, the output of this was read using a plate reader at an 









































Figure 4.14 Rimantadine does not effect the uptake of fluorescently 
labelled EGF 
A.  Schematic of experiment used to determine if rimantadine effects uptake of 
fluorescently labelled EGF by endocytosis. B. Rimantadine pre-treated cells 
endocytosed fluorescently labelled EGF, independent of the rimantadine 
concentration between 5 and 80 µM. The fluorescent EGF uptake of cells was 
measured using flow cytometry and quantified using median FITC, displayed as 
a % of maximum fluorescent EGF uptake at 0 µM rimantadine. Bafilomycin A1 










































Figure 4.15 Rimantadine has a dose-dependent effect on ZIKV infection in 
cell culture 
Rimantadine has a dose-dependent effect on ZIKV replication at an MOI of 0.1 
between 0 and 80 µM. A. Schematic showing experiment protocol. B. 
Quantified immunofluorescence staining for ZIKV E protein. C. Representative 
images of the immunofluorescence staining for ZIKV E protein at 0, 20 and 80 
µM D. Western blot micrographs probing for ZIKV E protein alongside 
housekeeping gene GAPDH at 0, 5, 10, 20, 40 and 80 µM. N=3 biological 
repeats for immunofluorescence and western blot experiments. Error bars 
represent standard deviation of the mean and statistical significance of ZIKV 
infected cells was assessed by unpaired t-test comparing rimantadine treated 





4.5.3 Rimantadine targets an early stage of the ZIKV life cycle 
Rimantadine was added over a time course corresponding to the early stages of 
infection to investigate at what stage of the virus life cycle rimantadine inhibits 
ZIKV replication; specifically we asked whether rimantadine targets ZIKV entry, 
when we believe M protein channels will form. The effects upon infectivity were 
determined via a plaque reduction assay (section 2.3.4.2).  
Rimantadine was pre-incubated with BHK-21 cells for 4 hr, or added at the 
same time as the virus inoculum or post inoculation for a 48 hour period, 
Rimantadine was also added at a combination of these stages for further 
analysis (Figure 4.16 A). Rimantadine was added to cells prior to infection to 
investigate whether it blocked virus uptake into the cells. Pre-incubation 
presumably causes rimantadine to be taken up and stored in endocytic vesicles 
for a short time after its removal from cell culture media during virus entry. While 
addition of rimantadine during virus inoculation examines the effect of it on virus 
entry. Finally, the treatment of virus-infected cells post-inoculation examines the 
effect of rimantadine on the later stages of the virus life cycle. Figure 4.16 
shows rimantadine has the most pronounced effect on inhibiting ZIKV prior to 
and during virus inoculation, therefore indicating rimantadine is likely to be 
inhibiting ZIKV replication via disruption of virus entry, further supporting our 
hypothesis of M protein forming channels during endocytosis and playing a role 








Figure 4.16 Rimantadine targets entry step of virus life cycle shown by 
time of addition plaque assay 
Rimantadine was added at 80 µM at various stages of the plaque assay 
protocol (section 2.3.4.2). Rimantadine was either added prior to inoculation for 
4 hr, during the 1 hr inoculation period, for the 48 hr post inoculation period or 
combinations of these. Error bars represent standard deviation of the mean and 
statistical significance of ZIKV titre was assessed by t-test comparing 
rimantadine pre-treated cells or cells treated pre and during inoculation to 
































































4.6 Rimantadine inhibits ZIKV infection in vivo 
Rimantadine reduced levels of ZIKV infection in vitro and in cell culture, yet it 
was unclear whether this would translate into an in vivo system. Murine models 
are popular ways of recapitulating viral infections, although ZIKV does not 
usually establish an infection in immunocompetent mice, due to its inability to 
antagonise the murine STAT2-dependent interferon (IFN) response (Grant et 
al., 2016). For this reason, ZIKV murine models either use IFN/IFNAR knock-
out (KO) mice, or mice treated with an anti-IFNAR1 antibody (Rossi et al., 
Lazear et al., 2016). Therefore, we decided upon IP treatment of mice with 1.5 
mg anti-IFNAR1 antibody allowing transient inhibition of the receptor, retaining 
the remaining immune response and preventing intracranial infection and 
subsequent encephalitis (Hayashida et al., 2019). The ZIKV infection was then 
given at the same site as up to five mosquito bites from an Aedes aegypti 
mosquito, the principal vector of ZIKV, which is reported to enhance 
transmission (Pingen et al., 2016).  
Ten C57BL/6 received a dose of 20 mg/kg rimantadine subcutaneously 30 min 
prior to ZIKV infection. The mice were then infected with ZIKV (1000 pfu) by 
injection into the sole of one hind foot and up to five female Aedes aegypti 
mosquitoes subsequently bit the foot once at the same site. Five hr post 
infection, a second dose of rimantadine in PBS at 20 mg/kg was administered. 
24 hr post infection the mice were sacrificed and tissue samples from the skin of 
the foot, spleen and the serum were taken from the ten treated mice and ten 
infected control mice. These chosen organs were chosen due to previous 
investigative experiments, where ZIKV was detected (McKimmie, unpublished) 
(section 2.4). 
This experiment was repeated, although the data from the first experiment was 
discounted due to use of incorrect needles for ZIKV injection, causing bleeding 
in some mice at the site of injection, therefore enhancing infection.  
The serum taken from the mice was titred by plaque assay on Vero cells due to 
issues with previously used focus forming assay (Figure 4.16) (section 2.3.3 
and 2.3.4.1). Rimantadine treated mice had significantly lower levels of ZIKV 
present in their serum. Conversely, the RNA was extracted from the skin and 




protocol in the absence of rimantadine ZIKV has been detected in these organs. 
The RNA was analysed by reverse transcription qPCR. However, the levels of 
ZIKV RNA in both skin and spleen samples of control and rimantadine treated 
mice were below the detection threshold for this experiment. 
The reduction of ZIKV titres measured in rimantadine treated mice compared to 
control mice show rimantadine acts systemically, inhibiting virus infection. From 
in vitro research reported in this chapter, rimantadine inhibits ZIKV through 






















* * * *
 
Figure 4.17 Rimantadine reduces viral titres of ZIKV infected mice  
Mice were given 20 mg/kg rimantadine half an hr prior to infection with 2000 
PFU ZIKV and up to five A. aegypti mosquito bites, followed by a second dose 
of 20 mg/kg rimantadine post infection prior to taking samples 24 hr post 
infection. Serum from the 10 control infected mice and 10 rimantadine treated 
mice was titred for ZIKV on Vero cells.  The graph shows individual data points 
with the mean value and SD shown. Statistical significance of ZIKV titre was 
assessed by t-test comparing rimantadine treated mice with control treated mice 






The role of M protein during ZIKV entry and in the virus particle has not 
previously been investigated. However, we hypothesised that ZIKV M forms 
oligomeric channels during virus entry within acidified endosomes, aiding 
Flavivirus uncoating. Uncoating is an under explored stage of the virus life 
cycle, with few published reports into its mechanism. Over the years, research 
has uncovered the necessity for acidic pH, the requirement for a non-
degradative ubiquitination step and very recently a proposed role for Valosin-
Containing Protein (VCP) and p97 to disassemble VCP/p97 ubiquitylated 
nucleocapsids (Gollins and Porterfield, 1986; Byk et al., 2016; Ramanathan et 
al., 2019).  However, there is no defined role for M protein during virus entry, 
despite the protein residing in the virion. M is known to have a role in 
chaperoning envelope protein during virus assembly, although within this 
chapter we have identified a novel role for M during entry. 
Chapter 3 described M protein forming hexameric channels in an in silico 
system, however it is important to validate these in silico predictions through 
using M in isolation. Viroporins with similar channel-forming properties have 
been successfully studied using prokaryotic recombinant expression systems 
using large soluble tags to aid purification. These include GST tags for 
alphavirus 6K (Melton et al., 2002), HCV p7 (Clarke et al., 2006), SV40 VP4 
protein (Raghava et al., 2011), Maltose Binding Protein for picornavirus 2B 
(Nieva et al., 2003) and SUMO for HRSV SH (Carter et al., 2010). However, our 
own attempts at expressing M protein using GST and HIS tagged systems 
resulted in low levels of expression and subsequent purification difficulties.  
To circumvent difficulties in recombinant protein expression, a commercially 
synthesised N-terminal truncated 55 residue M peptide was commissioned from 
AltaBioscience. The purified peptide illustrated the capability of M protein to 
form oligomers in a membrane mimetic detergent, the structures of these 
oligomers by TEM and the activity of these channels by a liposome-based 
assay, showing a novel oligomeric ZIKV M structure and activity. 
Membrane mimetic detergents such as DH(6)PC and DH(7)PC have previously 
facilitated studies of viroporin oligomerisation, including p7 peptides (Luik et al., 




al., 2010), by both native-PAGE or TEM. M protein underwent similar protocols 
with 300 mM DH(6)PC and, as shown in Figure 4.2A by native-PAGE, two 
Coomassie stained bands at around 45 and 66 kDa indicated oligomerisation 
took place in the membrane mimetic environment. Determining the molecular 
weight of the proteins within individual bands is ambiguous due to the limitations 
of native-PAGE. However, these could resemble hexameric and heptameric or 
larger oligomers, as the monomeric form of the M peptide is 6264 Da. These 
bands could have relevance to the different oligomer sizes seen by EM at 
different DH(6)PC concentrations (Figure 4.4). Additionally, these two sizes of 
oligomers  could relate to heterogeneity of M protein, similarly seen with p7 
(Clarke et al., 2006; Griffin, S.D. et al., 2003; Luik et al., 2009). 
Further analysis of M protein in the DH(6)PC environment identified ring-like 
structures by TEM. The channel-like complexes appeared to have an average 
protein diameter of 8.8 nm in 150 mM DH(6)PC, and are reminiscent of p7 
visualised by EM (Clarke et al., 2006; Luik et al., 2009). Previously visualised 
viroporins SH and p7 were 8.7-9.3 and 8.1 nm in diameter respectively (Carter 
et al., 2010; Luik et al., 2009). However, the diameter of the oligomer is likely to 
appear greater by TEM due to staining effects, as uranyl acetate has a grain 
size of 4 to 5 Å (Scarff et al., 2018; Haschemeyer, 1970).  
Dimensions of M protein hexameric channels from MD simulations range from 
7.6 to 8.9 nm for helix 2 pore-lining and 5.7 to 7.7 nm for channels with helix 3 
pore-lining. Chapter 3 results led to a hypothesis of M protein forming 
hexameric channels with helix 3 lining the pore, and with each monomer rotated 
to maximise interactions with the adjacent protomer. However, this lipid-
anchored structure has a hexameric channel width of only 5.7 nm, compared to 
7.6-10.4 nm which reside in detergent micelles. A slight difference between 
these measurements is to be expected due to the membrane differences of 
lipids and detergents, and the likelihood of small differences between in silico 
data and in vitro.  
Though as seen in section 4.2.2 the channels formed exhibit heterogeneity, in 
addition the use of a 2 % uranyl acetate stain will increase the size of the 




In comparison, HCV p7 hexamers are around 42 kDa and exhibit a diameter of 
8.1 nm at their widest point when hexameric by EM (Luik et al., 2009) and 11.1 
nm by MD (Chandler et al., 2012). Additionally, RSV SH channels are 
separated into two distinct channel conformations, measuring 8.7 nm or 9.3 nm 
by EM (Carter et al., 2010). 
However, the properties of M protein in detergents may not wholly reflect their 
properties in the virion membrane. Detergents have shorter chain lengths than 
lipids and form micelles as opposed to bilayers. Although, detergent to protein 
ratio is crucial for the oligomerisation of viroporin monomers, and either p7 
monomers or hexamers are seen in the literature, dependent on the protein to 
detergent ratio (Oestringer et al., 2019; Chen, W. et al., 2019).  
Additionally, analysis of the amino acid charges within the M protein sequence 
revealed helix 1, which lies parallel to the membrane and perpendicular to the 
TMDs in the cryo-EM structure and MD simulations in chapter 3 (Sirohi et al., 
2016; Sevvana et al., 2018), contains multiple positively charged residues and 
through the sum of negative and positively charged residue the overall positive 
charge +0.9 at pH 7.4. This positive charge will potentially attract to the 
negatively charged grid, theoretically helping to orientate channels in a single 
plane for visualisation. The linker region of the peptide contains no charged 
residues and therefore will not be as strongly attracted to the grid. 
ZIKV M was further investigated in liposomes, which more closely resemble 
ZIKV virion membranes. The ability of ZIKV M protein to mediate the release of 
CF from liposomes (Figure 4.6) was the first demonstration in vitro of a function 
associated to M protein oligomerisation, and further reinforces the molecular 
dynamic data from chapter 3, identifying M as a novel member of the virus 
encoded channels or viroporins. Similarly to viroporins HRSV SH, HPV E5, 
HCV p7, and IAV M2 all previously were shown to have channel activity using 
the liposome-based assay (Carter et al., 2010; Wetherill et al., 2012; StGelais et 
al., 2007; Atkins et al., 2014; Scott et al., 2020).  
In M peptide liposome assays (Figure 4.4) the plotted endpoint fluorescence 
never reached the maximum fluorescence set by the Triton X-100 control, 
indicating CF was not released from a proportion of the liposomes and the 




dependent effect of the endpoint fluorescence occurred upon increasing M 
peptide concentration. Furthermore, HCV p7, HRSV SH and HPV E5 all display 
dose-dependent effects when added to liposomes and were optimised to avoid 
maximum CF release (StGelais et al., 2007; Carter et al., 2010; Wetherill et al., 
2012). However, at high concentrations, greater than 5µM, M may form protein 
aggregates as is reported with HPV E5 and rhinovirus VP4, destabilising 
liposomal membranes (Davis et al., 2008; Wetherill et al., 2012). Therefore, 
amounts of M peptide that allowed sufficient CF release but did not cause 
membrane destabilisation were used in this assay (780 nM) evidenced by 
inhibition at these concentrations with small molecules.  
Additionally, if time permitted it would be of interest to determine the 
approximate hydrodynamic radius of the M peptide channels within liposomes, 
using a dextran size exclusion assay (Wetherill et al., 2012; StGelais et al., 
2007; Shukla et al., 2015). This would be done in conjunction with future TEM 
analysis of channel complexes. Furthermore, membrane flotation assays on 
sucrose gradients would determine whether M integrated within liposome 
membranes by incorporation of high pH washes and detergent treatment 
(StGelais et al., 2007; StGelais et al., 2009; Wetherill et al., 2012; Panjwani et 
al., 2014).  
Viroporin functions have been associated with several stages during the virus 
life cycle, including: entry (Ruigrok et al., 1991), assembly (Ye, Y. and Hogue, 
2007) or release (Beaton et al., 2002), and viroporins involved in virus entry are 
found within the virus particle (Gonzalez and Carrasco, 2003) as is seen with M 
proteins presence in the virus membrane. 
The presence of viroporin channels is known to alter membrane permeability 
within host cells and subcellular compartments. HCV p7 and IAV M2 sense 
proton electrochemical potentials and are gated by a decrease in pH (Sarkar et 
al., 2001; Pinto et al., 1997; Wang, C. et al., 1995; StGelais et al., 2007; 
Wozniak et al., 2010; Atkins et al., 2014). Amino acids arginine, lysine, and 
histidine detect variations in the pH and can become protonated and change 
conformation upon a decrease in pH (Bezanilla, 2008). 
Similarly, decreasing the pH to mimic the physiological endosomal environment 




at pH 6.2 and 6.7, compared to pH 7.4 (Figure 4.7). We speculate that a change 
in external pH may result in protonation of HIS28, as investigated by simulations 
in chapter 3, causing extended opening and or stabilisation of the channel.  
It is known that protonation of M2 HIS37 leads to a conformational change in 
gating residue TRP41. In addition, it has been reported some genotypes of HCV 
p7 may use a similar gating motif as M2 (Meshkat et al., 2009). However, 
mutations of the p7 HIS17 and TYR21 to ALA did not affect particle production 
and although HIS17 is highly conserved, TYR21 is not conserved throughout 
HCV genotypes (Montserret et al., 2010). Additionally, it is highly unlikely for 
two structurally unrelated viroporins to have the same gating motif and it has 
been suggested the gating residue could be PHE25 (Foster et al., 2014). 
Furthermore, proton-sensing properties of HCV p7 are not present across all 
HCV genotypes, for example HCV-H77 (Atkins et al., 2014).  
Unlike M2 & p7 which have pore-lining HIS residues, ZIKV M HIS28 is present 
on the N-terminal helix of M protein peptide and so is not lumenal. Thus, HIS28 
being cytosolic is more similar to HPV E5, where HIS75/77 are present at the 
channel opening (Wetherill et al., 2012). It is plausible these histidines can also 
act as a pH sensor. Additionally, there is a second histidine in ZIKV M protein, 
however this lies further towards the N-terminus in the unstructured region, 
which is absent from our peptide and the model used for MD simulations in 
Chapter 3. Interestingly DENV-2 M protein contains an additional histidine 
residue to ZIKV M at residue 39, which when mutated results in loss of virus 
infectivity (Pryor et al., 2004). If DENV-2 M also forms channels, this would be 
located at the neck of the channel, between helix 1 and helix 2.  
The data showing M protein channel activity increasing upon a reduction of pH, 
align with the published data showing ZIKV fusion during virus entry is likely to 
occur is late endosomes. Data shows ZIKV co-localises with both Rab5 of early 
endosomes and Rab7 of late endosomes, raising speculation that ZIKV is 
transported though the endocytic pathway and the late endosome pH is suitable 
for ZIKV RNA release (Li, M. et al., 2020; Owczarek et al., 2019). Additionally, 
ZIKV hemifusion is sensitive to pH and is greatest at a pH of 5.5-.5 (Rawle et 
al., 2018). Furthermore, blocking endocytosis inhibits ZIKV infection in cell 




Although ZIKV M channel activity has not been previously reported, DENV M 
channel activity has been measured. C-terminal peptides were reconstituted 
into voltage clamped suspended bilayers, and the conductance of sodium and 
potassium ions was measured. Additionally, this current was blocked by the 
adamantane compound, amantadine hydrochloride. Conversely, M proton 
channel activity has been disputed. Voltage clamping of Xenopus laevis oocytes 
producing DENV prM/M did not vary in proton conductance compared to non-
expressing oocytes. Additionally, conductance did not vary with changes to the 
surrounding pH. However the form of DENV prM/M at the oocyte membrane 
was not validated (Premkumar et al., 2005; Wong et al., 2011).  
The DENV M peptide used by Premkumar et al. was 40 amino acids in length, 
containing only helix 2 and 3 (Premkumar et al., 2005). By contrast, the ZIKV M 
peptide used in this chapter was 55 amino acids, ZIKV peptides retained helices 
1, 2 and 3 as they are required for channel formation as discovered through M 
protein MD simulations (data not shown). Suggesting, unlike DENV M, ZIKV M 
protein channel formation and activity in vitro requires helix 1, possibly due to 
the presence of HIS28 on ZIKV M helix 1, whereas DENV contains an 
additional HIS39. 
Viroporins are attractive targets for antiviral therapy and identifying M protein as 
a viroporin in the liposome-based assay highlights a new ZIKV antiviral target, 
which upon further development could be applied across the Flaviviruses. The 
TEM data IN section 4.2.2 and MD results from Chapter 3 highlight that the 
model of a hexameric M protein channel, support that future structural studies 
might be feasible.  
We tested rimantadine against M protein, a licenced IAV M2 inhibitor and 
known inhibitor of other viroporins (Griffin, S. et al., 2008; Wetherill et al., 2012; 
Hay et al., 1985), a strategy used to identify druggable sites, followed by further 
development to identify suitable compounds. Previously, rimantadine has 
shown viroporin inhibitory activity in the liposome-based assay and in virus 
culture, however not previously with ZIKV.  
Rimantadine had a dose dependent effect (Figure 4.8 and Figure 4.9), and was 
inhibitory at very low concentrations, suggestive of binding specificity. However, 




of CF from liposomes when added alongside protein. This phenomenon has 
been observed previously with other compounds for other viroporins, including 
HMA when tested with M2 (SG, personal communication). The effect on CF 
release is not seen in the absence of protein, meaning that it is likely due to a 
drug-induced effect upon how M interacts with the membrane.  
Inhibition of M using rimantadine results also translated into cell culture as seen 
in figure 4.5, the dose-dependent effect was seen between 5 and 80 µM, 
however not taken above this dose due to the cytotoxicity observed in Figure 
4.13. However, DENV-2 growth in peripheral blood leukocytes was entirely 
suppressed when incubated in 116 µM rimantadine (Koff et al., 1981). Similar 
cytotoxicity effects of rimantadine have been observed. A ~5 % reduction of live 
cells at 80 µM and cytotoxic effects seen at concentrations over 40 µM in 
Madin-Darby Canine Kidney (MDCK) cells from two sources (Govorkova et al., 
2004; Scott et al., 2020). 
Rimantadine time of addition assays show the most pronounced effect on ZIKV 
inhibition to be prior to and during virus inoculation indicating rimantadine is 
likely to be inhibiting ZIKV replication via disruption of virus entry. However, 
there is little effect of rimantadine addition during and post inoculation and post 
inoculation. Addition of rimantadine after the inoculation period is likely to be 
less effective as the virus has already entered the cells and the first round of 
infection has started, furthermore the presence of rimantadine prior to and 
during infection allows rimantadine to be present in endosomes prior to cell 
entry, whereas addition of rimantadine solely during infection does not allow for 
this build-up of rimantadine within the cell prior to virus entry, and rimantadine 
does not appear to have an effect on virus post-entry steps. 
Considering the successful inhibition of ZIKV infection by rimantadine in cell 
culture we took to replicate the results in a murine mouse model in vivo. As 
described previously (section 4.6) the ZIKV rimantadine in vivo experiment 
involved treating mice subcutaneously with rimantadine 20 mg/kg 30 min prior 
to ZIKV infection and 5 hr post infection. This treatment plan was chosen due to 
prior literature searching as described above totalling 40 mg/kg in the 24 hr 
experiment. However, to prevent ZIKV infection being cleared by mice we used 




Additionally, to enhance the viral infection the site of injection was also 
subjected to up to five mosquito bites (Pingen et al., 2016). After 24 hr post 
infection, titres of ZIKV in the serum of rimantadine treated mice were 
dramatically lower than those in the untreated mice, however due to time 
limitations this was carried out only once and exhibited low plaque counts.  
Rimantadine use in murine mouse models has been well documented via the 
treatment of IAV. For example, during a transmission study, rimantadine was 
given to infected mice 40-60 mg/kg/day. Uninfected mice were then placed in 
the same cage as rimantadine treated or untreated mice. It was observed fewer 
infected mice became infected when kept alongside treated mice (Schulman, 
1968). Additionally, more recent drug combination studies have been carried 
out with up to 30 and 80 mg/kg rimantadine per day in mice (Simeonova et al., 
2012; Bantia et al., 2010). Moreover, mice have been given 40 mg/kg by IP and 
PO and did not mention issues with the health or symptoms of treated mice 
(Hoffman et al., 1988; Herrmann et al., 1989). Our in vivo dosing regime was 
based on the treatments used in these studies. 
Furthermore, a clinical trial in 1981 tested healthy adults for symptoms after 
giving rimantadine or amantadine for 4.5 days and either 200 or 300 mg/day. 
Patients in the 300 mg/day group were given 200 mg in the morning and 100 
mg in the afternoon. At lower concentrations both drugs were well tolerated. At 
higher concentrations a greater percentage of patients treated with amantadine 
complained of central nervous system symptoms including nervousness, 
lightheaded, insomnia and fatigue. This gave way to preferential treatment with 
rimantadine (Hayden et al., 1981), however treatment with 300 mg/day equates 
to 5 mg/kg for a 60 kg human. Many previous experiments have used much 
higher concentrations of rimantadine in mice up to around 40 mg/kg. 
Rimantadine was used at 20 mg/kg in the ZIKV in vivo assay described in 
section 4.6, thus at a much higher translated concentration in humans than in 
the aforementioned trials. Therefore, providing a rationale to find an improved 
drug to be used at a suitable concentration. 
This novel function of ZIKV M as an ion channel active during virus entry could 
reveal the mechanism behind virus uncoating, not only for ZIKV but also 




commonality between previously identified viroporins and ZIKV M, including pH 
sensing, reminiscent ring conformations and inhibition by prototypic inhibitors. 






Chapter 5 Rational development of improved inhibitors 
targeting M protein channel activity 
5.1 Introduction 
Currently, there are no licensed ZIKV vaccines available for prevention or 
treatment of infection. There are a number of vaccines in phase I and II clinical 
trials (Dowd et al., 2016; Larocca et al., 2016; Abbink et al., 2016; Xu, K. et al., 
2018; Richner et al., 2017; Pardi et al., 2017; Brault, A.C. et al., 2017). 
However, there are challenges to overcome, including antibody-dependent 
enhancement of DENV and ZIKV due to their similarity and resultant cross-
reactivity of non-neutralising antisera (Bardina et al., 2017; Stettler et al., 2016; 
Fowler et al., 2018; George et al., 2017). Additionally, there are no currently 
available antivirals targeting ZIKV, or other related Flaviviruses, despite 
extensive de novo design and efforts to repurpose candidates from drug 
libraries against both viral and cellular targets. However, targeting ZIKV M 
protein has not previously been investigated (Devillers, 2018; Han and 
Mesplede, 2018). The identification of a ZIKV targeting therapeutic would be 
highly valuable in reducing disease severity, particularly neurological effects 
such as microcephaly and Guillian-Barré syndrome. 
A number of viral proteins comprise ideal enzymatic drug targets, primarily the 
ZIKV NS5 polymerase. Nucleoside analogue drugs selectively target viral 
polymerases to prevent genome replication, usually via their misincorporation 
and ensuing termination of nascent nucleotide chains. They are also highly 
specific for viral RdRp compared with cellular RNA polymerases (Eyer et al., 
2016; Lu et al., 2017; Hercik et al., 2017). Several ZIKV polymerase inhibitor 
compounds have been identified in preclinical studies, including a nucleoside 
analogue BCX4430 (aka Galidesivir, Biocryst), and the nucleotide analogue 
prodrug, Sofosbuvir (Gilead), which is approved by the U.S Food and Drug 
Administration (FDA), Medicines and Health products Regulatory Agency 
(MHRA) and European Medicines Agency (EMA) for treatment of HCV infection 
(Eyer et al., 2016; Hercik et al., 2017; Zmurko et al., 2016; Julander et al., 2017; 
Bullard-Feibelman et al., 2017). BCX4430 (Galidesivir, BioCryst Pharma) is 
currently in Phase I clinical trials (NCT03800173). Other viral proteins exhibiting 




also being explored as potential drug targets (Coutard et al., 2017; Lee, H. et 
al., 2017; Cao et al., 2016). An ideal therapy would involve targeting a 
combination of these proteins, mitigating the emergence of resistance 
mutations. 
The newly identified viroporin activity exhibited by the M protein in chapters 3 & 
4 presents an opportunity for the development of new ZIKV and Flavivirus 
therapeutics. 
Viroporin inhibitors have been used previously to treat virus infected patients, 
with the first approved in the 1960’s. The adamantane compounds amantadine, 
and later rimantadine, were used to treat IAV (Davies et al., 1964; Dawkins et 
al., 1968; Togo et al., 1968; Wingfield et al., 1969; Sabin, 1967), although it was 
many years later that their mode of action targeting the M2 viroporin was 
discovered; adamantane mediated prevention of M2 proton conductance 
inhibits viral uncoating during entry (Hay et al., 1985; Pinto et al., 1992; Sugrue 
and Hay, 1991). Adamantanes have since displayed genotype-specific 
inhibitory effects against the HCV viroporin, p7 (StGelais et al., 2009; Griffin, S. 
et al., 2008) and combination therapy comprising amantadine, ribavirin and 
interferon has been tested using small treatment groups as a HCV combination 
therapy in clinical trials and a slight increase in efficacy was observed. 
Genotype 1a patients saw the most promising results, however genotype 1b 
patients exhibited L20F mutations, which locate to the peripheral adamantane 
binding site and have been shown experimentally to represent genuine 
resistance polymorphisms (Berg et al., 2003; Brillanti et al., 2000; Foster et al., 
2014; Foster et al., 2011; Mihm et al., 2006; Castelain et al., 2007). 
Viroporins have also been targeted using amiloride derivatives (e.g. 
hexamethylene amiloride (HMA) and BIT225). Previously HMA was used as a 
HIV therapeutic (Karlsson et al. 1993; Ewart et al. 2004) due to targeting 
viroporin vpu (Ewart et al. 2002). Similarly to adamantanes, HMA can also block 
other viroporins including HCV p7 in vitro (Premkumar et al. 2004) and in a pH 
monitoring cell-based assay (Wozniak et al. 2010). Furthermore, HMA also 
inhibits viroporins encoded by the E proteins of human coronavirus 229 (HCoV-
229), Severe acute respiratory syndrome 1 (SARS1) and mouse hepatitis virus 




toxic, leading to a need for derivative development (Steinmann et al., 2007b; 
Chang et al., 2009). The inhibition of M2 by HMA was studied, however its 
inhibition was improved upon by the production of novel HMA derivatives, in 
addition to improved cytotoxicity (Jalily et al., 2016). Compound BIT225 
reportedly also has inhibitory activity against HCV p7 and specifically HIV-1 in 
monocyte-derived macrophages. The latter has led to phase II clinical trials 
within South East Asia, predominantly, comparing combination therapy of naïve 
HIV-1 patients with antiretrovirals and BIT225 or a placebo. The trials report a 
statistically significant benefit to patients CD8+ and activated CD4 T cell 
populations (Wilkinson et al., 2016). 
The effectiveness of antivirals targeting RNA viruses as monotherapies is 
limited. RNA viruses evolve quickly and administering viroporin inhibitors as a 
monotherapy potentially will become clinically unsuitable due to the selection of 
resistance mutations (Foster et al., 2011; Griffin, S.D., 2009). M2 and p7 gained 
resistance mutations to adamantane compounds, which were located to 
predicted binding sites (Pabbaraju et al., 2008; Castelain et al., 2007; Mihm et 
al., 2006; StGelais et al., 2009). However, the emergence of resistance of IAV 
M2 to amantadine was suppressed when given alongside neuraminidase-
targeting antiviral Oseltamivir (Ilyushina et al., 2006). Therefore, it remains 
important that the number of drug targets is expanded as even drugs with 
relatively low genetic barriers to resistance might have potential within 
combination therapies, and the lack of treatments to prevent or treat Flavivirus 
infection needs to be addressed.  
The development of new viroporin inhibitors is hindered by the difficulty in 
determining their structure and working with membrane proteins in high-
throughput systems. Therefore, our programme of drug development employed 
a rational approach involving structural information, in silico molecular models 
and compound docking software (Foster et al., 2014). This chapter describes 
our approach to discover compounds targeting using the in silico M protein 
hexamer model from chapter 1 as a structural template, and subsequent 
validation using the liposome-based dye-release channel activity assays used in 




5.2 M protein shows differential sensitivity to structurally 
distinct viroporin inhibitors 
Rimantadine inhibits the activity of sensitive variants of the M2 and p7 
viroporins (Wang, C. et al., 1993; Schnell and Chou, 2008; StGelais et al., 
2007). Now, based upon our findings (section 4.4, 4.5 & 4.6), we can place 
ZIKV M as another rimantadine-sensitive member of the viroporin family.  
Our previous work on viroporins has utilised rimantadine and other prototypic 
inhibitors to identify druggable sites upon channel complexes, which, in turn, are 
amenable to the development of more bespoke, and so more potent inhibitory 
series. Thus, we explored whether additional inhibitory compounds identified 
during previous viroporin studies could similarly block M protein channel activity. 
Whilst the effects of rimantadine appeared specific, its promiscuity made it 
desirable to ensure that the liposome assay was capable of discriminating 
effective inhibitory compounds from those lacking activity targeting M. Thus, we 
capitalised upon the availability of distinct compound series targeting a well-
characterised peripheral binding site upon the HCV p7 viroporin channel 
complex (Foster et al., 2014; Shaw et al., 2019). 
The series contains rationally developed compounds, with a defined structure 
activity relationship (SAR) versus the peripheral site and dramatically improved 
drug-like qualities. Thus, we predicted that the structural differences between 
hexameric M and heptameric p7 channel complexes should result in distinct 
patterns of activity for such compounds when tested functionally against M 
peptides. 
Small molecules designed to inhibit other viroporins were tested for inhibitory 
effects against M protein channels, these include ‘JK’ compounds. JK 
compounds are second generation compounds designed to target HCV p7 
channels, composed of an oxindole core, an N-alkyl substituent and a benzyl 
group. JK3/32 was the most active compound against HCV p7 (Shaw et al., 
2019), and is thought to target a peripheral p7 site. However, against ZIKV M 
JK3/34 and JK3/42 were the most effective. Although, these compounds were 
assayed in cell culture against p7, whereas they were tested against M in 




activity to 75% and 42 % respectively, however JK3/34 reduced activity to 51 %. 
Conversely, JK3/40 did not reduce channel activity in either assay. 
 
Figure 5.1 Representative JK compound chemical composition 
JK3/32 shown representing the p7 second generation compounds 



























































Figure 5.2 Inhibition of M protein channel activity by small molecules 
The Liposome-based channel activity assay was used to determine the activity 
of compounds against M protein channels. A. Inhibition of M protein channels 
by second generation p7 inhibitors alongside Rimantadine. Rimantadine, 
JK3/34 and JK3/42 reduced activity to 75, 51 and 42 % respectively. Data 
shown, JK3/32, JK3/40, JK3/42, DMSO and Rimantadine n=2 biological 
repeats, JK3/38, JK3/42 and JK3/46 n=1 biological repeat. Error bars represent 
standard deviation of the mean. Statistical significance was determined using 





5.3 Identification of candidate drug binding sites and docking 
of adamantanes into M protein channel models in silico 
Whilst no crystallographic, NMR or cryo-EM oligomeric M protein channel 
structure is available, the optimal in silico model generated and simulated in 
chapter 3 could comprise a surrogate template for the design and/or in silico 
screening of potential inhibitors, depending upon its accuracy. In this regard, 
previous studies utilising de novo models of both HCV p7 and HPV16 E5 
channel complexes enabled the design of bespoke inhibitory compounds 
(Foster et al., 2011; Wetherill et al., 2012). Thus, the in silico hexameric ‘helix 3 
pore-lining rotated’ model was scrutinised using Maestro software and SiteMap 
tool to identify potential drug binding sites (Halgren, 2009).  
SiteMap provides two analyses of potential binding sites, SiteScore and 
Druggability (Dscore). Sites with a SiteScore of >0.8 are classed as a possible 
binding pocket, and those with a score >1.0 are identified as binding sites with 
particular importance. Druggability categorises sites as either very druggable 
>1.0, druggable 1.0-0.8, intermediate 0.8-0.7 and difficult <0.7. 
The most favourable site, site L1 (GLU59, LYS60, VAL61, LEU64), was located 
within the channel lumen. This had a SiteScore of 1.111 and druggability score 
of 1.222, suggesting that this site had considerable potential for the 
development of novel ligands. Other drug binding sites (sites L2 and L3) 
identified within the lumen were less favourable according to prediction 
software, and were located towards the helix 1 neck of the lumen (site L2), and 
at the linker region between the TMDs at the opening of the pore (site L3) 
(Table 5.1).  
Binding site SiteMap Druggability 
L1 1.111 1.222 
L2 0.875 0.944 
L3 0.730 0629 





Rimantadine was predicted to bind most strongly to site L1. Rimantadine, 
docked into this site using Maestro software, was predicted to make 
hydrophobic interactions with VAL61, LEU64, VAL65 and LEU68 (Figure 5.4A).  
However, unlike some docking packages, the SiteMap tool does not effectively 
identify binding sites that incur significant hydrophobic penalties for bound 
ligands, such as those upon the membrane-exposed surface of the M channel 
complex.  Prior experience of other viroporin inhibitor binding sites (Foster et al., 
2011) and the use of protein surface representation in visualisation software led 
us to select a peripheral cavity (P1) as an additional binding site of residues 
TYR63, LEU64, VAL65, MET66, ILE67 & LEU68 (Figure 5.3B).  
Docking of rimantadine into the identified binding sites, accounting for 
hydrophobic penalties, found it preferentially docked into L1 site, which had the 
highest SiteMap and druggability scores. The adamantyl cage of rimantadine 
was shown to form the interactions with the cavity, as did amantadine (Figure 
5.4B). Additionally, derivatives of rimantadine (N-methyl rimantadine and N-
acetyl rimantadine) bound to the same lumenal site. However, these 
compounds posed in the opposite direction with their adamantane cages facing 
the lumen, seen in Figure 5.4B, C, D and E, this could be due to less 






Figure 5.3 Identified drug binding sites on in silico M protein hexameric 
model 
Surface representation of M protein model in white with the chosen drug binding 
sites highlighted in blue, and other binding sites identified. A. Identified lumenal 
binding cavities 1, 2 and 3 (Table 5.1), two protomers hidden for representation 
and favoured lumenal site 1 highlighted in blue. B. Peripheral drug binding site 1 





Figure 5.4 Docking of adamantane compounds into the lumenal 1 site of optimal hexameric M protein in silico model  
Adamantane compounds docked into lumenal (L) 1 site of the optimal in silico model, protein displayed top-down with the linker region 
facing up. A. Rimantadine docked with adamantane cage interacting with the lumenal cavity. B. Amantadine docked into model displayed 
top-down, with adamantane cage interacting with the luminal cavity. C. methyl-rimantadine docked into model displayed top-down, with 
methyl group interacting with the luminal cavity. D. acetyl-rimantadine docked into model displayed top-down, with methyl group 
interacting with the luminal cavity. E. Visualisation of interactions between protein and compound with Rimantadine docked. Docking and 




5.4 Identification and HTS targeting of peripheral and lumenal 
binding sites 
Identification of potential drug binding sites on ZIKV M protein led to screening 
of the structurally distinct targets with possible novel inhibitors. As rimantadine 
was not amenable to modification (Figure 5.4), and the previously screened JK 
compounds series didn’t prove promising (Figure 5.2), compounds identified in 
section 5.3 were screened in silico by Dr Ravi Singh.  
A TOCRIS drug-repurposing library was screened against L1 and P1 binding 
sites on the M protein in silico model. Of the 1280 compounds in the library the 
top ~50 docked compounds were picked to be assayed using the liposome-
based channel activity assay. These compounds were ranked using Glide by 
docking score and GlideScore. In the selection of the top 50 compounds per 
binding site, those common to both lists were eliminated, followed by a process 
of attrition to identify the compounds with the best molecular fit, through 
analysis of binding energies. Additionally, the lowest scoring compound of the in 
silico screening was selected as a negative control for each binding site. All the 
selected compounds are listed in Table 5.2 and Table 5.3 
5.4.1 Screening in silico selected compounds using dye release 
assays  
The top 50 compounds ranked by docking score for both drug binding sites, 
were tested using the liposome-based channel activity assay (section 2.6.3 & 
4.3). Compounds reconstituted in DMSO were assayed at 1 µM against M 





"Rank" Compound Name Tocris ID glide gscore Description 
N1 Mifepristone 1479 0.286 antiprogestogenic steroid 
N2 NAB 2 5131 0.603 Anti α-synuclein toxicity 
1 FR 139317 1210 -10.227 ETA antagonist 
2 ZCL 278 4794 -9.294 Cdc42 inhibitor 
3 Elinogrel 5316 -8.829 P2Y12 antagonist 
4 Taxol 1097 -8.711 Promotes microtubules 
5 UK 356618 4187 -8.401 MMP-3 inhibitor 
7 TC-1 15 4527 -8.216 α2β1 inhibitor 
8 AS 2034178 5035 -8.032 FFA1 (GPR40) agonist 
9 CP 775146 4190 -7.963 PPARα agonist 
10 GW 6471 4618 -9.092 PPARα antagonist 
11 Pravastatin sodium salt 2318 -7.825 HMG-CoA reductase inhibitor 
12 Fluvastatin sodium 3309 -7.717 HMG-CoA reductase inhibitor 
13 TC NTR1 17 5087 -7.683 NTS1 partial agonist 
14 VER 155008 3803 -7.686 Hsp70 inhibitor 
15 AMG PERK 44 5517 -7.618 PERK inhibitor 
16 Glibenclamide 0911 -7.537 KATP channel blocker 
17 Argatroban 1637 -7.454 Thrombin inhibitor 
18 KB SRC 4 4660 -7.444 c-Src inhibitor 
19 GBR 12909 dihydrochloride 0421 -7.965 DA uptake inhibitor 
20 (±)-NBI 74330 4528 -7.366 CXCR3 antagonist 
21 CU CPT 4a 4883 -7.331 TLR3 inhibitor 
22 A 887826 4249 -7.315 
voltage-dependent NaV1.8 channel 
blocker 
23 SR 2640 hydrochloride 1804 -7.296 LTD4 /LTE4 receptor antagonist 
24 NSC 74859 4655 -7.258 STAT3 inhibitor 
25 RWJ 67657 2999 -7.217 p38α and p38β inhibitor 
26 Lu AA 47070 4783 -7.659 adenosine A2A receptor antagonist 
27 Edaglitazone 4784 -7.176 PPARγ agonist; antidiabetic 
29 GSK 1562590 hydrochloride 5110 -7.11 urotensin II (UT) receptor antagonist 
30 Flurizan 4495 -7.098 γ-secretase inhibitor 
31 GW 9508 2649 -7.096 FFA1 (GPR40) agonist 
32 GSK 269962 4009 -7.051 ROCK inhibitor 
33 AC 5216 5281 -6.986 TSPO ligand 
34 DBZ 4489 -6.973 γ-secretase inhibitor 
35 PF 04418948 4818 -6.957 EP2 receptor antagonist 
36 GSK 2837808A 5189 -6.942 LDHA inhibitor 
37 Sal 003 3657 -6.935 Inhibitor of eIF2α 
38 PD 173212 3552 -7.029 CaV2.2 blocker 
39 NTRC 824 5438 -9.012 NTS2 antagonist 
40 ONO AE3 208 3565 -6.889 EP4 antagonist 
41 RS 17053 hydrochloride 0985 -6.88 α1A antagonist 
42 Pitavastatin calcium 4942 -6.864 HMG-CoA reductase inhibitor 
43 L-161,982 2514 -6.858 EP4 receptor antagonist 
44 AMN 082 dihydrochloride 2385 -6.871 mGlu7 agonist 
45 TC-N 1752 4435 -6.815 NaV channel blocker 
46 PF 431396 4278 -6.799 Dual FAK/PYK2 inhibitor 
47 GNF 5837 4559 -6.754 Trk inhibitor 
48 KS 176 4169 -6.731 BCRP inhibitor 
49 Sarpogrelate hydrochloride 3739 -6.769 5-HT2A antagonist 
50 GKA 50 5133 -6.689 Glucokinase activator 
Table 5.2 top 50 Lumenal in silico HTS compounds 
The top 50 compounds selected for the lumenal binding site are listed. As 
identified by glide. The two compounds identified as the least likely inhibitors by 
the in silico screen were selected as the two negative compounds, named N1 
and N2. The compounds are ranked according to docking score, the displayed 
glide score is the approximate ligand binding free energy. Channel activity 





"Rank" Compound Tocris ID glide gscore Description 
N2 AMG 548 3920 0.471 p38α inhibitor 
1 RWJ 21757 2719 -6.475 TLR7 agonist 
2 Ferrostatin 1 5180 -6.309 inhibitor of erastin induced 
ferroptosis 
3 AA 29504 3972 -6.31 Positive allosteric 
modulator of GABAA 
receptors 
4 L-732,138 0868 -6.167 NK1 antagonist 
5 API-2 2151 -6.158 Inhibitor of Akt/PKB 
signaling 
6 5-BDBD 3579 -6.13 P2X4 antagonist 
7 LY 225910 1018 -6.082 CCK2 antagonist 
8 Formoterol hemifumarate 1448 -6.065 β2 agonist 
9 TC-S 7006 5240 -5.979 Tpl2 inhibitor 
10 TCS 2210 3877 -6.005 Inducer of neuronal 
differentiation in MSCs 
11 Sumatriptan succinate 3586 -5.952 5-HT1A, 5-HT1B and 5-HT1D 
agonist 
12 MRS 3777 hemioxalate 2403 -6.964 A3 antagonist 
13 Thiamet G 4390 -6.079 O-GlcNAcase inhibitor 
14 Abacavir hemisulfate 4148 -5.894 Reverse transcriptase 
inhibitor 
15 DDR1-IN-1 5077 -5.99 DDR1 inhibitor 
16 Fexofenadine hydrochloride 2429 -5.859 H1 receptor antagonist 
17 6-Chloromelatonin 0443 -5.844 Melatonin agonist 
18 GSK 0660 3433 -5.864 PPARδ antagonist 
19 PCA 4248 0571 -5.783 PAF receptor antagonist 
20 Axtinib 4350 -5.765 VEGFR-1, -2 and -3 
inhibitor 
21 DSR 6434 4809 -5.971 TLR7 agonist 
22 Necrostatin-1 2324 -5.756 RIP1 kinase inhibitor 
23 Trifluorothymidine 4460 -5.838 Thymidylate synthetase 
inhibitor 
24 Cilnidipine 2629 -5.729 Dual CaV1.x and CaV2.x 
blocker 
25 Efonidipine hydrochloride monoethanolate 3733 -5.693 CaV1.x and CaV3.x blocker 
26 ITE 1803 -5.69 Endogenous agonist for the 
transcription factor aryl 
hydrocarbon receptor 
27 L-165,041 1856 -5.689 PPARδ agonist 
28 EB 47 4140 -6.033 PARP-1 inhibitor 
29 GSK 2830371 5140 -5.657 allosteric inhibitor of Wip1 
phosphatase 
30 AZD 1480  5617 -5.738 JAK2 inhibitor 
32 Amlodipine besylate 2571 -5.638 CaV1.x blocker 
33 Melatonin 3550 -5.628 agonist at MT1 and MT2 
34 Fludarabine 3495 -5.626 Purine analog 
35 PF 06447475 5716 -5.609 LRRK2 inhibitor 
36 SU 6668 3335 -5.608 PDGFR, VEGFR and 
FGFR inhibitor 
37 AZD 5438 3968 -5.836 Cdk inhibitor 
38 SU 11274 4101 -6.145 Inhibitor of MET tyrosine 
kinase activity 
39 FPL 64176 1403 -5.543 CaV1.x activator 
40 Sunitinib malate 3768 -5.543 VEGFR, PDGFRβ and KIT 
inhibitor 
41 YK 4-279 4067 -5.535 RNA helicase inhibitor 
42 Ralfinamide mesylate 4029 -5.678 Na+ channel blocker 
43 ML 298 hydrochloride 4895 -5.504 PLD2 inhibitor 






45 PLX 647 dihydrochloride 5102 -6.23 dual Fms/KIT inhibitor 
46 GPi 688 3967 -5.438 Allosteric glycogen 
phosphorylase inhibitor 
47 CP 94253 hydrochloride 1317 -5.441 5-HT1B agonist 
48 CGP 57380 2731 -5.44 Mnk1 inhibitor 
49 BW 723C86 hydrochloride 1059 -5.433 5-HT2B agonist 
50 LY 364947 2718 -5.84 TGF-βRI inhibitor 
Table 5.3 Peripheral HTS in silico top 50 compounds 
The top 50 compounds selected for the peripheral P1 binding site are listed. As 
identified by glide. The two compounds identified as the least likely inhibitors by 
the in silico screen were selected as the two negative compounds, named N1 
and N2. The compounds are ranked according to docking score, the displayed 
glide score is the approximate ligand binding free energy. : <50 % green, >50 % 





5.4.1.1 Screening of compounds docked to the lumenal binding site 
The top 50 compounds predicted to bind in silico to the M protein lumenal 
cavity, as ranked by glidescore, are listed in Table 5.2. The activity of these 
compounds was first assessed using the liposome-based channel activity assay 
(Figure 5.4) (section 2.6.3 & 4.1).   
Of the 50 compounds, several increased the fluorescence release from 
liposomes containing M protein, potentially fluorescing, activating the channels 
or disrupting liposome membranes similar to high concentrations of rimantadine 
(Figure 4.9). These included: GBR 12909, a dopamine reuptake inhibitor; KS 
176 a Breast Cancer Resistance Protein inhibitor; PF 04418948, a 
prostaglandin E2 receptor antagonist; and PF 431396, a focal adhesion kinase 
and proline-rich tyrosine kinase 2 inhibitor. However, most compounds reduced 
the fluorescence released from liposomes and 26 % of compounds reduced 
fluorescence by over 50 %, presumably through inhibiting M protein channels. 
The most active of these compounds included (±)-NBI 74330 a CCRX3 
antagonist (Piotrowska et al., 2018), GNF 5837 a Trk inhibitor (Albaugh et al., 
2012) and GSK2837808A a lactate dehydrogenase A (LDHA) inhibitor 
(Thongon et al., 2018). A cut-off of 50 % channel activity was used to choose 
compounds to be tested in cell culture. Of the 13 compounds below this cut off, 
which all improved upon rimantadine by over 25% channel activity inhibition, 
three were taken forward: GNF 5837, GSK2837808A and KB SRC 4. These 
compounds were selected from others below the cut-off based on their rapid 
commercial availability. However, in Figure 5.5 the negative control compounds 
Mifepristone and NAB 2 also reduced channel activity by over 50%, showing the 
docking process is not flawless, and only refines a list of compounds into those 





Figure 5.5 Inhibition of M 
peptide channels by lumen-
targeting compounds using 
liposome-based channel 
activity assay 
Compounds identified by in 
silico docking to the L1 site were 
used in the liposome-based 
channel activity assay at 1 µM 
alongside M protein at 390 nM. 
Released fluorescence of M 
was normalised to 100 % and 
the inhibitory effects of 
compounds were compared. 
Assay cut off shown in red at 




5.4.1.2 Screening of compounds docked to the peripheral binding site 
The top 50 ranked compounds docked into the M protein membrane-facing 
peripheral cavity are listed in Table 5.3. Screening of these 50 compounds 
against M by the in vitro liposome-based channel activity assay (Figure 5.5) 
(section 2.6.3) similarly showed some compounds at 1 µM increased 
fluorescence similarly to the effects of high rimantadine concentrations. These 
included: abacavir, a nucleoside analogue reverse-transcriptase inhibitor; 
ferrostatin 1, an inhibitor of non-apoptotic cell death; and ralfinamide mesylate, 
a sodium channel blocker. However, a variety of compounds also reduced 
fluorescence release, although not to the same extent as a proportion of the 
lumenal compounds. The compounds which reduced levels of CF released 
included formoterol hemifumarate, a β2-adrenoceptor agonist licensed for 
treatment of chronic asthma and Chronic obstructive pulmonary disease 
(Descalzi et al., 2008), AA 29504 an allosteric modulator of GABAA receptors 
(Hoestgaard-Jensen et al., 2010) and L 732,138, a tachykinin NK1 receptor 
antagonist (Munoz et al., 2010). A cut-off of 55% channel activity was used to 
choose compounds to be tested in cell culture and the negative control AMG 
548 resulted in a channel activity of almost 100%. Of the 6 compounds below 
this cut off 3 were taken forward: AA 29504, Formoterol hemifumarate, L-732 





Figure 5.6 Inhibition of M 





Compounds identified by in 
silico docking to P1 site were 
used in the liposome based 
channel activity assay at 1 
µM alongside M protein at 
390 nM. Released 
fluorescence of M was 
normalised to 100 % and the 
inhibitory effects of 
compounds were compared. 
Assay cut off shown in red at 




5.4.2 In silico docking of generic hits into ZIKV M viroporin model 
Three of the top hits from each of the binding sites were chosen for further 
testing. In Figure 5.7 and Figure 5.8 the structures of these compounds and the 
orientation in which they are predicted to bind to the cavities of M protein in 
silico structure are presented. In Figure 5.9 and Figure 5.10 the interactions the 
compounds are predicted to make with the M protein hexamer are shown, 
carried out by Dr Ravi Singh.  
All compounds are shown to make at least one hydrogen bond with M protein, 
shown by a pink line. Lumenal compounds are predicted to form a hydrogen 
bond with THR57 on either one or two monomers per interacting compound. 
Peripheral compounds are predicted to form a hydrogen bond with TYR63 in 
addition to ALA43 for formoterol. Furthermore, aromatic rings of L 732, 138 and 
AA 29504 interact through a non-covalent interaction with the aromatic ring of 
TRP51 and TYR63 respectively forming π–π stacking interactions shown in by 
green lines. The conservation of these binding site-defined residues varies; 
ALA43 is highly conserved throughout the Flavivirus genus (Figure 3.1), whilst 
TRP51 and TYR63 are partially conserved, found in WNV, and WNV/DENV4 
respectively. However, DENV2 and DENV4 retain residues with similar aromatic 
properties. Conversely, THR57 is not conserved across closely related viruses. 
As for ALA43, TRP51 and TYR63 are more highly conserved the peripheral site 






Figure 5.7 GNF 5837 and M protein predicted interaction data  
A. Surface plot of M protein hexamer in silico model with the GNF 5837 shown 
docked into the lumenal cavity, represented as sticks in white, orientated 
towards the linker region.  B. Predicted interactions between GNF 5837 and M 
protein lumenal cavity in Maestro software. Hydrophobic residues highlighted in 
green, positively charge residues in dark blue, polar residues in light blue and 







Figure 5.8 GSK 2837808A and M protein predicted interaction data 
A. Surface plot of M protein hexamer in silico model with the GSK 2837808A 
shown docked into the lumenal cavity, represented as sticks in white, orientated 
towards the linker region.  B. Predicted interactions between GSK 2837808A 
and M protein lumenal cavity in Maestro software. Hydrophobic residues 
highlighted in green, positively charge residues in dark blue, polar residues in 
light blue and hydrogen bonds shown as pink lines. Maestro image kindly 







Figure 5.9 KB SRC 4 and M protein predicted interaction data 
A. Surface plot of M protein hexamer in silico model with the KB SRC 4 shown 
docked into the lumenal cavity represented as sticks in white, orientated 
towards the linker region. B. Predicted interactions between KB SRC 4 and M 
protein lumenal cavity in Maestro software. Hydrophobic residues highlighted in 
green, positively charge residues in dark blue, polar residues in light blue and 








Figure 5.10 AA 29504 and M protein predicted interaction data 
A. Surface plot of M protein hexamer in silico model with the AA 29504 shown 
docked into the peripheral cavity represented as sticks in yellow, orientated 
towards the linker region. B. Predicted interactions between AA 29504 and M 
protein peripheral cavity in Maestro software. Hydrophobic residues highlighted 
in green, glycine highlighted in white and hydrogen bonds shown as pink lines. 






Figure 5.11 L-732, 183 and M protein predicted interaction data 
A. Surface plot of M protein hexamer in silico model with the L-732, 183 shown 
docked into the peripheral cavity represented as sticks in yellow, orientated 
towards the linker region. B. Predicted interactions between L-732, 183 and M 
protein peripheral cavity in Maestro software. Hydrophobic residues highlighted 
in green, hydrogen bonds shown as pink lines and π–π stacking interactions 
shown in green. Maestro image kindly generated by Dr Ravi Singh. 





Figure 5.12 Formoterol and M protein predicted interaction data 
A. Surface plot of M protein hexamer in silico model with the Formoterol shown 
docked into the peripheral cavity represented as sticks in yellow, orientated 
towards the linker region. B. Predicted interactions between Formoterol and M 
protein peripheral cavity in Maestro software. Hydrophobic residues highlighted 
in green and hydrogen bonds shown as pink lines. Maestro image kindly 





5.4.3 Testing selected screened compounds in cell culture 
The in silico screen of 100 TOCRIS library identified a number of compounds 
which reduced M protein channel activity in vitro. Three of the top inhibitory 
compounds which had a greater than 50 % reduction of M protein channel 
activity in vitro from both sites were selected to be further tested in cell culture. 
Compounds selected targeting the Lumenal site comprised: GNF 5837, GSK 
2837808A and KB SRC 4. Peripherally targeting selected compounds were AA 
29504, formoterol hemifumarate and L-732,138. 
Additionally, the effects of JK3/34 and JK3/42 (section 5.2) in viral cell culture 
was investigated, however upon addition to cell culture media the compounds 
were toxic and caused media discolouration at low concentrations.  
The TOCRIS repurposing library contains previously licensed generic 
compounds and biologically active compounds shown to have activity against 
GPCRs, ion channels, kinases, enzymes, nuclear receptors and transporters. 
The effect of these compounds on Vero cells was investigated, to determine the 
concentrations used in the future cell culture screening against ZIKV. MTT 
assays were used to quantify the effect of the compounds on cell viability 
(section 2.2.4). 
Selected lumen-targeting compounds for cell culture assays were found to have 
no adverse effects upon cellular metabolism when applied to cells across the 
µM range, with the exception of GNF 5837, which was only tolerated by cells at 
nM concentrations (Figure 5.13). Similarly, the majority of chosen peripherally 
targeting compounds did not affect cell viability at µM (Figure 5.14). Chosen 







Figure 5.13 The effect of lumen-targeting TOCRIS selected compounds on 
cell viability  
A. The effect of GNF 5837 on cell viability at 48 hr between 0 and 80 nM. B. 
The effect of GSK 2837808A on cell viability at 48 hr between 1 and 40 µM. C. 





   
Figure 5.14 The effect of peripherally targeting TOCRIS selected 
compounds on cell viability 
A. The effect of L-732, 138 on vero cell viability at 48 hr between 0 and 100 µM. 
B. The effect of formoterol hemifumate on vero cell viability at 48 hr between 0 
and 100 µM. C. The effect of AA 29504 on vero cell viability at 48 hr between 0 
and 20 µM. 
Compound Concentration (µM) 
GNF 5837 0.08 
GSK 2837808A 40 
KB SRC 4 0.25 
L-732, 138 40 
Formoterol 80 
AA 29504 10 




5.4.3.1 Do selected TOCRIS compounds target ZIKV in cell culture? 
The selected six compounds were assayed in cell culture to determine their 
effect on ZIKV infection. (section 2.3.4.2) Cell viability assays as shown in 
section 2.2.4 led us to suitable concentrations. Compounds were all 
reconstituted in DMSO and were added to both plaque assay virus innoculae 
and overlay.  
Figure 5.15 shows the results from the plaque assay of the six different 
compounds, showing ZIKV infected cells treated with GNF 5837 and AA 29504 
significantly inhibited ZIKV in cell culture at 10 µM and 80 nM respectively. 
Notably these concentrations are a considerable improvement on rimantadine, 
used at 80 µM to achieve similar antiviral effects. Additionally, when these two 
compounds thought to target different sites were used in combination at the 
previously described concentrations, they did not have a synergistic effect, 
however a smaller significant inhibitory effect was still observed. For 
comparison, a negative control, JK3/32, was chosen due to its lack of activity 
against M protein channels using the liposome-based dye release assay, 
furthermore this compound did also not have an effect on ZIKV infection in cell 
culture. 
Throughout this chapter, we have researched the potential for repurposed 
compounds to inhibit ZIKV M protein in vitro and cell culture. When tested in 
vitro more compounds predicted to target M protein lumenal cavity were 
inhibitory compared to those targeting the peripheral cavity. However, of the six 
compounds taken forward into cell culture lumenal targeting AA 29504 and 
peripheral targeting GNF 5837 were the most potent ZIKV inhibitors of the drug 
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Figure 5.15 Effects of selected TOCRIS compounds on viral titre   
TOCRIS compounds were added to cells at the same time as cells were 
inoculated with virus. Compounds were used at the following concentrations: 
AA 29504 10 µM, GNF 5837 80 nM, KB SRC 4 250nM, Formoterol hemifumate 
80 µM, GSK 2837808A 40 µM, L-732, 183 40 µM, Rimantadine 80 µM, and 
negative control JK3/32 40 µM. Data shown of triplicate wells from one 
experiment, except for AA 29504 and GNF 5837 which contain 3 biological 
repeats of triplicate wells. Data shown from three biological replicates subjected 
to T tests of the mean. AA 29504, p value=0.0005, GNF 5837 p value=0.0002. 
Combined AA29504 and GNF 5837 treatment data is from two biological 






The current treatment of ZIKV infection is solely best supportive care, therefore 
will not prevent the virus crossing the placenta of pregnant women and 
establishing an in utero infection. There are compounds undergoing research 
and testing for their ability to treat ZIKV infected patients, however no therapies 
are currently licensed for the treatment of ZIKV. Additionally, the current ZIKV 
vaccine development is ongoing, and a vaccine may not address the need for a 
treatment preventing cross-placental infection prior to the third trimester. 
We have previously identified M protein channels as a novel target throughout 
chapter 3 and 4. However, the lack of structural data has prevented screening 
and identification of new or repurposed compounds, capable of inhibiting M 
protein. We have avoided the inherent problems associated with hydrophobic 
membrane protein purification and adopted a rational approach to identifying 
repurposed drugs capable of inhibiting M protein channels, providing progress 
in the Flavivirus antiviral development field. 
The licensed M2 viroporin inhibitor rimantadine was screened in vitro, in cell 
culture and in vivo, and inhibited M protein and ZIKV infection respectively in a 
dose-dependent manner (chapter 4). Additionally, in the liposome-based assay 
the levels of rimantadine needed to inhibit the channel were similar to those 
used for p7 inhibition (1 μM) (StGelais et al., 2007; StGelais et al., 2009), 
whereas inhibition of E5 required much higher concentrations (>400 μM) 
(Wetherill et al., 2012).  
M protein activity was reduced to ~60 % by 1 μM rimantadine. Rimantadine is 
known to target multiple viroporins and is therefore relatively promiscuous. 
Thus, we used the liposome-based channel activity assay to test other 
compounds previously used or developed against viroporins. The compounds 
included JK3 compounds developed as potential p7 inhibitors (Shaw et al., 
2019). The repeated testing of these compounds at 1 μM found the most active 
and repeatable being JK3/42. JK3/32, which has been identified as a potent p7 
inhibitor does not show any inhibitory effects on ZIKV M protein and was 
subsequently used a negative control (Figure 5.15) (Shaw et al., 2019).  
Small molecules with greater efficacies for ZIKV M are clearly needed and a 




repurposing library. The drug-repurposing library from TOCRIS is made up of 
1280 compounds, which are known to target, GPCRs (27%), kinases (20%), 
enzymes (19%), ion channels (14%), cell biology (10%), nuclear receptors 
(5%), transporters and other pharmacology (5%). 
Although an atomic channel structure remains elusive, our work in silico 
constructing and simulating a model has provided us with a template for rational 
drug library screening. Our first step utilised computational tools to identify 
potential binding cavities to go forth and screen the large repurposing library.  
Our preferred in silico model of ZIKV M protein hexameric channel was studied 
to identify potential drug binding sites. In silico software Maestro identified 
rimantadine is predicted to bind to a lumenal cavity of the model, with a 
promising glide/binding score compared to other binding sites identified on the 
model. Rimantadine is predicted to bind to this cavity positioned with its 
adamantyl cage away from the channel lumen (Figure 5.4A), similarly 
rimantadine docks to the HPV E5 channels in a lipophilic luminal binding site, 
although with the adamantyl cage facing the lumen pocket, however the binding 
of rimantadine onto HCV p7 resides on the periphery (Foster et al., 2011; 
Wetherill et al., 2012). Similarly, amantadine docked in the same predicted 
orientation to rimantadine, however N-acetyl and N-methyl rimantadine were 
positioned with their adamantyl cage towards the lumen (Figure 5.4) this could 
be due to more hydrophobic R-groups. Furthermore, rimantadine is shown to 
interact most closely with VAL61, LEU64, VAL65 and LEU68. These pore lining 
residues, particularly LEU64 and 68 were found in Chapter 2 to be consistently 
involved with closure of the MD simulation channels.  
Additionally, Maestro software was not capable of considering the peripheral-
membrane, so we identified a potential peripheral cavity, which bared a 
resemblance to the peripheral rimantadine binding cavity of p7 (Foster et al., 
2014). Furthermore, these two binding sites were taken forward for in silico drug 
screening.  
After screening the 1280 compounds against the two binding sites in silico the 
top 50 ranked according to binding capacity were screened in vitro using the 
liposome dye release assay, the liposome assay has been previously used and 




StGelais et al., 2009; Wetherill et al., 2012). This system has also been used as 
a high throughput in vitro screen  of a Pharmaceutical company drug library, 
although some components of the liposomes were altered to improve stability 
(Gervais et al., 2011). A higher proportion of lumenal targeting compounds 
effectively inhibited M protein than periphery-targeting, this could be due to the 
hydrophobic and polar interactions of lumenally targeting compounds. Also due 
to the biased nature of this screen by utilising in silico screening, the success 
rate of these compounds was much higher than a blind drug screen (Lionta et 
al., 2014).  
Three of the top lumen-targeting compounds and peripherally targeting 
compounds were taken forward for testing in cell culture against ZIKV infection. 
However, AA 29504 and GNF 5837 showed the highest level of ZIKV inhibition, 
which are known as an allosteric modulator of GABAA receptors (Hoestgaard-
Jensen et al., 2010) and a Trk inhibitor respectively (Albaugh et al., 2012).  
The in silico predicted interaction data between the compounds and its binding 
cavities interestingly shown rimantadine is not predicted to form any hydrogen 
bonds or π–π stacking interactions with the residues in the lumenal cavity. 
However, the six identified compounds taken forward into cell culture all form at 
least one hydrogen bond with the cavity, namely THR57 for the three lumenal 
compounds, with two THR57 hydrogen bonds forming for one molecule of GSK 
2837808A. For periphery targeting compounds TYR63 forms a hydrogen bond 
to all compounds in addition to ALA43 for formoterol. Furthermore, π–π 
stacking interactions are also found for AA 29504 and L-732, 138 between 
TYR63 and TRP51 respectively. The presence of these bonds would suggest 
the compounds are more likely to strongly inhibit M protein viroporins in 
comparison to the weak binding of Rimantadine. 
AA 29504 a triamino-benzene compound enters the brain modulating GABAA 
receptors and is effective in vivo. Additionally, in vivo dosing has been carried 
out in rats at 4 mg/kg and 10 mg/kg successfully (Hoestgaard-Jensen et al., 
2010). AA29504 is predicted to bind to the periphery of the M protein viroporin 
complex by virtue of its planar composition (Figure 5.10), and successfully 
reduced ZIKV plaque formation in cell culture by ~50 % at a concentration of 10 




GNF 5837 is an orally-administered potent and selective TRK-inhibitor, which 
inhibits mice Xenograft tumour growth (Albaugh, 2012). Interestingly GNF 5837 
is also a planar compound, but contains an oxindole core, similar to the p7-
targeted JK compound series. However, GNF 5837 was predicted to bind to the 
lumenal cavity of ZIKV M protein channels (Figure 5.7), and similarly to AA 
29504 was seen to reduce ZIKV infection in cell culture by ~50 %. Moreover, 
GNF 5837 was used at a 1000-fold lower concentration than rimantadine, 
indicative of a promising improvement in inhibitory properties. 
The in silico approach undertaken to identify inhibitors of the ZIKV M protein 
viroporin was validated, as compounds AA 29504 and GNF 5837 exhibited 
specific, inhibition of M peptide viroporin activity in vitro and in cell culture. 







Chapter 6 Final Conclusion 
Controversy over the channel activity of Flavivirus M proteins exists due to 
conflicting published DENV data. Previous work with DENV-2 M protein C-
terminal peptides supported cation channel activity in vitro, sensitive to 
prototypic viroporin inhibitors, amantadine and hexamethylene amiloride. In 
addition, amantadine and rimantadine have also inhibited DENV infection in 
vitro (Koff et al., 1980; Koff et al., 1981). However, no evidence was found 
supporting the ability of M to act as a proton channel in electrophysiology 
studies using Xenopus oocytes (Premkumar et al., 2005; Wong et al., 2011). 
This study has demonstrated ZIKV M protein can form oligomeric channels 
through work in silico, in vitro, in cell culture and in vivo. MD simulations have 
shown M protein can dimerise within a lipid bilayer in different orientations and 
can be influenced by lipid composition and structural restraints. Furthermore, 
MD simulations have shown M can remain stable as a hexameric oligomer and 
possess a water channel with helix 3 lining the pore. In addition, rotating the 
monomers to increase interactions causes the pore to remain open for a greater 
proportion of time upon HIS28 protonation; this may be reflective of the 
physiological environment experienced by the virus during endocytosis.  
The first indication in vitro of M protein oligomers was seen in a DH(6)PC 
detergent environment using native-PAGE, where oligomers suggestive of 
hexamers or heptamers were seen on a Coomassie-stained gel. Subsequent 
visualisation by TEM of M protein channels in this detergent environment 
showed that varying the detergent concentrations generated protein oligomers 
in different orientations and oligomeric sizes. Unfortunately, the stoichiometry 
could not be determined. 
M protein channel activity was demonstrated in an in vitro liposome assay, used 
previously with many other viroporins. The assay showed M peptide 
concentration-dependent activity and dose-dependent inhibition with 
rimantadine.  
Discovery of rimantadine as an inhibitor of ZIKV M protein was successfully 
translated to cell culture and in vivo. Mice infected with ZIKV and treated with 




These results show M protein as a successful drug target in vivo, however as 
rimantadine did not reduce viral titre fully and due to it is promiscuity, history 
and simplicity. This pipeline was applied to discover other potential M protein 
inhibitors. 
Thus, the most favourable in silico model comprising the rotated M protein 
channel with the pore lined by helix-3 was used to identify potential inhibitor 
binding sites. These two identified sites L1 and P1 are found in the lumen and 
periphery respectively. The chemistry department assisted the TOCRIS drug 
repurposing library in silico screening for potential hits, the top 50 appropriate 
hits were taken forward per binding site. 
The in vitro liposome assay was used for a rapid throughput screen based upon 
in silico enrichment, which highlighted several promising compounds. 
Implementation of the pipeline using six compounds identified in vitro, confirmed 
the activity of two compounds in cell culture, one for each P1 (AA 29504) and 
L1 (GNF 5837) binding sites were seen to have significant ZIKV infection 
inhibitory effects at 10-fold and 1000-fold reduction in concentration. 
Future work testing these compounds ensuring they have no off-target effects 
and testing in vivo is crucial to determining their role in targeting ZIKV infection, 
however the nature of the library reduces the likelihood of this. Furthermore, 
looking at the effect of targeting ZIKV M protein in utero with Rimantadine and 
the identified AA29504 and GNF5837 would prove instrumental at displaying 
the effect of a drug targeting ZIKV M in a clinical anti-microcephaly setting.  
Moreover, determining the stoichiometry and structure of ZIKV M protein 
oligomers by cryo-electron microscopy would provide not only functional 
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Appendix A Recipes 
A.1 Vero cell culture media: 
DMEM + 10% FCS + 5% PenStrep 
A.2 BHK-21 Cell culture media: 
BHK-21 media + 10% FCS + 5% PenStrep 
A.3 Freezing media: 
Cell culture media + 10% DMSO 
A.4 EBC lysis buffer 
50 mM Tris HCl pH 8.0, 140 mM NaCl, 100 mM NaF, 200 µm Na3VO4, 0.1 % 
SDS, 1 % Triton X100, 1 tablet protease inhibitor per 50 ml (complete ULTRA 
tablets, Roche) 
A.5 2x Laemmli Buffer 
100 mM Tris HCl pH 6.8, 4 % SDS, 20 % Glycerol, 10 mM DTT (Dithiothreitol), 
0.025 % Bromophenol Blue   
A.6 Tris Glycine running buffer 
25 mM Tris base pH 8.0, 250 mM Glycine, 0.1 % SDS 
A.7 Towbin 
A.8  
25mM Tris base, 250 mM Glycine, 20 % Methanol  
A.9 Tris-buffered Saline 
50 mM Tris HCl pH 7.5, 150 mM NaCl  
A.10 ECL Solutions: 
a. Solution 1: 0.4 mM p-Coumaric acid, 2.5 mM Luminol, 0.1 Tris 
pH 8.5;  
b. Solution 2: 0.02 % H2O2 0.1 mM Tris pH 8.5 
A.11 Liposome Assay Buffer 
10 mM HEPES pH 7.4 107 mM NaCl  
A.12 Native-PAGE Loading Dye  




A.13 Native-PAGE running buffer: 
0.025 mM Tris-base 0.192 mM Glycine pH 8.5 
A.14 Coomassie Blue Stain solution 
0.1% Coomassie Blue, 10% acetic acid, 50% methanol, 40% H2O 
A.15 Coomassie Blue destain solution 
10% acetic acid, 50% methanol, 40% H2O 
A.16 Carboxyfluorescein (CF) Buffer  












Appendix B Supplementary Data 
Simulating M protein in the absence of the second TMD 
The linker region between the two transmembrane domains is only short, 
however the simulations of M protein with two TMDs shown in Figure 3.9 
Monomeric M protein with two TMDs is stable in a POPC bilayer (Figure 3.9 
and Figure 3.10) shows this region interacts with the lower leaflet of the lipid 
bilayer causing the membrane conformation to alter, pinching up due to the 
short length of the transmembrane domains. To determine whether this linker 
region alone, without the presence of the C-terminal TMD could still interact with 
the inner leaflet and cause the membrane conformational change we ran an 
additional set of simulations with M protein truncated at the C-termini of 20 
amino acids, forming a 38 amino acid protein. 
After 3 μs of coarse grain simulation the absence of the C-terminal TMD did not 
affect the conformation or interactions of the truncated protein with the 
membrane (Figure B1.). The same membrane alterations occurred and there 
was less RMSF variation between repeated simulations (Figure B1). From this 
set of simulations, it appears H3 is not important for M protein to remain 









Figure B.1 Monomeric M protein truncated after the linker region is stable 
in a POPC bilayer 
Conformations of monomeric H3-truncated M protein before and after 3 μs 
simulation. Protein backbone shown in pink and phospholipid bilayer heads 
shown in orange. A. Monomeric M protein simulation starting conformation, 
shown side on with and without phospholipid bilayer heads. B. Monomeric M 










B.2 Simulating heptameric M protein channels in silico 
Oligomerisation of channels such as viroporins can result in multiple higher 
order structures forming. Previous work of HCV viroporin p7 displayed the 
capability of forming both hexameric and heptameric channels with the 
possibility of less favourable tetrameric and pentameric complexes additionally 
forming (Chandler et al., 2012). In light of this we additionally generated and 
simulated Heptameric M protein channels using the same protocol used in 
section 3.5 simulating Hexameric M protein channels. 
B2.2 Helix 2 pore lining radial conformation 
Heptameric channels with helix 2 pore-lining in the same radial conformation as 
mentioned in section 3.5.3.1 were simulated for 200 ns. Channels had a wider 
pore radius of 7.122 Å compared to the 3.2 Å pore radius of hexameric 
channels. Increasing the number of protomers forming these channels results in 
an increase in both pore size and interactions holding the channels together 
(Figure B.2.1). The residues lining the pore were LEU52, TRP51, ALA48, 
ALA45 and GLY41. 
Analysis of simulations showed two of the channels remained open throughout 
the 200 ns with respective channel radius of 4.253 and 4.146 Å and the third 
began to close after 112 ns and fluctuated between open and closed for 28 ns 
before closing at 140 ns (Figure B.2.2).  
However, protonation of the channels did not increase the duration they 
remained open, one channel closed after 25 ns, opening and closing twice 
before closing fully at 58 ns, the other channels remained open for 110 and 58 
ns before closing fully. The protonated channels had an increased pore radius 
prior to simulation beginning with a radius of 7.43 Å, resulting in closure of all 







Figure B2.1 Heptameric Helix 2 pore-lining ‘radial’ channel starting 
conformations 
A. Ribbon representation side on and from above with histidine residues 
highlighted in red. B. Surface representation side on and from above with one 







Figure B2.2 Heptameric Helix 2 pore-lining radial channel conformation 
after 200 ns simulation 
A-C, Surface and Ribbon representation of simulations at 200ns from above 
and side (with one helix cut away) B. HOLE profile pore radius of simulations 1-





Figure B2.3 Heptameric Helix 2 pore-lining 'radial' protonated channel 
conformation after 200 ns simulation 
A-C, Surface and Ribbon representation of simulations at 200ns from above 
and side (with one helix cut away) B. HOLE profile pore radius of simulations 1-





B2.3 Helix 2 pore lining compact conformation  
The compact Helix 2 pore lining heptamer structure has a pore radius of 6.815 
Å (Figure B2.4) at the start of the simulations with LEU52, ILE49, ALA48, 
ALA45, PHE42 and GLY41 lining the pore. 
Over the 200 ns simulations two of the neutral pH channels remain open for 
over 20 0 ns and the remaining channel closed with a final pore radii of 2.85, 
1.827 and 0.994 Å (Figure B2.5). After protonation the channel has an 
increased pore radius of 6.88 Å and remain open for 40, 200 and 23 ns with 
respective pore radii of 0.81, 2.9 and 0.66 Å respectively (Figure B2.6). 
B2.4 Helix 3 pore lining radial conformation 
As previously, heptameric channel conformations were arranged comparably to 
the hexameric channel conformation. However, this resulted in the pore radius 
decreasing to 2.41 Å, due to the angles of the pore-lining helices, allowing for 
closer placement of protomers without overlapping (figure B2.7). The residues 
lining the pore were LYS60, TRP63, LEU64, ILE67 and LEU68. 
Despite the much smaller pore of the channel all three repeat simulations 
remained open for the 200 ns with respective pore radii of 4.64, 1.34 and 2.5 Å 
(Figure B2.8). Upon histidine protonation the simulations the starting pore 
radius was 2.35 and channels remained open for 195, 192 and 200 ns with pore 
radii of 0.46, 0.5 and 4.04 A respectively (Figure B2.9) 
B2.5 Helix 3 pore lining compact conformation 
The rotated conformation of the Helix 3 pore lining channel is more compact in 
comparison to the radial conformation, resulting in increased interactions 
between protomers, particularly increasing the interactions between the N-
terminal helices which are no longer as flexible, due to their proximity to the 
neighbouring protomer. The starting conformation of the channel exhibits a pore 
radius of 7.012 Å allowing many water molecules to fill the lumen with THR57, 
LYS60, VAL61, VAL65, LEU68, LEU69, PRO72 and ALA73 lining the pore 
(Figure B2.10). 
After 200 ns of simulation two channels remained open with a water column and 
pore radii of 3.8 Å and 3.78 Å, however one channel did close after 75 ns 




After protonation of the Helix 3 pore lining rotated channel the simulations 
started with a pore radius of 7.0 Å. Once more two of the three channels 
remained open with radii of 2.5 Å and 5.8 Å, and the remaining channel closed 
after 90 ns of simulation resulting in a pore radius of 0.8 Å (Figure B.12). 
 
 
Figure B2.4 Heptameric Helix 2 pore-lining ‘compact’ channel starting 
conformations 
A. Ribbon representation side on and from above with histidine residues 
highlighted in red. B. Surface representation side on and from above with one 





Figure B2.5 Heptameric Helix 2 pore-lining 'compact' channel 
conformation after 200 ns simulation 
A-C, Surface and Ribbon representation of simulations at 200ns from above 
and side (with one helix cut away) B. HOLE profile pore radius of simulations 1-








Figure B2.6 Heptameric Helix 2 pore-lining ‘compact’ protonated channel 
conformation after 200 ns simulation 
A-C, Surface and Ribbon representation of simulations at 200ns from above 
and side (with one helix cut away) B. HOLE profile pore radius of simulations 1-







Figure B2.7 Heptameric Helix 3 pore-lining ‘radial’ channel starting 
conformations 
A. Ribbon representation side on and from above with histidine residues 
highlighted in red. B. Surface representation side on and from above with one 






Figure B2.8 Heptameric Helix 3 pore-lining 'radial' channel conformation 
after 200 ns simulation 
A-C, Surface and Ribbon representation of simulations at 200ns from above 
and side (with one helix cut away) B. HOLE profile pore radius of simulations 1-





Figure B2.9 Heptameric Helix 3 pore-lining 'radial' protonated channel 
conformation after 200 ns simulation 
A-C, Surface and Ribbon representation of simulations at 200ns from above 
and side (with one helix cut away) B. HOLE profile pore radius of simulations 1-
3 and the starting conformation in black, red, green and blue respectively. C. 





Figure B2.10 Heptameric Helix 3 pore-lining ‘compact’ channel starting 
conformations 
A. Ribbon representation side on and from above with histidine residues 
highlighted in red. B. Surface representation side on and from above with one 








Figure B2.11 Heptameric Helix 3 pore-lining ‘compact’ channel 
conformation after 200 ns simulation 
A-C, Surface and Ribbon representation of simulations at 200ns from above 
and side (with one helix cut away) B. HOLE profile pore radius of simulations 1-






Figure B2.12 Heptameric Helix 3 pore-lining 'compact' protonated channel 
conformation after 200 ns simulation 
A-C, Surface and Ribbon representation of simulations at 200ns from above 
and side (with one helix cut away) B. HOLE profile pore radius of simulations 1-
3 and the starting conformation in black, red, green and blue respectively. 
 
